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SUMMARY
It has been postulated that antibody may affect tumour growth
directly, or indirectly by modulating the activities of T-cells, K-
cells snd macrophages. Therefore, these studies were designed to
gain some insight into whether the pleomorphism exhibited by immuno¬
globulin classes and sub-classes might account for the numerous roles
that have been postulated for antibody in tumour immunity. The
model chosen was the inhibition of syngeneic tumour growth (s.e.) by
an infection of C.parvrart (i.p.) in CBA mice, and three serological
parameters were measured after administration of C.parvum, tumour or
both. These weret 1) immunoglobulin binding to tumour target cells
in vitro (aom.times designated "anti-tumour antibody", in an operational
sense); 2) total immunoglobulln class and sub-class levels; 3) snti-
C.parvum antibody titres.
WLth the aid of serum from appropriately immunised mice, an iso¬
tonic antiglobulin assay was developed to detect immunoglobulin binding
to target cells in vitro. It soon became apparent that C.parvum
(CN 613U) administration (i.p.) to normal mice resulted in the production
of immunoglobulin binding to tumour cells in vitro, accompanied by
elevated levels of certain serum immunoglobulins (most markedly and
consistently IgG^) and high anti-C.parvum antibody titres. These
serological changes were dose and route dependent, although not depend¬
ent on an intact thymus, and they occurred with other adjuvants. The
immunoglobulin binding to tumour cells in vitro was IgM, and exhibited
no specificity for tumour cells.
C.parvum (CM 613U) administration (i.p.) to tumour bearing mice
also elicited immunoglobulin capable of binding to tumour cells in
vitro, accompanied by elevated levels of most immunoglobulin classes
and sub-classes and high aati-C.parvum antibody titres. Again the
changes were route dependent and could he diminished (or, in the case
of immunoglobulin binding to tumour cells in vitro, abolished) by the
administration of gold salts. They were also apparent in thymectom-
ised mice and in mice treated with other adjuvants. The immmoglobulin
binding to tumour cells in vitro occurred in all classes and sub-classes
except IgA, and the 7S immunoglobulin exhibited a degree of specificity
for homologous tumour ce2fe, although the 19S did not.
Preliminary experiments were also undertaken to see if; 1) the
antibody detected by the antiglobulin assay was due to genuine antigen-
antibody reaction; 2) immunoglobulin binding to tumour cells in vitro
could be elicited without the intervention of adjuvant; 3) the sero¬
logical changes could influence tumour growth; U) tumours of lymphoid
origin could affect the immune response to defined antigens.
The results are related to findings from other laboratories, and
discussed from the standpoint of possible mec! missis of ad. uvant action.
Suggestions are made for improvement of techniques used and for further
work in this area.
Systems, scientific end philosophic, come and go. Each
method of listted understanding is at length exhausted.
In its prime eaoh system is a triumphant success* in Its
decay it is an obstructive nuisance. The transitions to
new fruitfulness of understanding are achieved by recurrence
to the utmost depths of intuition for the refreshment of
Imagination. In the end - though there is no end -
what is being achieved, Is width of view, issuing in greater
opportunities.
from "Adventures of Ideas"
by Alfred Worth Whitehead
PREFACE
The discipline of honour innunology is in a stats of flax at
present. Therefore to give this work .-me structure the hypo¬
thesis 1«- adopted that tsBRmosurveillinice of sub-clinical nropl -jss
t* a reality only for certain vir&ily induced turour**, and li uMtfr
or nan- d-tmt for "spontaneous* and chrairally induced tuwsttrs*
sa-eeptibllity and resistance to an oncogenic agent being governed
sy non-ismnological genetic factors in these ca."#?. This does
not preclude the possibility that tunours nay be recognised by the
host when the antigenic load is big enough , i.e. when the tmaar
is clinically o senraMe.
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1. EMERGENCE OF TUHOTO IMMPNOLOOX
It has long been the experience of alert clinicians that the
growth of an observable tumour is not always inexorable. Apart
from the well attested cases of hormone-dependent naoplasus (1)
there are a number of cases In which other, nor® capricious, mechan¬
ism? of homeostasis- might be responsible. As Ion# ago as 1*21
W.B. Coley observed a connection between a stimulated immune <?y*t*m
mid regression of sarcomatous growth. Strangely, in spite of the
celebrated work of his contemporaries Pasteur Mid Koch, he attributed
the anti-tumour activity t.o a direct effect of the immune stimulant
(S. pyogenes) on the cancer cells or "cancer bacillus" (2).
?tob then up to the present day there has appeared just enough
evidence to keep the immunology of human tumours a live Issue.(3).
This evidence usually takes the form of increased survival time*, or
duration of remission after iuaminotherapy. these are "oaewhat
marginal for solid tumours but more dramatic for cancers in which
the disease can b© objectively controlled before commencement of
immunotherapy, such a? the various forms of leukemia. There are
also well attested individual cares in which iwmodeprescion has
been followed by malignant outgrowth (K), or the association of a
good prognosis with a high degree of lymphocyte infiltration into
the regional node (£).
Tumour immunology acquired a theoretical basis in the immuno-
'urvcillanee concert, due initially to Thomac (6) and subsequently to
Burnet (7). This concept, that the role of the thymus-dependent
arm of the immune system was to seek out and destroy.clinically
unreoognisec^ln site tumours which arose through donatio mutation,
gave a satisfying explanation of the selective preasur* culminating
in the allograft reaction. It also accounted for the observa¬
tions of increased tumour incidence associated with insrone-depression
or imune-dirorder. With a few notable exceptions the theory was
accepted and widely invoked in an explanatory capacity. It also
made empirically testable predictions which have made it possible to
adjudicate on the validity of the theory.
The results of the numerous experiments designed to test the
israunorurveillance concept have recently been reviewed extensively,
(see "or example B) and it seems apparent the experimental prediction,
that imiwunosuppression should lead to a greater yield of all types of
tumour,has been fulfilled only in a very restricted sense. Thus
there is evidence that surveillance operates against widespread,
potentially oncogenic viruses in a number of species, for example
polyoma virus in mice, hsrpee vItus saladrl in squirrel monkeys,
Marak-s disease virus In chickens, feline leukemia virus in cats and
Enstein-Barr virus in man. As regards carcinogen-induced tumours
the evidence is contradictory,hut on balance the effect of a carcin¬
ogen appears to be genetically defined at the level of the cell (or
organ) exposed to the carcinogen; immune intervention making a
marginal difference (9).
With the benefit of hindsight itfe possible to see that the
iranmosurveillance concept is based on a circular argument (set
Fig. 1); however, this would have been immaterial if the theory had
Fig-1










hecn sound. Bat V-eaue« it is the business of science to progress
from hypotheses that here exceptions to hypotheses that have no
exceptions, the surveillance concept tract he reformulated to take
account of the good correlation in some viral systems between an
intact immune system and low tumour incidence, and the meagre effect
of immune-intervention on the incidence of carcinogen-induced tumours.
Such a theory has been proposed by Klein (10, 11 >, the central
tenet of which is that genetically determined variation in immune
responsiveness to a given timour-assod ated ntigen may account for
the difference between susceptibility and resistance to the oncogenic
effect of a given agent. The effects of the Immune response games
can range between states of complete unresponsiveness and high reac¬
tivity* f-ey may influence the timing or the quantitative level of
the response? or they may modify the effector mechanisms involved
in the reaction.
The theory would predict that a species harbouring a potentially
oncogenic virus would be subject to selective pressures, resulting in
a high degree of immune responsiveness against cells transformed by
the virus. Members of a similar species not harbouring the virus
would be susceptible to the oncogenic effect of the virus. As
discussed later this has been found to be the case.
What of tumours produced by carcinogen? These oncogenic
agents are very recent additions to the mammalian environment and no
selection of IR genes against carcinogen-induced tumours would be
expected. Thus, the empirical evidence that the induction of
carcinogen-induced tumours is only marginally influenced by immune
factors, is in accord with the theory of genetic preelection of IR
genes. There is, however, no doubt that under certain experimental
conditions (e.g. large doses of carcinogen, manipulation of tumour
presentation to the host) and on certain genetic backgrounds, there is
exe llent recognition by the host of carcinogen-induced tumour
antigensj on the other hand sometimes there is no recognition at all.
This random, and comparatively weak, recognition could be explained by
assuming that the well recognised carcinogen-induced tumour antigens
are those that cross-react with some natural product for which the
host possesses the relevant IR genes.
As a footnote, it might be added that the genetic preselection
theory does not provide an explanation of the selective pressures
culminating in the allograft reaction, as did the immunosurvedllance
concept of Burnet. However, this in Itself is not necessarily
against the preselection theory as other explanations of the basis
of the allograft reaction have been put forward (12).
2. SURVEILLANCE OF NASCENT TUMOURS
a) Virally induced tumours
As stated in the proceeding section, there is evidence for
surveillance of sub-clinical^ virally induced neoplasms in certain
well defined systems. In some of these systems it has been
possible to vreed animals that are susceptible to the oncogenic
effect of the virus (or virus-transformed cells), and animals that
are resistant, thereby permitting a genetic analysis. When this
has been done it has generally been found that histocompatibility
linked genes are associated with susceptibility or resistance.
(This may implicate IR genes, but it is realised that histocompatibility
genes may well be linked (or be identical) to genes coding for receptors
on the cell surface, thereby perhaps influencing the severity of virus
infection.) Furthermore, in some systems the difference between
resistance end susceptibility can be abrogated by immune intervention,
i) Surveillance of vlrally induced tumours in mice.
Possibly the most studied system in tumour immunology is the
induction of tumours with polyoma virus. As the virus is a
ubiquitous constituent of wild mice this model may be particular¬
ly relevant. There is agreement that iramunodepression of in¬
bred laboratory mice (treatment with anti-lymphocyte serum or by
thymectomy) results in an increased tumour yield after infection
with polyoma virus, and this can be at least partially reversed
by reconstruction of the immune system (!?, 10). Furthermore,
nude" mice and "imunodepressed" neonates are similarly susceptible,
all of which is strong evidence for the classical surveillance
concept. The fact that wild tyoe neonates do not show a high
incidence of polyoma-indueed tumours could be due to the prophyl¬
actic effect of maternally transferred antibody to polyoma virus,
a protection not available to neonates of polyoma-free laboratory
mice. The polyoma system appears to be reasonably typical of
other oncogenic HIA viruses such as adeno-virus-12 and SV~!jO.
ere are also laboratory analogies for some of the "natural"
C-typc HRA viruses of wild mice. Thus, in the Gross virus
system there is some evidence that the difference between
susceptible and resistant strains is due to a gene located in the
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IK region of the H--2 coralta, Host mouse trains carry the
resistance allele, but the susceptibility allele can he selected
*or, e.g. in AKR alee (10). In the Frien virus system two
genes have been defined. One determines r< -overy from leukemia
and is located in the H-2 region} the second determines recovery
from vireraia and is due to three or more- Ccr?31 genes independent
of the H-2 complex. These CijfKt genes were necessary for the
expression of the H-2 mediated effect on regression (*3). It
is interesting that although C^Bl mice differing at the H-2
linked gene both recover from vlremia, the rate of recovery is
faster in the mice with the gene coding for recovery from leukemia
(13). This may indicate that the timing of recovery "rom
viremia is critical. If it is too late the neoplastic trans¬
formation may be too far advanced to halt.
In general it can be said that immunosuppression increases
the yield of tumours induced by the C-type viruses. However
there are complications; for example thymectomy may remove the
target cell on which the virus exerts its oncogenic effect, and
ALS may react with the transformed cells,
ii) Surveillance of virally induced tumours in cats
Cats also harbour a C-type oncorna virus, feline leukemia
virus (FetV). When a cat is infected the virus is first
located in the bone marrow, and subsequently in the mucous
membranes of the respiratory and alimentary tracts. Yom
there the virus particles are shed, and infection of other cats
by horizontal transmission occurs (tla). An important
-7-
conseqtienee of Fr-LV infection is the onset of i state of
immunosuppression so that the cats receiving a heavy infect¬
ing dose do not mount a substantial immune rf -ponse, end nay
subsequently develop tumours. Conversely, eats infected with
a small dose of virus produce a good antibody response and are
tumour fre (1 f).
In Glasgow infection is rare below f months of age, but
later, when cats mix socially, there is a rise in the infection
rate, so that of animals over 3 years /Of have snti1 odies (t6).
Thus, the situation of horizontal transmission and a high infec¬
tion rate with relatively low morhitity would indicate that
imminosurveillance is operative. However, the antigen recog¬
nised, and used in vaccination in this system, would appear to
be a viral envelope antigen (if). This is different "rom
say a Moloney virus-induced tumour, in which the tumour antigen
and the viral proteins do not cross-react (17).
ill) Surveillance or heroes virus-induced tumours
A number of widely divergent snlmal species are thought to
be susceptible to the oncogenic effect of herpes viruses: these
are frogs, chickens, monkeys and mm.
The leopard frog (Rana pipiens) is particularly susceptible
to a kidney carcinoma, implying some genetic predisposition. The
nuclei! of some tumour cells contain inclusions which are thought
to be caused by virus. Subsequently it was found that the
inclusions were only observed at low temperatures, when the tumour
cells released infectious virus. In wars temperatures, spon¬
taneous tumours occur which do not release infectious virus.
-8-
The cycle can be completed by recovering the infectious agent
from a tumour induced by injection of a tuaour extract, and
using thi3 in turn to induce another tumour. Thus, Kochs'
postulates are satisfied, and the tumour is Laced among those
transmitted by an infectious agent (13).
In tokens, cells of the lymphoid system nay become cancer¬
ous and invade the nervous system, resulting in paralysis. The
disease, Msrek's disease, progresses to other organs and the bird
eventually dies. Tumour cells apparently do not contain virus
but cell of the feather follicles do. Furthermore, it can be
shown that chicken feathers and bits of sloughed off skin are high¬
ly infectious, there'y establishing the route of transmission (19).
It is possible to breed chickens resistant and susceptible to the
oncogenic effect of the virus, and neonatal thymectomy converts
resistant ' irds to 8U3eepti le. Furthermore, resistance may be
coded for by a single dondn nt gene which could well be an IK
gene that influences recognition of the virus-transformed cells
(10).
Vaccination of susceptible chickens with an apathogenic
turkey herpes virus dramatically reduces the tumour incidence,
without affecting the degree of virus shedding (?0). This
neatly illustrates two points: firstly, in Merck's disease it is
impossible to immunise with the onaog* ic virus (compare the poly¬
oma system), presumably because the recognition of virally induced
tumour antigens is not as good as in the polyoma system. How¬
ever, if the timing is right, susceptible birds can ve alerted to
mount a tumour rejection response. Thus, susceptible birds can
-9-
respond, but their primary response Is overwhelmed by the develops
ing tumour. Secondly, the rejection response must be due to
recognition of tumour antigens and not anti-viral immunity.
In monkeys we have the nicely defined situation in which
hopes virus saimari, wldlch exists in sn uneventful manner with
its natural host, causes a malignant lympho-proliferation in other
species of rtonksy. Primary virus infection leads to compar¬
able peak anti-virus antibo<$r titres; howeveg the natural host
responds more promptly than the susceptible species (21). This
is similar to the Friend leukemia virus infection of susceptible
and resistant strains of mice discussed above, and is evidence for
the genetic control of resistance to the oncogenic effect of
viruses. That this control tabes place by an immune reaction
against the transformed cell, and not by anti-viral immunity, is
indicated by the fact that continuous lymphoid.astold cell lines
containing the viral genome can be isolated from both resistant end
susceptible species of monkey infected with virus.
In man Kochi* postulates cannot be fulfilled, so the implica¬
tion of viruses in human tumours is essentially guilt by associa¬
tion and extrapolation from animal models. There are, however,
a number of observations which indicate that the relation of Homo
sapiens and the Epstein-Barr virus (WW) is akin to some of the
surveillance models previously discussed*-
i) 30 - 90^ of adults harbour the virus, in all geographical
locations (22), and consequently have high arti-viral antibody titres.
ii) Human 3-lymphocytes can be nImmortalised" in tissue
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effects of chemical carcinogens can be readily disi ociated on the-
basis of dosagej both the inntmodepreagive and oncogenic effect being
apparent at high doses, and only the oncogenic e.f act at low (9).
There is considerable evidence, from in vitro cytotoxicity tests
an* in vivo concomitant immunity, for en immune -esponse against an
established tvour (vide infra), so the problem nay well turn on the
question of how many cells constitute a nascent tumour as postulated
in the original surveillance model. That is to say, there may be
0 threshold number of cells at which point immune recognition takes
place, but by -bis time the tumour has a "head start". The alerted
imrnun*" response may have a minor enti-tumour effect at this stage, but
in the main will be irrelevant, or possibly tumour enhancing (26).
It has been pointed out that experimental evidence for surveil¬
lance of carcinogen-induced tumours is contradictory (?), ranking a
synthesis impossible. Therefore, two seemingly unimpeachable
experiments will ^e discussed which lend support to the notion that
the effect of a carcinogen on an individual is decided by the geno¬
type, at the level of the cell (or organ) which is subject to the
insult of the carcinogen. However, there would appear to be a minor
effect due to immunological intervention.
In a well controlled experiment Stntman (27) examined the induc¬
tion of tumours by sub-immunosuppressive doses of methylcholanthrone
in susceptible and resistant sdce. Aft r being tolerleed to rabbit
IgG both strains of mice were treated with rabbit anti-mouse ALG, and
the incidence and latent period of tumours on application of methyl-
cholanthrene was measured. It was observed that in susceptible
mice the latent period and tumour incidence were the same in untreated
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miee and nice treated with ALG or normal rah-it IgG. However, in
the resistant strain ALG reunited in a doubling of trrrour incidence
and a slightly reduced latent -period. Resistant nice treated with
normal IgG, and ^treated mice, had tbe same turrour incidence and latent
period. This doubling of tumour incidence 'from ih^ to 33$) after
ALG treatment would indicate a role for surveillance in this system.
However the raa.1or part of the resistance (67$) would appear to be due
to non-immunological genetic factors.
In another system Heston et al. (23) transmitted lungs from strains
of mice resistant and susceptible to carcinogen-induced lung tumour
formation to the hybrid, and examined the incidence of tumour in the
transplanted lungs. The susceptible strain and the resistant
strain differed by at least •''our gene pairs and su*cemtibility *as
dominant. He observed that susceptibility and resistance were
retained in the lungs when transplanted to the F^ host, indicating that
these ccnee controlled the degree of susceptibility through mechanisms
limited to the lungs rather than some general systemic action. How¬
ever, it may be worth noting that the incidence of tumour in susceptible
lungs in susceptible hosts was slightly greater than with susceptible
lungs te F, hybrids, indicating n minor influence on suseeuti! ilifcy by
the F.j host.
However, is tumour immunology dependent on the cone ->t of ls-anne
surveillir e of nascent tumours *or its validity? Granted thet
surveillar e against carcinogen-induced, clinically unrecognised, in
situ tumours is weak or ron-eadstant, does this mean that when the
antigenic load la increased in a frank neoplasm, or the antigen is
presented to the host in a suitable w«y, the host is still unable to
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recocnlse it? Thi i latter p->int was recently exeadned by Andrews
(29) wvo showed that incipient tuteours produced by methylcholanthrene
were non-immunogenic unless the presentation of the tumour antigen to
the host was altered by full thickness antografting of the area con¬
taining the methylcholanthrene pellet. Unfortunately this proce¬
dure was ineffective with non-antigenic tumours. Furthermore, the
numerous studies of in vitro cell-mediated cytotoxicity (for review
see 30) and the reports of concomitant tumour immunity (31) indicate
that although surveillance of nascent carcinc -en-induced tumours is
ineffective, there may yet he antigens that can be exploited.
It is o' considerable interest to note that both responsiveness
to carcinogen-induced tumours, and indeed the tumour antigen produced
by the carcinogen, may be controlled by the H-2 complex. Thus,the
well known phenomenon of hybrid resistance or allogeneic inhibition
can he explained by proposing better recognition of tumour antigens
by certain genetic backgrounds containing the relevant IR genes.
T is would be analogous to the virally induced tumour systems discus¬
sed earlier, although the degree of recognition is much smaller.
V&llisms et si. (32) have examined the growth of a carcinogen-induced
tumour in the parent strain end various hybrids. By using con-
genic mouse strains the increased survival times could be related to
the H-? type of the host, some hybrids exhibiting resistance and
some not. The results indicated that in this system a single IR
gene was inadequate to explain the hybrid resistance and it was sug¬
gested that interaction of more than one F-2 genes was possible. It
was also demonstrated that mice identical at the H-2 locus but
diffirent at other loci could also exhibit different degrees of
-tig*
resistance, presumably of a non-issuaological nature.
There i" al~o evidence that connects the H~2 type to the anti¬
genicity of tumoure. It hai been suggested that cytotoxic ?-
lymphooyte* can recognise lyngeneie H-2 determinants that hare
become "re-arranged* by riru* infection (31) or chemical notifica¬
tion (%). furthermore*the major histocompatibility complex
determines cucecptibility to cytotoxic ?-c«Xls directed against
minor hi - toco??patibility antigens (3?). It is therefore tempting
to suppose that tumours, at least those subject to T-wsll control,
might be recognised by such a mechanism. Tor virus-induced
tumours there is rearon to suppose this might be the care as it has
recently been reported (36) that the H-2 region of the murine sarcoma
virus- trans formed target cell is iagjortant in iji vitro ?-eell cyto¬
toxicity.
For carcinogen-induced tumour" the evidence is contradictory.
Oth at al. (37) induced a sarcoma in F^ hybrid nice and two isoantl-
genic variants were selearted by loss of one parental H-2 type. When
the specificity of the tumour-ar-ooiated transplantation antigens of
these variants were compared in F^ mice it was found that the trans¬
plantation antigen,*! did not cross-react, thereby indicating that the
loss of the H-2 antigen was associated with the loss of the tumour-
sspeelfio antigen. An odd feature in this experiment was the find¬
ing that the original F^ tumour va-- non-antigenic in the host
whereas the variants were antigenic. Klein et al. (3'),using
somatic tumour cell hybrid® end variants selected for loss of parental
chromosome 17 (known to code for major histocompatibility complex),
■bowed that lots of either parental chromosome resulted in Ids'- of
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antigenicity when tested in a homorygous parental strain. They
concluded that the tumour-specific antigen was not localised in the
na,1or histocompatibility complex, ut its expression was controlled
by it. There nay be some similarity between this mechanism and
the control of T-cell recognition of minor histocompatibility anti¬
gens by ma,1or histocompatibility antigens which are on different
chromosomes (vide supra).
The hypothetical anti-tumour mechanisms discussed above depend
on T-cells and are suMect to control by the ma "or histocompatibility
complex. There are, however, reports of non-T and non-*b-cell killing
of tumour cells across H-? barriers. This activity would enpear
to be directed against a Moloney virus-induced antigen (J") and occurs
naturally in certain strains of mice. It is 'mown that in vitro
killer activity and in vivo resistance correlate !«&th the H-2 type of
the host and it has been postulated that these effects are exerted
through IR genes.
Another source of antigenicity in tumour cells is mbryonlc anti¬
gen. These antigens are putatively cross-reectine and although in
some reports the relevant negative controls (with normal tissue target
cells to exclude non-specific background noise) are absent, the exis¬
tence of cross-reacting antigens se<ms beyond dispute. It has b en
suggested that tumour-specific transplantation antigens are of embry¬
onic nature, normally not expressed in fully differentiated non-neo¬
plastic tissue (hO). However, the findings that lyr ph-rtode cells from
multiparous rats (hi) or mice (h2) can kill a range of ttaour types
in vitro, and that trsrsplstation «« igsna can be demonstrated
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in vivo on cells that lac"* embryonic antigens in in vitro tests (h3),
indicate that cross-reacting embryonic antigens detected in vitro ere
different to tumour-specific transplantation antigens. This posi¬
tion was formally demonstrated by Fritze et al. (h)i) who showed that
tumours raised with different chemicals, in the same strain of mice,
did not cross-react in transplantation tests hut the mice were able to
produce antibody to the tumours which cross-reacted completely in
complement-dependent in vitro antibody assays. In this experiment
however, embryo cells could not absorb out the anti ody activity.
Although in vitro detected cross-reacting embryonic antigens are
separate from tumour-specific transplantation antigens, are they exp¬
loitable by the host to combat the tumour? The answer to this is
complex as it depends on a) the genetically determined capability of
different species and different strains to respond immunologically to
foetal antigens; b) the quantitative expression of foetal antigens
which can vary between tumours; c) the modulation that foetal anti¬
gens may undergo in vivo (U3)« Thus Cg-pSl mice, which are good
responders to foetal antigens (liV), can he immunised with foetal
tissue against a syngeneic fibrosarcoma which has a large amount of
foetal antigen on its surface, as detected in vitro (h3, U1?). Under
less favourable circumstances foetal immunisation may be ineffective
(U6).
In addition to the factors discussed above, there is evidence that
the mode of presentation to the host may influence the effectiveness
of foetal immunisation. Thus, only I-irradirated foetal cells induced
immunity in hamsters against SV-hO transformed cellsj viable cells did
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not (U7). Furthermore, Forbes showed that the patterns o * cross-
reactivity when syngeneic tumours were used as immunogens with
reundk complete adjuvant were different to when they were used for
challenge (US).
3. NATURE mggn NURTURE AS ETIOLOGICAL FACTORS IN HUMAN
NEOPLASIA
The age old dispute between what Dobzhansity (US') has called
the mytfaa of Genetic Predestination and Tabula Rasa is apparently
in the process of being reconciled by the following formulation.
All individuals are bundles of particular potentialities which can
be called forth, or left dormant, by the action o. the environment.
Medicine affords numerous examples of the interaction of genotype
and environment. These include schizophrenia, haemophilia and,
perhaps the beat understoc ^phenylketonuria.
The study of phenylketonuria has been rendered considerably
easier by the discovery of a genetic marker which is the cause of
tike disease. !he physiological defect is disturbance of the
metabolism of the amino acid phenylalanine, accumulation of phenyl¬
alanine in the body fluids causing irreversible brain damage.
Thus, phenylketonuria can be s. own to be due to a recessive gene,
untreated homozygotes suffering severe mental retardation. Row-
ever, the r ivironaent of such individuals can act ko fret them from
their generic constraints. If the disease is diagnosed early
enough lta manifestations can be controlled by a diet nearly free
of phenylalanines diets coming assuredly from the environment.
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The above example illustrates a principle aid is not typical
of all nature-nurture interactions. In practice it is not always
possible to manipulate the action of the genes due to our present
state of knowledge (or ignorance). Thus, in some conditions such
as schizophrenia, which have given hints of a genetic component, there
is no obvious genetic marker to give a handle for investigation, or
the condition may be under polygenic control^which may be the same
thing.
In oncology there may also be examples of the nature-nurture
interactions. Thus, MSller has recently proposed a scheme in which
oncogenicity is linked to mutagenicity; the carcinogen accelerating
the appearance of rare genetic changes leading to neoplasia. The
oncogenic event could take place by carcinogen binding to the OffA
and initiating errors in replication, or possibly a somatic mutation
could occur daring repair of the ERA lesions caused by the carcinogen
(50). It may be envisaged that the lesion induced by the carcin¬
ogen is random, leading to unique tumour antigens, whereas the
oncogenic lesion of virus-transformed cells would be expected to take
place at a specific point in the genome, leading to common antigens.
Support for this preposition comes from the work of Pialkow (51)
which indicated that the cells of many neoplasms were monoclonal by
means of the isozyme glueose-6-phoophate dehydrogenase and immuno¬
globulin idiotyne markers. This isozyme exists in allelic forms
and is I-linked. Therefore, heterozygous women will express only one
of the two alleles on each somatic cell, as only one random X-cbromo-
some is expressed per cell. Thus, tumour cells expressing only
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one »arker demonstrate that a frantr neoplasm is a monoclonal entity
(although a nwomt tursour in not necessarily m (*>2)).
If filler's schema is correct then,in a sense,cancer offers an
example of nature-nurture interactions! with the inimical influence,
in the rhape of the carcinogen, cosing fro® the environment. It
follows that this situation could be alleviated by identifying as
many mutagens an possible in the ■nrironnsnt, and promptly removing
the®. The former has been dona for tobacco (?1) but sociological
and economic factors preclude the latter.
It would be incorrect to see cancer as a disease afflicting
only po«t-inch**trlal nan. The evidence fro® fossil remains' of
bone sarcomata and other osseous tumours bears witness to the anti¬
quity of cancer, and is not inconsistent with the view that cancer is
coterminous with life ($0. Although it say be true that cancer
is evident in sngr environment, with the cmset of the Industrial
Revolution it becaae obvious that the milieu ntqjporting life was also
responsible to some extent for the incidence of cancer} some author¬
ities putting the figure as hi# as 90% (<5).
Are there then any cancers which can be assigned to a unifac¬
torial genetic cause? The answer is yes,bat the conditions m
might be expected are rare (56)i polyposis coli, a precancerous
lesion of the large bowel, is inherited as an autosomal dominant
trait? neuroflbromatosisjin which tumour? of the nervous system
occur,is Inherited as a dominant trait; and another example may be
xeroderma pigmentosum,inherited a® a reees.-iw trait. In contract




















Epidemiological studies cm Japanese migrants to the USA (!>) showed
that the high gastric cancer rates seen in Japan also oretired in the
immigrants j the rates for Japanese born in the U3A were however much
lower than for their par«ntf<, although still greater than for American
whites. Conversely for cancer o'* the large intestine the rat® in
Irs?igrants rose rapidly fmsa the low level prevailing in Japan to
that of American whites. In contrast to these demonstration,® of
environmental influence It was found that migration failed to raise
the low breast cancer rates found in Japanese women.
It should he noted that despite the implication of genetic
factors in catteer, there is no evidence fron the cytological studies
carried out so far that specific changes at the chromosome level
lead to neoplasia (£?).
U. ESCAPE FROM IMWatOaPHVEILUgCg
If we take surveillance of cells transformed by various ubiqui¬
tous viruses as m established fact,then two questions become impor¬
tant i a) is the surveillance of transformed cells distinct from
antiviral immunity? b) how do transformed cells escape from sur¬
veillance?
R.T. Frehn (60) has stated that it is not always clear whether
the immunai response is active against virus-transformed cells or the
virus itself• However,if we consider the models discussed above
we see that for Marefc's disease there is no difference in virus shed-
ding between infected assistant or infected susceptible chicks,or
between untreated and vaccinated susceptible chicks j in spite of
large differences in tumour incidence (61). In polyoma oncogenesis
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autiviral immunity, induced by passive transfer of antibody or killed
viral vaccines, does not protect against the outgrowth of transformed
cells. However, immunisation against polyoma-indneed cellular antigens
does, in the absence of antiviral antibody (62). Furthermore,
there is evidence in monkeys and nan that the levels of antibody to
K. aalmlri and EJW antigens respectively are not directly related to
the tumour incidence (10). In the case of feline leukemia virus
(FeL?) the situation is the reverse of polyoma oncogenesis, FeLV-
transformed cells being recognised by a viral envelope antigen on
their surface (l£).
The central question of tumour immunology is whether, at some
stage, the proliferation of a nidus of malignant cells in humans is
capable of being checked by immune surveillance. One might expect
ncomorts would afford excellent substrates for such experiments? how¬
ever, more investigation seems to have I een done on live subjects.
In a Bcientifically correct but ethically dubious study Brunschwig et
al. (63) showed that large numbers of autotransplanted cells were
necessary before a take could be achieved. An optimistic view would
be that this was due to an immune reaction.
Another study examined the fate of tumour cells inadvertantly
transplanted with a renal allograft (6h). In two cases it could
be unequivocally shown that recipients on immunosuppressive therapy,
with distant metastases, could eradicate tumour deposits if the primary
tumour (transplanted kidney) was removed and immunosuppression was dis¬
continued. It should be noted that discontinuation of immunosuppres¬
sion alone was inadequate. Although the malignancies were rejected
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as allografts the hi3 tocospatibi21 ty match must hare been good a??
the ktdMgra had achieved normal function at 1 and 36 months, albeit
under liaasamoKupprefffiion.
Although iratnjnosurveillance against nascent tumourr- appears to
be a perfect example of this next® that "yesterday's troths become
today's special eases*, considerable ingenuity has bem expanded in
formulating escape mechanisms, some of which have taken precedence
at various stage® in the evolution of tumour iasunology. The
following list is taken from Klein (62)t
a) Inadequate recognition of tumour antigens (lack of
antigenicity of tumour)
b) Xasnatoreslstanee
e) Giavral in unodeficiency of the host
d) "Sbeaking through"
e) Abb*, itlen in the irrrune raapQBaa.
a> Inadequate recogxltlop SLSS&BLJSMBSBS.
It does not follow that because a tumour 1# not antigenic in
rejection test®, that its cell membrane is indistinguishable Prom
that of a norr.al cell. Indecdjif contact inhibition is taken f»
a measure of the difference between malignant and normal cells then
all Balignant cell lines are different. What it does mem is that
the tumour antigens are not recognised by hosts of a given genetic
constitution! example* of this for virus-and ** arcino•?m-Induced
tumours have been discussed in the section on ffurveillmce. Al¬
though ®ost of the flMMMI virally induced tumours are well reeogBtsed,
it would appear that the carcinogen itself is i important in determining
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whether carcinogen-induced tUROur# are recognised in the syngeneic
hort. Thus, nethyleholanthrene and dimetbjrlarsdnoaroben?ene
elicit well r**opilled tunours in the syngeneic host, wherea? ace-
tjlaKlno -fluorenc -indnred tumour? are not detectably antigenic In
rejection teste (6<).
An analysis of the data on lymphocyte Rilling o* tumour cells
in vitro '-oilId seen to allow the following formulation: an.irsal
tumors peases* unique antigens which elicit rejection responses,
and common essbryonlc antigens which in general do not. Ftiman
tumour' nay possess tumour antigen# which are peculiar to the his¬
tological twaour type (30). Baldwin ha* speculated that erosr-
reacting antigens detected in vitro,In both hnnaes and aninals,nay be
of -irailar significance (66). X' this is so, previou* attempts
at prophylaxis with embryonic tissue ir animal models do not hold
out much hope a* they hare met with only limited succes* (!b3).
Interestingly, in mice,the refection of a syngeneic tumour transplant
a*ter embryo iEKani^ation eeens to occur only in mice with a €<?B1
genetic background.
Reasons "or the inefficiency of embryonic antigens as trans¬
plantation antigens hare been postulated. Baldwin has disett"sad
the possibility that tumour-associated embryonic antigen* are exp¬
ressed transiently on the cell surface,dua to intracellular location
or feeble attachment to the plasma »»rbrene (!;1). Klein has
ruggested (10) it may be because tissue differentiation antigen
expression is nodulated in simo by antibody, via nechanisns akin to
the thymus - leukemia jmticen ny»te» (67). Indeed,Lapp# (6 )
control that * crucial function the immune system is to "orch¬
estrate" tissue development in the embryo and keep cell types at an
appropriate level of differentiation. Thus tumour immunology is
subsumed under this general heading.
b) laagunoreeigtmce
Variability arises in a tumour sell population In an apparently
ran lorn, genetically stable, clonal manner,as evidenced by the pro¬
gression from solid to ascites tumour (69). When a selective
pressure is exerted on these variants by an iaaaune reaction against
a specific antigen, cells with reduced amount; of the surface antigen
will grow preferentially (70). As the .select!on exerted by the
immune system is via the cell phenotype and not the mechanism by
which it arose,it might be expected that, like drug resistance,
irasunor siatance can have a variety of underlying mechanisms. In
two ismronorcsistent tumour lines studied by somatic cell hyrbl Ra¬
tion (10), It was found that the Ehrllcb ascites tumour suppressed
cell antigens on its partner cell and that these reappeared after
chromosome loss from the hybrid, suggesting that the Ehrlieb cell
suppresses antigenic expression la a dominant fashion. Conver¬
sely another imsmnorcdistant, H-2 antigen deficient,tumour line
regained its antigen complement on hybridisation with a normal cell
line.
c) Immunodeficiency of the host
Studies on the incidence of neoplasia in Vadef nice and in
iswunodeficlent human subjects show some agreement. Thu*,in W-'e*
mice reared under germ-free conditions a high degree of spontaneous
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lyrphoretieular neoplasm-*, wr noted in homozygous nice md a virtual
absence in their haired heterozygous littermates (conversely the
incidence of carcinogen-induced fibrosarcoma? ««s siadlar (71In
humans there is no doubt that primary iraaunodeficiency states favour
development of leukesd.es and lymphoma** over other malignancies.
Indeed,each form of primary 1re-iunodeficiency seems to be a**?ociated
with its own constellation of malignancies (72). Furthermore,in
an analysis of 6,297 immmosuppressed transplant patients the risk
of reticulum cell sarcoma development in men was 350 times great4r
than expected, whereas in women breart cancer was not increased (73)*
As the increased Incidence of lymphoretleular tumours is not in
complete accordance with the surveillance theory, other explanations
have been advanced»-
i) Chronic mtlgen stimulation accompanied by lack of suppres¬
sor activ"" ty. However$it should be noted that no diff©ranee
in observed and expected incidence of lympboreticular tuaourt
waii observed in leprosy patients,who are subject to iicsnmo-
depresrion and chronic antigen stimulation <Tii)»
ii) Infection with lymphocytotropic herpes virus due to iaauno-
suppreealen.
iii) Oncogenic effect of iawmodepressant.
d) "Sneaking through"
This term graphically describe© the situation ids en a small number
of tumour cells will Hake",when a larger n« 1 r is rejected,and a
larger mahar still will overwhelm the host defences and also "take".
The factors involved here, such as the manner of antigen presentation,
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are of paramount Importance In defining suitable irmmotherapy
realises. What this mechanism demonstrates Is that the animal?
inoculated with small number? of tumour sells are not tolerant of
the tumour antigen, but that their immune system is inefficient
and 8iu**t be mobilised in an appropriate manner,
e) /bberafcion in the Iturunc response
This mechanism car be «wvleared as operating at the level of
the terpet or effector cell. Thus,free tumour antigen may
"blindfold" the effector cells{ tunour-"pecific antibody may impede
recognition of target sell ant! pen; or antigen-antibody coraplexe®
may do both. However, if as seams likely,classical iamurourveil-
lance is operative only in a limited context and that for the most
part nascent tumour? are unrecognised, then It follows that specific
antibody can play no oart in an escare "rora surveillance in the maj¬
ority of cases. This is not to deny however that antigen alone
nay promote escape of nascent tumours in the t$croenvironnent,or
that antigen, antibody, er corapJ.cxec may play some part at a later
stage in tumour development. At this time the concensus seems to
be that the scrum of animals bearing progressing tumour? contains
blocking antigen-antibody complex*?, whereas when the tfom is removed
the serum contains "unblocking" free antibody (6<).
The?e results were obtained using In vitro systems aid their
jrcneral in vivo relevance is questionable, It is,however, of int¬
erest that the systems in which "blocking" mr "unblocking" factors
appear to operate In vivo (7£) are the very <mm in which irmrnno-
surveillaioe wgjr be « reality, i.e. polyoma-an-i Moloney virus-induced
tumours in sd.ee.
S. EFFECTOR MECHANISMS IN THE imm RE5POH5E TO HTMOtTP.
JWTIfllWS
To m no thn« far j there »we»rs to be an iroame response
wans ted in the host to a variety of tumours. As a broad gener¬
alisation the response is of early onset in some virally induced
tumours (where it corresponds to classical Immubosurveillance) and
of late onset in some carcinogen-induced tumours. It remains
oneis to investigation whether tumours,that aire not dtteotably anti¬
genic at all in syngnelc systems, cam be rendered so by experimental
manipulation. On this last point the future of iumunotherapy,
as a credible alternative to existing cancer treatments, may rest,
a) T-cell response
Although the debt of tumour immunology to transplantation
immunology is great it may not prove to be totally beneficial. One
possible pernicious influence is the Idea that T-cells are the sole
immunological mediators of an anti-tumour effect in syngeneic systems.
However the central role of cytotoxic T-lynphocytes can readily be
demonstrated in allogeneic combinations. Thus,Freedman ggjj el. (76)
showed that a tumour allograft of DBA/2 origin was rejected in
Irradiated C,H mice reconstituted with immune spleen cells,but not
with normal spleen cells. They furthermore showed that snti-Q
treated immune spleen cells were ineffective but appropriately
sensitised thymocytes were, and not surprisingly concluded that the
rejection was due to T-cells. In various in vitro systems the
cytotoxic effect of T-lyaphocytea against allogeneic cells can be
blocked specifically by antigen, antibo<iy, or antigen-antibody
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complexes (77)j central and peripheral blocks also seem to exist
in vivo (7^).
There is good evidence in aloe that sub-sets of f-lymphocytes
are able to "scan" the H-2 regions of autologous cells,and can be
triggered by a "rearrangement" of the H-2 antigens into differenti¬
ation to helper f-cells or cytotoxic T-eells. A rearranged H-2
type could be an allogeneic cell (79h a virus-infected cell (*H)j
a chemically modified cell Oh)* or a lyrohoid/reticuloendksthelial
cell with antigen on its surface (^0). The production of eyto-
toxie T-cells against allogeneic cells, vlru--infected calls, and
chemically modified cells depends critically on the "re-arranged"
H-2 E and D regions, whereas the production of helper T-cells is
dependent on differences in the IR region ( l). It may be of
considerable significance for cellular co-operation in the immune
response that "*1 gene associated antigens (la antigens) are expres¬
sed on most macrophages and 3-cellr, but only tg sub-sets of T-cellf.
That is to say a sub-set of ""-cells suy "scan" la antigens on auto¬
logous macrophages and 8-eells for "re-arrangement" due to antigen,
before being "triggered" into pro11 feration to helper cells,
b) Ion T-cell response
Certain it is that the remarkable chromosomal region called
the Hafor Histocompatibility Complex is a unifying concept which
explains many diverse Immunological phenomena. However not all
iswunological reactions fall within its orbit. For instance
sensitization agfin-t xenogeneic tissue can b© at least partially
independent of T-cells (32). Thu<*,immunity against the !®A
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mastocytoraa is ?-cell-dependent in allogeneic sice but antibody dep¬
endent in rats (83). Also "nude" mice are notoriously free of
metastases after transplantation of xenogeneic tumour (9).
Furthermore, immunological activity against syngeneic tumour antigen?
raay (36) or asy not (cUj) reside in T-cells.
One mechanism of non-T-cell killing is antibody-dependent lym¬
phocyte cytotoxicity (ADLC), There is some debate as to the
characteristics of the effector cells and antibody involved, but
what is not in doubt is that specific antibody and Fc-receotor besrinp
effector cells are necessary. Some of the confusion may arise
because t^e source of antibody in in vitro assays may be either
extraneous, or from immune 8-cells In the effector cell peculation
(85). In the Moloney sarcoma/leukemia virus system, which has
perhaps been the most studied, it would appear that antibody activity
capable of rendering normal lymphocytes cytotoxic in vitro to Moloney
antigen bearing tumour cells is present in progressor and repressor
serum. However in the absence of antiko^ progressor lymphocytes,
compared to repressor lymphocytes or lymphocytes tested before
tumour development, were unreactive towards this antigen (85). It
should however be noted that autochthonous combinations of serum
and lymphocytes from progressor and rfpressor animals gave similar
levels of ADLC (86).
In contrast, using the same system but different assay techni¬
ques, Harada et al. (8?) found antibody capable of activating
normal lymphocytes in vitro in regressor serum only. These
authors also showed an excellent correlation between high levels of
serum antibody (as measured by immurofluores er -e) to the Moloney
antigen and recession of the tumour. The kim hies of antibody
formation In this system seem to parallel those in a complement-
dependent antibody s stem (88). Thus, Tamerius et al. found
that antibody to Moloney antigen in repressor mice was present more
often, and in higher titre, than in progressor animals.
In the non-syngeneic systems the ADLC antibody is generally
found to be IgG (83), although as yet it is unclear whether one or
all of the antibody classes and sub-classes is active in ADLC
■
against a syngeneic tumour. There would seem, however, to be no
doubt that passive- transfer o" antiserum with a high titre of anti¬
body to the Moloney-determined tumour antigen can be effective
against Moloney virus-induced sarcomas and lymohomas in vivo (89),
although it is noteworthy that regressions deoertd on an Intact
thymus (90).
The -niigen in question in the Moloney «arcom8/leuk<-mia system
is the Moloney leukemia virus-determirrd antigen which is present on
transformed cells producing MS7 and MLV (91). Transformed cells
producing only MS? (9i), or no virus at all (92), have been found to
be "non-antigenic". However, a^ter superinfection with MLV the
antigenicity is recovered. It is interesting in this respect to
note that s non-producer Moloney sarcoma virus-transformed line may¬
be antigenic in F, hybrids (93).
Another immunological cytotoxic mechanism, also directed
against the Moloney leukemia virus-induced antigen, has recently
been described (39). It appears to be different to the classical
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itamunologieel mechanisms in that cytotoxicity i? not dependent on
on intact thymus or specific antibody; also, the effector cell has
no 3-cell markers said appears in certain strains of ostensibly
uniTOTunined mice (9li). It is also different from in vitro T-
cell killing in that the effector cell can kill non-histocompati-
ble target cells (39). Using high responder (R) and low
responder (L) strains a genetic analysis, involving (R x L)F^ xL
back-cross mice, showed that in vivo and in vitro resistance to
Moloney virus-induced lymphoma cells was H-2 dependent ( JC0.
o) Macrophage response
There is evidence from concomitant immunity studies that
animals bearing chemically induced (96), spontaneous (?'•), and
weakly antigenic (31) aninal tumours have a degree of resistance
to further tumour transplantation. It is interesting that
animals bearing a primary tumour appear to be imperfectly immunised
against itj however, it can ' o rendered immunogenic in the autoch¬
thonous host by excising the primary tumour (98), or in syngeneic
hosts by X-irradiated cells (99). Conversely, using transplanted
tumours Fisher et al. (100) have shown that the degree of immunity
is identical in rets whether or not they are deprived of their
tumour burden. The first phase of concomitant immunity is specific
but the second phase, ar the tumour enlarges, f«? not (96). Cell
transfer studies support the theory that macrophages participate in
one or both of these mechanisms (1Q1).
Usin various criteria numerous authors report Infiltrating
macrophages in a growing, solid neoplasm, although not all are phago-
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eytic (102). The macrophage content is similar for primary and
transplanted tumours (103) and correlates directly with the immuno¬
genic! ty and inversely with ability of the tumour to metastasis©.
In addition, it is generally thought that macrophages, unless non¬
specifically stimulated, need lymphoid cells or cell products to
exert an anti-tumour effect. Thus they can be activated in vitro
and in vivo to kill target cell monolayers in a specific manner.
Furthermore, it has been reported that macrophages derived from anti¬
genic solid tumours are specifically active in vitro against tumour
cells j however, macrophages from a non-antigenie tumour were not (lOii).
Support for co-operation between cells In control of tumour
growth comes from the observation that tumour cell populations,
deprived of macrophages ' y trypsin-resistant plastic adherence,
produced metastases when injected into syngeneic hosts. However,
tumour cell populations deprived of all infiltrating host elements
did not metastasize (103). Cell co-operatics in combating human
neoplasia appears a reasonable proposition when it is considered that
some breast tumours contain 10 - 30% macrophages (10*0, and that sinus
hlstocytosis and follicular hyperplasia are associated with a good
prognosis in breast cancer (50.
d) Antibody responses
In the early days of contemporary tumour immunology GSrer (106)
emphasized that isoasatibodies could act synergistically or antago¬
nistically with lymphoid cells. Another pioneer, Prehn, has con¬
sistently argued that an incipient immune response is harmful and
promotes tumour growth, whereas a full-blown response is beneficial
 
•3S-
Tbere is no evidence that antibody is effective against cojid
ttnourr stid indeed it nay occasionally enhance their growth.tfLth
regard to disseminated intravascular tumour cells (leuVenla and
metastatic calls) the situation may be different. thus,using
suitably absorbed xeno- or alioantisera a protective effect
against syngeneic lymphomata could be obtained (111). Tumours
that do not metastasize in the syngeneic host can be induced to do
so by i?»inunosupprerfsive treatments such as AL3 (ill), thoracic
duct drainage, and thymectomy plus X-irradiation (11!?)* There
is a correlation between the ability of a tumour to Metastasize
and its Macrophage content (tt5X, and it has bom shown that tumour
cell populatic selectively depleted of macrophages may metastasize
(103).
It is of considerable interest that tumour cells depleted of
macrophages by continuous culture do not metastasis# (lOf), suggest¬
ing the growth regulatory role of macrophages is itself influenced
by humoral factors md/or cellular elements which are removed by
continuous culture. Proctor et ftl. (116) hare also detected m
immunologically specific humoral factor which urevanta the occur¬
rence of lung metastases in rats with localised tumours. Pretm's
group hare recently confirmed earlier data,which suggested, tha
presence of an mtitody specific for antochihoneur hxmsa rclmous
cells in the cora of patients with localised disease (117).
Patients with metastatic spread did not possess this antibody acti¬
vity. In a rirdlsr human system It has been postulated that
tumour-spedflc antibody activity may be depressed due to a specific
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antibody against the tumour-specifie antibody, and not due to
antigen -anti ody complexes as generally supposed (118).
It will be obvious from the above that antibody alone, or in
conjunction with cells, is potentially canable of mediating numer¬
ous effects concerned with the growth of tumours. This however
is catered for in the polymorphism exhibited by antibody classes
and sub-classes.
6. AUGMENTATION OF IMMUNE RESPONSE TO TUMOUR AHTIGMS
It may not be completely illusory to say that all tumours have
antigens (6$), although not necessarily recognised or capable of
mediating tumour rejection (hit). The central problem may then
be to promote a rejection reaction in the host against such anti¬
gens, that is to overcome immunological unresponsiveness. As
yet there is no agreement as to what factors, or combination of
factors, constitutes a rejection reaction. However, immunological
theory offers at least two ways in which unresponsiveness may be
overcome. These are a) the action of aduvants such as C.parvua
and SCG} b) by coupling the unrecognised antigen to a carrier that
can be recognised by the host, for example by chemical modification
of the tumour cell surface or by the use of somatic cell hybrids,
a) Action of adjuvants
The principles of tumour immunology could have been vindicated
by the unequivocal success of immunotherapy. Such success, however,
hsa not attended efforts to passively transfer immunity, and active
immunisation seem most ^effective" when tumour antigen is injected
together with, adjuvant. The most widely used adjuvant in clinical
trials has been BCG, and with some reservations about retrospective
controls in clinical trials, it would appear that it is beneficial
to some extent in the treatment of human neoplasia (119). Thus,
Mathe' et al. showed that in acute lymphoid leukmraia patients brought
into remission with chemotherapy and maintained on BCG plus allo¬
geneic leukemia cells, there have been no relapses in 1* years. This
is in marked contrast to what usually occurs with patients on mainten¬
ance chemotherapy. Gutter-man jst al. reported similar findings in
adult acute leukemia patients using BCG only. In contrast, Russell
et al. using a different BCG to the above authors reported that
acute myelogenous leukemia patients in readssion all relapsed,
whether treated with chemotherapy or chemotherapy plus immunotherapy
(BCG plus allogeneic cells). The most noteworthy fact about this
study was the markedly increased survival time of the immunotherapy
group after relapse compared to the chemotherapy only group.
There are a number of reasons which would account for the
differences in the results of Mathe et al. and Russell et al. The
disease is different and in acute myelogenous leukemia the prognosis
is generally worse than acute lymphoid leukemia. In addition,
the Glaxo BCG used in the unsuccessful trial hes been shown to be
considerably less efficient in animal tumour models than the Pasteur
BCG used in the successful trial (119).
for tumours in which an objective minimal residual disease
situation is hard to attain, some clinical improvement has also been
reported after adjuvant therapy. Thus, Morton et al. report that
intrelesional BCG is "a most effective treatment" for localised
and in edition rwy have a tnall effect in tenia of recur¬
rence and survival rate*, a- an adjunct to *urgery in 9t.r-*e H and
III relanora patients. Gutternan et al. report that In dissem¬
inated breast cancer patients brought into partial remission with
chenoth'-rany, rem! *r ion and -urvival are prolonged on subsequent
treatment with chemotherapy pin' ^CQ compared with cbemtherapy
alone ("H9).
The literature on the clinical u*e of C.parvum a* an anti¬
cancer agent in man is not as extensive a - for bCG, although in
arsimel model* it would «eem to be a effective a« BOG. There
ia iapreasslve agreement a? to the mode* of action of C.r arvtm as
an srtUr-oanecr agent in experimental models (120, 121, 1??).
Admini "stored systemically (i.p. or l.v.) it exert* a predominantly
thyvms-indepcndent snti-tumour effect in which growth of tuncror-
i» inhibited in treated mlmal* hut no repr*':" Aon* occur. ^hen
adrtLni'tered intralesionally or mixed with irradiated tumour cells
the effect is specific, T-cell-iependapt,and result* in freouemt
tumour regrec-ton*. Generally the systaaio mechanism need- wore
C.parvum then the local infection, sad it ha* recently hears shown
that in none case* pre ensitla ation with C.r>arena fail* to modify
the anti-tumour effects mediated by either meehanina (121). In
addition to direct activation of macrophage* and the potentiation
of the tumour- sped fte re'TX*n««, C .parvum-immune ?-cells msy also
activate nswroph&rr^ indirectly (1?U) at a later stage than direct
activation.
It eight be envisaged that different Permutation* of these
mechanisms, together with humoral mechanism.*? recently described
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(if), would participate in cny #rrn situation depending or the
tunor-hoct relationship. Thus,it fear bean shown that tSi two
different tusaonr-ho t swtelr the route.? of f .parvus** Infection that
gave optimun protection were different for each atodel. Use
rpVnectoiqgr abolished the protective effect of Cvpsrmr in arte modal
hut not the other (126). More than one mechanism r*y re11 oper¬
ate in the »y«tanie snti-tur-our effect ■ eeattse g.parrur, although
•.•till active in ?-cell-deprived mice, in not as effective a* .in
intact nice (127).
There is some *us/»jreation that Raerophaa^r activated with high
doses of C.parttaa yupppaas T-cell killing in Cr-relea* e a"- *$■«
{if"5). A direct extrapolation to the in vivo situation would
Indicate that T-eell l&lliiip as such i* unimportant in uediating
the «B»ti-twa©MP effects of C.parrra. Such conclusions however
should He treated with reserva.
> ) Activation of helper T-cell?
It has been postulated that hlctoconcatelbllitgr linked IT gene*
Hm a role la the recognition function* of f-lymph©cyte?,i« *aa»
way comparable to the imnunoclohulin sysia* (129). The general
feature* of responses regulated "*-y H-linfced IB' fane.- are* 1) The
rosponaas are T-ocll-dependent lit evayy eacej there have not been
K-lirskad IR rents identified that control antibody response*? to T-
ind<mc«n<lSRt antigens? 2) The IP panes control the carrier recog¬
nition function of T-colls,either in the davelopwwtt of helner T-
eella for ^-lyiaphocytes or in the elicitatlm of call-medishad
Inmune response*? "*) The absence of carrier function at the ?-
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cell level in en individual lacking a certain IR gene, and thereby
preventing a response to an antigen, can bo circumvented by linking
that antigen to an immunogenic "carrier" molecule to which the
individual is capable of responding at the T-cell level.
Attempts to overcome unresponsiveness to tumour antigens based
on the above have not received a great deal of attention, although
there are some indications that they have some chance of success.
Jasd. and Rita have shown that it is possible to immunise mice
against syngeneic tumour cells by inoculation of somatic cell hybrids
having such cells as one parent and allogeneic cells as the other
parent. Furthermore, the hybrids expressed their tumour-specific
antigens in pure bred mice even when -they did not produce tumours in
the F.^ hybrid (730). Chemical modification of tumour cells has
also been reported to render the® immunogenic in the syngeneic host.
Thus, indention of mice with glutaraldehyde-{131) or trtnitrophenol-
(132) treated syngeneic tumour cells has been reported to result in
rejection of s challenge with untreated viable tumour cells. In
the first example, however, most of the activity could be ascribed
to a non-specific inflammatory response to gluiaraldehyde-treated
cells.
7. PURPOSE OF THE PROJECT
During the last few years there has appeared some evidence, and
considerable speculation, concerning the roles of lymphocytes (30),
macrophages (733) and serum factors (30) in tumour—immune processes.
It therefore seemed timely to examine a model of tumour immunity in
-14*!-
detall, and to dissect the mechanisms involved by means of in vitro
assays of cellular (and humoral immunity. The model chosen was
the immunotherapy of a CBA mouse methylcholanthrene-induced fibro¬
sarcoma, with the adjuvant O.parvura.
It was originally envisaged that the proieet would be divided
into three separate, although ideally integrated, parts, The
first part was concerned with extending the observation that C.parvum
produced inhibition of tumour growth in vivo, and elucidating the
mechanisms involved by the use of lmsramosuppressive procedures such
as thymectomy and X-irrediation.
Part two was concerned with developing an in vitro assay of
cellular immunity against syngeneic tumour cells. The technique
chosen was the cytostatic assay, which utilises the in vitro uptaire
of a thymidine analogue by tumour cell monolayers to assess the "snti
-tumour" activity of effector cells. After showing that the cyto¬
static cells in C.parvus-treated mice were macrophages, this work wan
concerned with showing a correlation between the in vitro and in vivo
anti-tumour effects in C.oarvom-treated nice, eg. in T-ce11-deprived
and X-irradiated rdcej and also with examining the possibility that
macrophages could be activated in vitro with lymphocyte products.
Part three of the project was concerned with examining the
general humoral immune status of mice, either bearing a tumour or
treated with C.parvum. This was done by assessing their ability to
form antibody to defined antigens such as sheep red blood cells.
Work was also undertaken to examine directly the. humoral response to
tumour elicited in mice treated with C.parvum. An isotonic anfci-
-U2-
globulin assay, which measured the in vitro uptake of souse israuno-
globulin onto target cells, was used for this. In addition, anti-
C.p rvugi antibody and serum immunoglobulin class and sub-class levels
were measured concurrently.
It was considered that m investigation of the involvement of
immunoglobulin classes and sub-classes in tumour growth might help to
reconcile the apparent differences between, for instance, blocking
antibody, unblocking antibody, cytotoxic antibody, and antibody promot¬
ing cell-mediated cytolysis. As the complexity does not and with
the above examples, but extends to the antigens against which the anti-
tody is directed, and the mechanisms by which antibody is produced,
these factors are discussed below.
a) Immunoglobulin classes and sub-classes and immune phenomena
!aJhile ad uvsnts are being increasingly used in the immunotherapy
of tumour", there are few reports on their effect on immunoglobulin
classes and rub-classes, or on the development of serum antibody which
interacts with tumours. We felt that studies in this area were
warranted for the following reasonst-
1) M uvants are known to have a variable effect upon the sub¬
class of antibody elicited in response to other antigens (13U,135).
2) C.parvum, which is widely used in tumour immunotherapy^has
been shown to exhibit a differential effect on IgO sub-class
levels in man (136).
3) IgG sub-elasses are known to differ widely in their in vitro
and in vivo properties, including their ability to promote antibody-
dependent cell-mediated cytotoxicity (lb), md their ability to
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ftx complement and promote opsonization (133).
h) There is preliminary evidence that the blocking activity
which abrogates the cell-mediated destruction of tumour cells
in vitro espy be confined to certain sub-classes (139).
There is some debate as to whether C.parvum exerts its ad'uvant
action on T-cells or non-?-cells (ie. 8-cells or macrophages). It
has been suggested that C.parvua is primarily a 3-eell adjuvant and in
certain circumstances it can enhance the antibody response to type III
pneumococcal polysaccharide (1I1O). In addition it can enhance the
antibody response to SR3C in experimentally produced •3'-mice. Other
indirect evidence that C,prrvum acts primarily on 3-cells comes from
the o nervation that it affects the IgG, sub-class response the least.
The significance of this is that the IgG, zntibOdjr response is thought
to be the most thymus-dependent (1L.1).
It would appear that to demonstrate the T-cell-independent
adjuvant effect of C.parvum on the antibody response to SRBC the
ad'uvant must be given before the antigen. Thus,intact mice
injected with C.parvum and type HI pneumococcal polysaccharide simul¬
taneously do not show an enhanced tyne ITT antibody response (1Jj2).
'^irthermore,"nude" nice injected simultaneously with C.o;yvu^ end SRBH
failed to show an enhanced anti ody response, although intact mice did
under the same conditions (l3h). In addition to the dependence on
the time of adjuvant administration with respect to antigen, the
adluvmt effect of C.parvum may also depend on the dore, route of
adminlstration, and the physical nature- of the antigen (t3li). This
latter point may make comparison of results obtained with SRBC and
~bk~
tumour cells rather difficult, although there are some parallels
between the two systems as both seem to involve 7-oe11-dependent and
T-cell-independent effects.
It has been observed that unless a given dose of antigen is itself
large enough to elicit an Immune response, an additional injection of
adjuvant will not help to initiate sueh a response (1350. Thus,®
small dose of SR3C will elicit an IgM response but not an IgG^ responsej
an injection of 3.pertussis will increase the IgM response but does
nothing for the IgG^ response. However, once initiated the response
can be radically changed; for instance an injection of adjuvant can
make the difference between tolerance and specific antibody formation
(lU3)• The former result suggests that B.pertuesis may act by
mechanisms other than by effectively increasing the antigen dose;
conversely, the latter is compatible with the notion that it does in
fact do so. These phenomena may reflect T-cell-dependent and T-
eell-independent mechanisms respectively. The T-cell-dependent
activity may be due to the adjuvant stimulating T-cell proliferation
(135>)» whereas the T-cell-independent activity may be due to an
effectively increased anMgen concentration presented to 3-cells which
therefore do not need helper T-cells. The latter could be via
activated macrophages or antigen depot formation as is the case with
Freund's complete adjuvant.
It is of interest that whereas C.parvus (13k) and B.pertussis (1350
enhance the IgGp response to SKBC, only the latter gives a comparable
increase in the IgG^ response to this antigen. Again this may
reflect the fact that B.pertussis is more dependent than C.parvum on
-h$-
T-cell-mediated mechanisms of adjuvssxt expression.
It has been a consistent, though little studied, observation that
animals injected with Fpeund's complete aduvsnfc alone show a large
increase in Mm iimunoglobulin. When an antigen is added to the
adjuvant a large proportion of the extra &-globulin is specifically
prccipitable by the antigen. Humphrey (II4I4.) has put forward the
following possibilities for the presence Of extra <5 -globulin in the
absence of added antigens a) non-specific stimulation of antibody
production against antigens which the animal has experienced in its
past history! b) antibody against constituents of the adjuuant (eg.
the tubercule bacilli)! c) autoantibody agrinat tissue components
altered by the adjuvant! d) genuine non-specific ^-globulin produced
by stimulating ^-globulin producing cells without this bearing the
impress of & particular antigen.
In experiments to decide between these alternatives rah' its were
injected with an antigen end when the titre of specific antibody sub¬
sided Freund's complete adjuvant was injected. It was observed that
although the serum ^-globulin level rose the titre of antibody
specific for the pre-injected antigen did not. In another experi¬
ment it was shown that then all of the mtibody activity against the
tubercule bacilli hod been absorbed, out there was still a considerable
excess of 'S-globulin unaccounted for. As it could also be shown
that autcantibody against normal tissue we® not raised after adjuvant
injection it was concluded that the excess <5-globulin production was
mainly due to a genuine non-specific or random mechanism (1 U>).
The phenomenon, seems to occur in other species, as injection of
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C.parvum into hum an? (136) and alee (lii5) resulted in increases in
serum IgQ? and IgG^ levels respectively. However these may not
be directly comparable as mouse and human IgG., are thought to be
homologous (138). In chickens elevated ser^ 6-globulin levels
after adjuvant administration were found to be dependent upon granuloma
formation at the site of injection and a delayed-type hypersensitivity
response to bacterial constituents of the adjuvant (1I16).
The biological activities of Immunoglobulins may be divided into
two categories« the specific reaction with antigen via the Fab portion
of the molecule, and the consequences of antigen-sntibddy reaction
mediated via the Fc portion. r 1eossorphisa in the Fab region is of
necessity almost limitless; however,structural, variation in the Fc
region also occurs on a more modest scale. This may indicate a
corresponding range of functions for immunoglobulins in immune proces¬
ses. Five classes of immunoglobulin have been defined in man on the
basis of non-cr ss-reacting antigenic determinants on the Fc portion,
and these have further been divided into so celled sub-classes accord¬
ing to minor antigenic differences in the Fc region. As the sub¬
classes as well as the classes reflect a distinct amino acid sequence,
the distinction between classes and sub-classes is rather arbitrary.
This is particularly so in the mouse where the cross-reactivity between
IgG sub-classes is less than for human Ip-G sub-classes (113).
As animal work is expected to have some relevance to humans, it
is necessary to compare the immunoglobulin classes and sub-classes of
man and mouse. Analogies between immunoglobulins of human snd other
-»t?~
species are usually made according to ohysiocheiaicaLl similarities or
r.b* mlc i ll|»i MUX lintUlUTi Thus,IgO has the slowest elecfcroohore-
tic mobility and a relatively low molecular weight? IgA forns polymers
and binds to secretory component in the gastrointestinal tractj and
I r:M is a maeroglobulin of a" out ''00,000 Daltons. Wo direct
relation '-etween human raid mammalian InC- sub-classes has been estab¬
lished, although Tg01 raid IgG^ in humans are probably analogous to
I«0g and IgG?b in mice (11°).
Of the phenomena that may be mediated by particular classes or
sub-classes of imntunoglobulin ,that of in vifrro I locking of cell-media ted
cytotoxicity has been the most studied. There would seen to be no
doubt, at leapt in vitro. that turxrar-specific antibody combining with
a critical amount of soluble tumour antigen can "block" cellular cyto¬
toxicity against turour coll" ^';7\5 furtbermore,anfcigen antibody
complexes may "block" in in vitro models of immunological tolerance
OUfi). The investigation of the nature of the antibody mediating
the in vitro "blocking" effect is done by absorbing out a particular
anti ody class or sub-class said seeing if the "blocking" effect is
still present in the antibody deficient serum. It it is found that
only certain classes or sub-classes "block",and others do not,this
could mean that the phenomenon is confined to these antibodies. Alt¬
ernatively it could mean that the antibody that does not block has not
been produced in response to the tumour ant±-~en.
Using these methods it has been shown that the antibodies? in nmlti-
peroue mouse serum which "block" in vitro cell-mediated killing of
jaetkylcholanthrer.e-induced fibrosarcoma cells are of the IgC-,. end
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IrGov sn^-clssses In humans the In vitro "blocking* activity
towards tunoxrr cells from melanoma and colon carcinosis oatienis was
absorbed cmt by Stcphylococcus aureus which Is brown to bind selectively
to human IgG^, IfG^ end TgOj (l^O). Fnrthermore the "blocl'lnp"
activity against htossn neuroblastoma cells resided mainly in the IgQ
and IgQj sub-classes (139). It is of interest that souse IgQja
ipl thought to correspond to human TgG1 and X0L respectively (131).
M rcgstrde the antib ody participating in antibody-dcbendent
lymphocyte cytotoxicity (ADIT) in vitro, ^ollecb at si. (if?) have
shown in a syngeneic carcinogen-induced tumour systean that it can be
absorbed out of the serum op tumour bearing mice by an anti-monre
TrtfU serum. However experiments with other specific sntleera were
not nerforned. In another syngeneic virus-Induced tumour system
both 1 S and 73 serum fractions of repressor serum were able to nronote
AHLC in vitro. Furthermore in this system the IgM antibody appeared
to be active at high concentrations and the TgG *ntibo<tr at low (3*0.
In humans the antibody participating in ABIC mjy be confined to the
IgG class. Thus, serum from a choriocarcinoma patient could render
•mltaMe allo^neic target cells sensitive to ADLO end the antibody
activity was confined to the ?S fraction of gerura TTsinr the
whole range of human class and ^ub-class myeloma proteins it wan shown
that only IgO^ and TgG, inhibited AftLC in a xenogenie system using
^uman effector cells and rabbit anti-target cell antibody. However,
when the myeloma protein® were heat aggregated IpO,, also became
inhibitory (13?).
•4*9-
h) Antigen against which wantl-tumour" antibody Is directed
Antibody to syngeneic tumour cells has been demonstrated In the
serum of experimental animals by either excising the tumour or render¬
ing them immune to tumour challenge. A variety of techniques hare
been used such as the isotonic antiglobulin test (li!?), mixed haemabsor-
ption find complement-dependent lysis The level of
antibody observed is in general low by comparison with serum from
animals immune to allogeneic or xenogeneic cells, and the function of
the antibody in vivo is far from certain. It would mpear that it
is still to be unequivically shown, by extensive absorptions and use
of a range of malignant and non-malignant cells, that the antibody
response to a carcinogen-induced tumour can be directed towards tumour
-specific transplantation antigens. On the contrary, syngeneic asnti-
tunsaar anti ody is often fotmd to be directed against embryonic antigens
(h£, 1">6) and is cross-reactive with other tumour cells (Ui).
Apart fro® antibody activity against unique and common tumour
antigens there have been recent reports of naturally oocurlng antibody
against a variety of tumour types (1^7), end shared antigens between
bacteria md neoplastic cells (l?8). These observations may have
the sflne underlying basis as there is evidence for the existence of a
wide woeetruB of environmental antigens capable of cross-reacting with
tissue components of different mammalian species, including' histocomp¬
atibility antigens (1$9). Rapenort and Lawrence have surgested that
the need tor immunity against bacterial, fungal and viral infections
provided the selective pressures which culminated in an efficient
Uiymus-dependent imrane system. Presumably fortuitously,the cross-
-SO-
reactions between microbes and mammalian tissue antigens produced the
allograft reaction (t£9). In support of the theory these authors
advance the arguments that the allograft reaction appears to he a
secondary response and that certain bacterial tctigens can induce
allograft sensitivity in mammals. In addition the cross-reaction
between mammalian heart tissue and certain strains of Group A strepto¬
cocci Blight be considered (160).
c) Mechanisms by which antibddy may influence tumour growth
Complement-dependent cytotoxicity has been extensively used to
demonstrate antibody to tumour antigens. However,because this
reaction generally needs heterologous complement (161) the in vivo
implications are uncertain. It is of interest that the IgG sub¬
classes which most effectively bind complement (IgG^ and IpG^ in humans
and in mice (138)) may be the very ones that mediate in vitro
"blocking" of cellular cytotoxicity (lit?, 139).
Macrophages and monocytes are known to bind certain classes of
antibody, either free or oomplexed with antigen. In man monocytes
were shown to have receptor's solely for IgG, and IgG.,; only these
myeloma proteins inhibited rosette formation of IgG -coated heterologous
red blood cells (138). This may mean that IgGp and IgG^ are not
cytophilic or opsonizing; alternatively it could be that they are an
insignificant part of the response to red blood cells. It also
seems apt* rent that opsonising and cytophilic IgG^ and IgG-, antibodies
bind at the same site. A direct examination of the binding bet ecu
monocytes and IgG sub-classes by autoradiography revealed that only
IgG^ and IgG^ bound strongly to the monocyte surface (162). The
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binding could be inhibited by fresh serura or an tigen-antibody complexes.
It therefore apoears that IgG^ and IgG^ are not cytophilic,
although they nay bind to monocytes in the form of antigen-anti t ody
complexes as it can be a! own that heat-aggregated IgG? and IgG^ do bind
to monocytes. IgM failed to bind to monocytes when heat aggregated,
and would only do so in its native form when complement was added (133).
Thus,for the human IgG sub-classes the ability to fix cajolement corre¬
lates with the ability to fix to monocytes,and the available data from
mouse studies is in agreement with this in that cytophilic activity has
been shown to reside in the IgO^ sub-classes. However IgG^ also
bound to mouse monocytes although with a lower binding affinity (163)•
The relevance of antibody classes and sub-classes to "blocking"
of in vitro cell-mediated cytotoxicity and antibody-dependent lymphocyte
cytotoxicity has already been discussed, it therefore only remains to
point out other, more speculative mechanisms of antibody involvement in
tumour immune processes. Inanmoregulation via receptors on the
surface of cells of the immune system may be considered here.
Mammalian cell membranes posse® recognition sites that enable them to
respond to various environmental stimuli. These are of interest in
endocrinology, pharmacology and immunology. In the latter it is
known that all lymphocytes bear receptors for antigen, but in addition
certain subsets say have receptors for the Fc portion of immunoglobulin
and also complement components (16U).
The Fe-receptor appears to be ubiquitous in the immune system;
thus,it is present on mast cells, neutrophils, monocytes, macrophages,
platelets, 3-lyrphocytes and perhaps "activated" T-lyiaphocytes (16^).
-<2-
This is not to that the Fc-receptors on all cells are the sameJ
differences exist as to the avidity of interaction and the class or
sub-class of antibody that is bound. Thus,the adherence of antigen-
antibody complexes to lymphocytes was mare sta'le than free antibody
(166), whereas macrophages eould bind antibody in the absence of
antigen (162). Also the binding of mouse IgG^ to lymphocytes is
strong compared to the other classes and sub-classes (16?), in marked
contrast to macrophages which bind I.f^a 811(1 !SOSt 5tronfl5r (163) -
The receptors for antigen, Fc portion of antibody, and complement
would appear to be ideal mediators for imminoregulation. Indeed,it
has bean shown that feedback suppression of antibody formation by
specific antibody is easier to achieve with whole antibody molecules,
as opposed to (Fab)^ fragments (16?). furthermore,it can be shown
that delayed-type hypersensitivity reactions are promoted by procedures
that suppress antibody formation (167). Thus a delayed-type hyper¬
sensitivity reaction to SRBC, which was known to be suppressed by anti-
tody formation to SR.BC, could be promoted by treatment with cyclophos¬
phamide. The suppression of the reaction was due to complexes of
anti ody end antigen.
The phenomenon of immunoregulation may embrace the process of in
vitro "blocking" of cell-mediated cytotoxicity by antigen-antibody
complexes. In this respect the experiment describing the interaction
of anti ody formation and delayed-type hypersensitivity reactions may¬
be relevant. In addition,it is known that enhancement of allogeneic
tumour growth depends on the Fc portion of the enhancing antibody (168).
Another system of immunoregulation has been pronosed by Jerne (16°).
This theory depends on idiotypic determinants of the entibody being
recognised by anti-idiotypic antibodies in the same animal. There
is, therefore, a network of antibody molecules that recognise other
antibody molecules, which in turn recognise still others. Since
the patterns of variable region idiotypes are determined by the
variable amino acid sequences of the polypeptide chains there are
millions of different idiotypes. This is postulated to correspond
to the vast range of antibody combining sites available In the Immune
system. Thus,lymphocytes are subject to continuous suppression by
other lymphocytes and by antibody molecules, until introduction Of
antigen upsets the equilibrium and causes proliferation. However,
the system will always tend to return to the original position of
equilibrium.
Lewis et al. (116) have described a system in which a specific
antibody against a tumour-specific anti ody may be the "blocking" agent,
rather than antigen-antibody complexes. In these experiments serum
from a melanoma patient with, and without, tumour-epeciflc antibody
activity towards melanoma cells was used. It was shown by gel
diffusion and passive haemagglutination that IgG from serum without
tumour-specific antibody activity reacted with X-globulin from serum
that had this activity,
d) Plan of the project
From the foregoing it should readily be appreciated that antibody-
is potentially capable of mediating a vast range of activities which
may influence tumour development. Therefore,what we have done is
try to relate various serological parameters to models of tumour
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immunity, principally the inhibition of tumour growth by C.parvum.
The parameters chosen were: total inmmoflobulin class and sub-class
levels in 3<?rum; anti-C.parvura antibody; and iianrano^lobulin capable
of binding to syngeneic tumour cells in vitro*
To achieve this aim mtisera against mouse immunoglobulin classes
and sub-classes were produced by standard techniques, and an indirect
antiglobulin assay to detect imfsunoglobulin binding to tumour cells in
vitro was developed. It was soon apparent that C.parvua elicited
increased levels of immunoglobulin binding to tumour cells in vitro.
and elevated levels of certain immunoglobulin sub -classes, concurrently
with high ar.ti-C.paryuB antibody titres. Therefore, studies were
carried out to ascertain their cellular basis and to compare the effects
of different treatment schedules and different adjuvants. Further¬
more, the specificity and characteristics of the immunoglobulin bind¬
ing to tumour cells in vitro were examined, and an attempt was made to
confirm the existence of "anti-tumour" antibody by a different technique.
Finally, immunetherapeutic treatments based on the a ove in vitro
results were attempted.
In addition, preliminary experiments were performed to investigate
a) whether the C3A fibrosarcoma elicited a humoral response without the
intervention of adjuvantj b) whether tumours o" the lymphoid system
could exert a general immunosuppressive effect on the humoral response
to defined antigens, or influence K-cell activity.
MATERIALS MSB METHODS
1) ANIMALS MB ANItlAL HAKDLIKQ
a) Mice
Syngeneic Rale sni fewale alee of the A/He J SAL3/c
(a-?4) and C3A (H-2fe) strains were used In there studies. They
were originally obtained from the MRC Laboratory Anisaal Centre,
Carshaltoo, Englmd. Since then they hare been inbred for 12,
10, and 12 generations respectively In our own animal hems®, where
they were housed in alartio boxes (5 - $ to a box) lined with wood
shaving'*. The temperature of the room we * Raintained at 2?°C
and a constant sir exchange rate to provide adequate ventilation was
ensured. Mice were maintained on a eoirsercl al mouse cake diet
(McGregor? of Leith, Edinburgh) and water.
Mice deficient in thywus-derlved cells (T-ceUe) were obtained
by thymectomy at h « 6 weeks, followed by whole body irradiation
(350 rod.) erne week later and rccon 1.button at that tine with an
i.v. injection of l* x 10^ «nti~© treated bone marrow cells. The
nice were allowed to recuperate for 6 week before being used in an
experiment.
The cong'tii telly athymic (nude) mice used in one experiment were
homozygous, and baofe crossed to a 3ALB/c background. They war® either
madntidned at the Welter and Elisa Hall Institute for Medical Research,
Melbourne, Australia^ or obtained from Bomholtgard Ltd., Denmark.
Mice injected with viable feuaour cells in the foot were deprived
of their tumour burden as follows. After mild ether inhalation
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the tumour bearing leg was swabbed with 'G# ethanol and the tumour
excised at the knee loint with "bone crushers". A flap of skin
was drawn over the thigh bone and sutured with cotton.
b) Rabbits
Adult New Zealand white female rabbits were used for the produc¬
tion of antisera to mouse proteins. They were kept in solitary
confinement in metal cages and fed on a diet of rabbit pellets sup¬
plemented with greens.
c) Goats
The goata used for the production of anti-rabbit IgG were kept
under standard conditions at the University Centre for Laboratory
Aniit!'"Is {The Bush, Milton Bridge, Midlothian).
d) Guinea pigs
Guinea pigs, used as a source of complement, were kept under
similar conditions to the rabbits.
®) Bleeding of laboratory animals
Mice were killed by ether inhalation and bled from the inferior
vena cava.
Rabbits were secured in a suitable box with an ear protruding.
After applying xylene to the ear a cut was made with a scalpel in
the marginal vein and the blood collected. After stopping the
flow by light pressure on the cut, the ear was swabbed thoroughly
with ethyl alcohol to remove the xylene.
The goats were kindly bled by Dr. E.G. Dp!ton.
Freshly obtained blood samples were allowed to clot for 30
ominutes at room temperature, rimmed and left overnight at It C.
The clot was removed and the senna '-mm at 1 - 5?,000 r.p.s. for
tO minute a to remove remaining blood cell?. Senna w»- rtored
at -20°C until needed.
2) PHODPCTIOM OK AHTIflffiA
ft) Technique :■ for production of nurlfled w&eloaa proteins
i) Arisonixm sulphate precipitation. Mouse sterw (t vol.)
u&: diluted with 60 af pho-phate 'mffer at physiological pH
( vol.), then precipitated using UM annanium sulphate (h vol.)
added dropvise with eontant itirring. The precipitate wt?
harvested by centrlfugafcion, redi solved in 66 mh phosphate
(U vol.) and reprecipitaied with hM ©imonium sulphate a- above.
After further rnmardxt® -ulphate precipitation the globulin
fraction war di*->solved in 10 raM oho phate buffer (pH 7*5) and
dt*ly-*ed exhan-ilvely again t the -'tarting buffer used for Ion
exchange ehroiaatographjr.
11) Ion exchange chrouatorTaphr. The ion exchange used In
the • s tuHe.? war- a aderogrannlar pre-swollen anion exchanger
on a cellulose matrix, EE?2 (H. Reeve Angel fc Co. Ltd., London).
It war first equilibrated with a large voluae of starting buffwr,
u sually 10 wM phosphate (pit 7*5)# and left overnight at room
temperature. The upemntimt war? decanted off, the BE52 re-
na'oended in starting buffer aid filtered through a wintered
funnel u- inf vacuum suction. After washing thoroughly with
starting buffer the exehsnrfr war reruupended in it, brought to
toe correct pH with iiCl or MaOH, then degassed on a vacuum pump
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before oaoking the column, After use the I$#2 *r regener¬
ated in a large volujse h* 0*211 HaHgPO^ (pH !r ?), then re-
e^uilibrated with 10 at! pbo-phate tmf^er (oH 7*<),
The labour involved in each separation was reduced to aspply-
lnr the ?ancle and pooling the fractions, by the u*e of an
1*1^701 A Bricord 1 to locate fraction* of intere*tj 1KB chopper
bar recorder to record thenj and an DCB7000 UltraRae to collect
then. The mixing of solution* to form gradients or aactuao-
tial etaps was simplified by the use of an IK011100 tfltraarod
(1KB Instruments Ltd., L.K.B. louse, 212 Addington Road,
S. Croydon, Surrey). See Fig. 3 and Tables 3j5>>6,7.
iii) Gel filtration. Sephadex 0-200 (Pharmacia Fine
Chemicals A3, Uppsala, Sweden) was suspended in a large excess
of pho sphate buffered - aline (0*1dM) and swollen by heating on
a tolling water bath for 5 hours. To remtnm fines the
Snellen gel was allowed to settle and the supernatant removed.
After a further cycle of *U"pea?ion and decanting the gel w»>
reru ponded at the correct consistency, degassed end applied to
the column. See Fig. 2 and Table k-
iw) Starch block electrophoresis. Potato starch (600g) was
washed three time with an eatress of 0*0$M barbitone buffer,
poured on to the block md cxeasa buffer allowed to drair away.
The starch was left to solidify overnight then a well (6 em x
1 cm) wa" cut in the centre of the block. To apply the
sample (5 »l) it wa« mixed to a thick paste with potato starch
and applied to the well. The block was then wrapped tn
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polythenr and sub 'acted to electrophoresis OOOV, 35«lhO»A)
for 23 hour.® at h°G* At the end of the run the block was
cot into hO x 1 en. slices and each slice suspended in PBS
(20 Bil) overnight. The protein content of each upematant
wan estimated by the aathod of Lewry (17c) and the «u*p®jis»ionis
pooled on the ba-ie of this. Bach pool was extracted with
PBS (500 ml) and the extract* pre-our* dialy-ed to manageable
volume . See Fig. 2 and Table 1±.
v) Eneye digest*.
Solution A - 9 mM X9TA, 20 »M eyetelr -WC1 in 0*?H phosphate
buffer pH 7.
Solution B - Protein for digestion (30 - <0 m~ in 5 ml of PIS)
nine 0*5 or 1 mg of mereurinsoain (Koob-Light
Laboratori.es Ltd., Coinbrook, Buck*.).
Solution C - Iodoacetesiide (0* !'M) in ?0mH pho phate pH7.
Solution A (5 al) was added to rilution B (5 ml) and left
at 3?°C for U - 5 hour*. Ute reaction mixture was then made
?0 wK in iodoacetasside to atop the reaction, left for 30 minute 1
at root* temperature, aad dialysed against 10 pho'--filiate buffer
pH 7*6. The fragrant? were *eo®rated en ££52 (r.«e tg. h )•
It was noted that 0*5 mg of merouripepsin gave the better
rerulte when wa* digested, whereas 1*0 mg was better for
b) In 'action of rebhlte with purified wyeloiBa protein-
Sew >alaad white rabbit* ($) were used for the production o?
antif era to monx^e immunoglobulin cla® -e*» and *ub-elaei*aa» The
60-
In* fiction schedule* are shown in Table 2.
e) 3olid-ph&re imgunoab-urption of rat It antl.-.era
globulin classes md sub-classes
The eolttwns for ijsmmoabsorption were made u°lng Cn tr-aetiTated
Sepharosc l»B (Fharaacia Flna Chemical*) follower. Sepharose i*F
gel was swollen and washed for 15 rdnuter on a gXm* filter with
exeofc-s 10**\ HC1 to remove dextrm aid laotore. The protein to
be coupled warn dissolved in coupling buffer (0«1M KaHfH, buffer
containing 0*9? Wafl, plffi; at a concentration of appr sximately
2 ag/al, mixed with the 1 in a teat tube and the mixture rotated
end oxer end («MM Table 8 ). Eijr>ound material va.*? washed away
with coupling buffer and any remaining active group? were reacted
with 1K sthanolemlne at pB 3 for 1-2 hours* Three washing
cycles were u-ed to remove non-covalentlr afc»orbed protein, each
cycle co? 1- ting of a wa«»h at r>H l» (0*1H acetate -mffer containing
IK EaCl) followed by a wash at pH f (0*1K borate suffer containing
1M lad). Finally* the solid-phase lmrunoeb. or" ant w& su-ponded
in coeqpling buffer and poured into a suitable pise syringe barrel.
JUrther details of Individual columns are given in Table 8.
Irjranoab^orrtiQn- of antiserum were carried out by concentrating
the antiserum to a manegeable volume (sgy 20 ml to 5 ml) then dialys-
ing against coupling buffer. The concentrated antiserum ut
spoiled to the column and the progress of the serum constituents which
did not ab orb to the column monitored with the DTBh70l A Uvicord 1.
When all of the unabsorbed antiserum had been tinted the buffer was
changed to anc of a low oH (0- IK glycdnc/HCl containing 0*51' WaCl,
pi *2*8) to elute antibody that had been ♦pecifically retained on the
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colursn. l%der optima® condlfelons this retained antibody mm
virsble «f a discrete peak on the recorder.
The ef flcianey of Imsunoab - or1 ent columns prepared In this way
is illustrated in 5 and 6.
1) A.? tegsaaat of spedflcity of ln'-mnoah orbed antieera
Crude oatiaera were first examined by iRmmoelectrophore ~ia
afadnst nomal bums* serum ,in order to obtain an idea of the tmamo-
absorption® neoessary to render the ;.tl'-erum IHiitftn (~ec? Fig®. 7 -
1D. Thus we see that anti-IgK reacts faintly with nonce XgOf
anti-IgA reacts with IgG, IgK and an unknown component In the ^ ~
rogionj anti-IgG) reactc with a slow component (TgOg^).
Gel diffusion analyse?* of anti- mb-cla?~ snti - ra were performed
wring a battery of purified myeloma protein' to confirm thlch ir sujO-
absorptions were nocossatyi by this method it was fcund that anti-IgG^
reacted with mouse IgG^ as well as IgG1 snd that eanti-IgG^ reacted
with mouse ZgG^ as wall as Table 9 shows tla absorptions
naeasnaaty before the mtlcera gave (l) single lines? on 1® unoeleet-
rophorr sis again? t normal warn* heron, Fig.- . 7-11 ; (2) lines
of identity with the homologous commercial mil; era, Fig*. 7-111
(.1) no reaction apain't purified myeloma nroteln® not used in the
production of that antiserum, Fife. 7 - 11.
As commercial standards became available the ranti-era were tested
against the 'e. It was again found that m antiserum only reacted
against the protein that it had been raised against (Fig. .12).
e) Comment? on production JS£i-era
labile the production of antiserum is in general straight forward
-61 a-
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Peaksmearedover1?S, 7Sendregions- IgAinascending(B)nd descending(C)portions. Immuniserabbitwith3.
Noteq 1)illfractionations!werecarri dutlt°Cithf owr f10-2ml/ r 2)Allsolutionsfa twerebuff redith10r MphosphateH7*6f rion-exchangechromatography,d6mMph sphateH7*2 forgeliltration 3)PurityoffractionsanalysedbImmunoelectrophoresisandgeldiffusi n.
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TABLE 4 PURIFICATION OF iKM
STEP PROCEDURE COMMENTS
1 Separation of myeloma serum
(22 ml) on G-200 sephadex
Select the 19S fraction
2 Recycle o** 19S peak
3 Separation of 19S peak
into its components by
starch block electro¬
phoresis
Divide IgM peak into
ascending and descending
portions - both found to
be pure IgM. Use each
fraction for immunising a
rabbit.
Uote
1) G-2QQ runs were carried out at 22°C, in phosphate buffered
(jaline pH 7*2, at a flow rate of liO ml/hr, using a
100 x h'h c® eoluwa.
































Note 1)AllfractionationsnIEAEcellulo ec rriedth°Cwithflowra f20l/ r 2)Allsolutionsfaltwerebuff redith10bMphosp ateR7*6 3)PurityoffractionsanalysedbImm noelectrophoresisdg ldiffu ion
TABLE6FPRIFICATIOWOfj|gU.( )
STEPPROCEDURE^°FCOMMITSPBDTEIKAPPLI D(mg)NaClUSE PEAKEWTEB 1SeparationonBEAEcellulosef fractionobtainedfr mthe ammoniumsulphateprecipit tion ofpooledmyelomaseru(27l)60x2 3000,L0,100,1?0,200mM
PeaksA&B, lj.0-1 0mM






































PeakCpureIgG„p -usedfor in ectionofrabbit























PRODUCTION OF Fc FRAGMENT OF IgG?aCfl
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Descendingpartof1?S peakofs rumfromge freesice(containing IgMbutnoA)
1*6
3
LeaveCn3reepharose LBincouplingbuffer for3hatL^C beforeaddingpr tein. LeaveovernighttL°C.
Didnotabsorbnti-IgM activity.
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TABLE 9 I^1UM)J»130^TIQN5 ygr£3&akt -re-ORE mtbfiu wm- sryrric
«n SERUM IHMDUOABSORPTIOHS
Aatl-IgM IgO





Anti-IgO^ (I) Fab(l), XgO,, IgM
Anti-IgO?a (II) Fab
D Fab fragments were pooled fro® papain dig© tion' of
(a) motre myeloma protein' j (b) IgG from normal
jerua. • 1
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Fig. 3 EFFECTIVENESS OF IMMUNOABSORBENT COLUMNS (1 )












RAM IgG0 _ (II) before
c. 9.
absorption with Fab
RAM IgG„_ (II) after
<_ 3.
absorption with Fab








A - normal mouse serum
B - " " » 1/2
c - " " "
D - " " " 1/s
E - » » » yl6
3 - RAM IgA before absorp¬
tion with IgM
U - RAM IgA after absorp¬
tion with IgM.
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Fig. 6 EFFECTIVENESS OF IMMUNOABSORBENT COLUMNS (2)














RAM IgG0. before absorption
<— 3.
with IgG^
RAM Ig02? after absorption
with IgG 1
Mouse IgG0 immunoabsorbent column
































Wells contain normal mouse serum
(A) A - normal mouse serum (NMS)








- /7F\ /^\ D - mouse IgM
E - mouse Fab
F - mouse IgA
a
1 - RAM IgA
2 - RAM IgA (Meloy
Laboratories)
3 - RAM IgA (Nordic
Diagnostic)
a) Single line on electrophoresis against NMS
b) Line of identity with homologous commercial antisera
c) Reaction only with IgA.
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Fig. 8





Wells contain MOPC IOI4E myeloma serum
CRUDE RAM IgM
RAM IgM abs IgG
abs IgA
G - normal mouse serum (NMS)
H - mouse IgG
I - mouse IgA
J - mouse Fab
K - mouse IgM
U - RAM IgM
5> - RAM IgM (Meloy Laboratories)
6 - RAM IgM (Nordic Diagnostics)
9 .
Note
a) Single line on Immunoelectrophoresis against NMS
b) Line of identity with homologous commercial antisera
c) Reaction only with IgM
■61,
Fig- 9




































1 - RAM IgG 1
2 - RAM IgG^ (Meloy Laboratories)
3 - RAM IgG^ (Nordic Diagnostics)
Note
a) Single line on immunoelectrophoresis against NMS
b) Line of identity with homologous commercial antisera
c) Reaction only with IgG^
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Fig. 10













RAM Ig^2a abs Fab
abs IgG1
Q - normal mouse serum (NMS)
R - mouse IgG_
c. 3
S - mouse IgG^
T - mouse IgA + IgM
U - mouse Fab
U - RAM IgG2a (I)
5> - RAM IgGQ (Meloy Laboratories,
c. 3
Springfield, Va 221^1 )
Note
a) single line on immunoelectrophoresis against NMS
b) line of identity with homologous commercial antiserum

















V - normal mouse serum
W - mouse IgG_
c. Si
X - mouse IgG^
Y - mouse IgA + IgM
Z - mouse Fab
6 - RAM IgG2a (II)
7 - RAM IgG2a (Meloy Laboratories)
Note
a) single line on immunoelectrophoresis against NMS
b) line of identity with homologous commercial antiserum
c) reaction only with IgG0
c. cl
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Fig. 12 EXAMINATION OF SPECIFICITY OF RABBIT ANTISERA TO
MOUSE IMMUNOGLOBULINS, USING COMMERCIAL STANDARDS
Commercial Standards : A - mouse IgA; B - mouse IgG^;
C - mouse IgG2a> D - mouse IgG^^.
Antisera : 1 - RAM IgA,* 2 - RAM IgM; 3 - RAM IgG^;
U - RAM IgG0 ; 3 - RAM IgG.
c. 9,
Note
T5 Commercial standards at 1 mg/ml (Litton Bionetics, Kensington, Md 20795)
2) Antisera only react with the appropriate antigen.
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the following points may obviate the dlffioultims that did occur.
They are,boweviTjnot the reult of rigorou- experimentation but of
retrospective amly i hindsight and generalisation.
i) A sdnimum of 1 mg per injection (more if the Fe fragment
is Injected) is necessary to rai a an antiserum that cm be
used in Manclni analyla.
ii) I.a. la superior to ».e. injection.
iii) It is not necessary to inject the Fc fragment. It is
preferable to inject the whole molecule and absorb the Anti¬
serum with Fab.
iv) In the production of snti-IgA ensure the injected antigen
i» free of IgM. This caused considerable difficulty because
raou*>e IgH is difficult to separate from IgA aad ^furthermoreyit
is labile when coupled to Sepharor e UB. Thi i: to he eomp-




Fibrosarcomas were induced in 3 - 10 week old CBA and A/HeJ mice
by an intramuscular injection of sseth Icholanthrene (0*5 ®f) in tri-
octsnoin (0*1 ml). CBA ©mbiyonie fibroblasts were obtained from
minced embryon, usually in the third wr-ek of gestation. Normal
fibroblasts were obtained from the kidney* of adult mice. Pla raa-
eytomas were originally produced in IJLB/e mice by the injection of
af'Uvant or mineral oil) they were generously donated to thin labor¬
atory by tbo-e listed in faMe 1.
-63-
b) In vivo propagation of tumour
The in vivo propagation of plaaseytoaa and fibrosarcoHta' was
carried out by fc s.c. injection of a cell suspension. A plasma¬
cytoma call u pen'ion wa=- made by mincing tip tumour ti sue with a
teflon hosjogeni-er, decanting the cell u pen ion and ia'ceUai
mesured volume • . Ms crude technique wa~ adequate for routine
propagation of plasmacytoaa?, but for experiment with the CBA fibro-
•reoma the following a*-optic technique we- used* Ttuaour tissue
va? out into nail piece.? sand poured into a Helnick jfla-k. The
upernatsnt we- decanted, store tcrile Dulbeceo A ♦ B added and the
upematsmt again di carried. After a further wa-h in prona e/
Dulhecco (2*f" g prona c, 20 rag HA-« per litre of Dulhecco A + 3) at
3 ;°C for 30 a&nutes, the tumour tissue was re u rendkd In prona e/
Dulbecco and slowly stirred for 10 ulxrate? at 3T°C. The >tperna~
taut was deented through 2 ply ganse into a flayk containing Dulbeceo
A ♦ S at 1»°C md the tissue remaining in the fla k further digested as
above. Cell - obtained in thi? way were wnhed three tine? In
kilbecco A ♦ B before being used. They were at lee-t 90£ viable.
c) l-p. propagation of tumour cell line*
A cell m pension was made as in the previou- section said It x 10'
cells in 10 ml growth medium (HPKI - 16I1O, 10$ foetal calf serum,
2 jrM/L glutamine, 100 units cry tanycin/nl) needed in ti sue culture
flasks kept at 17°C. The next ley the nonadherent cells were re¬
ceded {"♦ x 10" cell? in 10 ml) aid «i intervslr of 3 - U day were
ub-cultured at thi density.
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d) jft ilJrtJtti propagation of embryo cell lines
A CBA son e In the third w*ev of gestation wa-» killed by ether
inhalation and the «t*r« , with the embryos, removed sceptically.
After detaching the embryos from the uterui they were decapitated,
their viscera discarded, then the i-emein? cut into mall pieces and
lamer?-eel In fcryp in/Dulbecco (2«*> I trjro in, 20 ®gf DNAae per t.. of
Thilbecco solution) in a Helniek flask. The sub-'ftquent procedure
wear a- for the dlge-tlon of tumour cells,except that the period of
tirrlnc wa 20 adnutn instead of 10 minute*.
Embryonic fibroblast* were propagated in vitro by the 1 "«e
method a* for tumour cells. It vr observed that wher< » tumour
cells had e nwilliiflji limitless existence,the life span of the
embryo line i w« about ? sub-culture .
e) In vitro propagation of normal kidney flbrobla. te
This method wa based on that of Paul (17]). Mkmfly an
adult nou « kidney, rtLiar the membrane, we? minced md left In trypsin
/Oolbecco |2-5> g trypsin, 20 ag MAse per L. of Dulbecco A ♦ B) for
20 minutes it room temperature. The •upernatant was spun down ted
discarded then the minced kidney wen re-upended in 20 ml of trypin/
Dalbeceo sod kept at it°C overnight. Next day the cell- were ®aln-
tained at 37®G for 30 minute* in a water bath, large piece* of tissue
allowed to efctle and the cell u pen ion ramoved and wa had In cold
Dulbccco A ♦ 3. Undigested tissue wn re-incubated in trypsin/
Dulbeeco for a further 30 minute* at 3?°C, snd the unernetsnt con¬
taining cell- removed.
Cell- were washed three time in Dalbeceo A ♦ B before weeding
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in tissue culture vcsrels at < x 1</' cell' per bottle. The in
rltro propagation vv similar to the propagation of embryo cell line*.
Again it wa found that non-ualignsnt mouse fibroblasts had a restri¬
cted life-:pan under culture condition .
f) Storage of cell?- under liquid nltgogen
Freshly excised tuaour tinsue wa finely minced and left for 1
hour in the "freezing olution" (199 nediuB, 201 foetal calf erus,
100 units/ml Cry tMajrcin, 7*51 dinethyl-ulphoxide). Aliquot®
were poured into suitable container® and cooled at 1°C per minute over
the range 0°C to -15°C. After freezing (town to about -30°C the
ampule.® were stored in the vapour phase of liquid nitrogen. Alter¬
natively a cell su pension could be froasen down in a similar Banner.
g) Tumour transplantation and aee urewent
*.c. tran -plantation The CM fibrosarcoma wa« transplanted
by a s.e. injection into the right thigh of 10^ or 10** prona
dige-ted tuaour cell' (see Materials aad Method® 3b) or in vitro
cultured tumour cell* (see Material® md Method? ?e). Prior
to the*® studies the CBA and A/He* fibrosarcoma' had been trans¬
planted 1" and 23 tine* respectively. Tumour growth wa*
a sewaed throughout th# period of experimentation by measuring
two dimeter® at right angles. It could be readily demonstra¬
ted that the CBA fibrosarcoma, wa? immunogenic in the yngeneic
hot (Teble 37).
l.v. trann>lf«tation A putetively more sensitive technique
then we» -urement of tumour diameter*' is the enumeration of tumour
cell colon!e-? in the lung* after i.v. injection of tumour cells.
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Thi?! method was used to assess the effect of merest from
various source on the ability of tumour ceil' to form lung
colonic • The serum (diluted 1/?) was incubeted with CBA
fibre arcoaa cell - (2 x tQ^/mi) for l*< minuter ct 17°C.
After wa iting once mice were injected ivia the tail vein
with £ x 1c/4 cells. fotirtean days later they were kille
by cervical <H location, their lungs excised then wa bed and
iaeaer ed in fixative. The smbcr of colonies on both sides
of each lobe ws. counted using a low power magnifying glass.
The Bouin'a solution used as fixative con i ted of aturated
picric acid solution (7"t ml), tfjfeK formaldehyde (2£ ml),
glacial acetic acid (f ml).
ii) ASSAY TECHHIQCTRS
a) Antiglobulin array
An antiglobulin a*c?y wa used to detect motive immunoglobulin
binding to tumour target cells i£ vitro. The pacific!ty of
inding wa examined by a) absorption with non-malignant cell^j
b) UHinr non-malignant cell ' »- target • In the *ntlglobulin assay.
This technique needed,* target cell*} test 'crua in which antibodies
to the target cells were su pectedj md a reagent, labelled with
radioisotope, capable of reacting specifically with immunoglobulin in
the test serum. Thu~» the ^-radiation retained by the cell® was
proportional to the «»fei-target cell antibody in the test serura.
Reagents for use in the antiglobulin a-say were prepared as
follows. Mouse IgG wan prepared by fractionating whole erum on
0-200 sephadex, then precipitating the 75 fraction with 16% Wa^SO,.
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The precipitate was analysed a pure mouse IgG by gel diffusion m<A
imiwa»#leeiropftoreKi«. Rabbit anti-?«m<-e IpO wa« prepared by
in :acting s Sew ?eali«nd white rabbit °.e. with approximately 1*< mg
of noure IgQ in Freund*a complete adjuvant, and repeating the dose
two weeks later. After another two week a final l.p. injection
of ar-nroxinatcly !•<> ®g mou e IgO in Alhydrogel was given, then after
a farther two weeks, the rabbit war bled from the ear. As Judged
by gal diffusion precipitin analysis thir antiserum reacted with all
the principal immunoglobulin elerre^ and rub-el&saes in mouse serum
(Ftg, 13 ). Before use in the antiglobulin a«s«gr the nntl^erum,
7
or normal rabbit serum used as control, was absorbed with 10 cultured
tuxour cells per millilitre of serum, for one hour at 22°C.
Rabbit IgO was prepared by batch chromatography on DffJAE cellulose
s•• described by James (172)* Ooat anti-rabbit IgC was prepared
by a s.c. injection of 8 mg of rabbit IgO in Freund'- complete adju¬
vant, followed >y « similar in 'action six week- later. A'ter a
'birther eight days the goat wa- bled. It should he noted that
the ireat wa aloo bled orlor to isamni .» ation to provide a normal goat
-crux control.
The IgG from both the goat anti -rabbit IgO serum and the pre-
bleed sample were prepared by batch chromatography on DEAE cellulose.
Both goat IgO preparations were labelled with by the iodine mono-
chloride method (see Materials »»d Method > *?).
In these studies four variation * of the bade technique have
been used (Table 10 )• The method" for each are am followst-
A. CBA fibrosarcoma cell* (ncrox. 2 x 10^) were incubated
at h°C for "'O minute* with the test mouse "eras (1 ml diluted 1/12)
in ©pliable test tubac?, then *pun down and washed twice. The
cells were then recuapended In rabbit «nti-won"e IgO "©run (1 ssl
diluted 1/20 - l/0)j incubated at for "10 minute- «u.i acain rptra
down md washed twice. Inally the cells were incubated with
-labelled globulin fraction of goat anti-rabbit XgO (t ml
60 jag - 100 pg) and croce-ied ** before. After the final v» -h
the cell- were counted in a ^- cintillation -pectrometer.
In this method all dilutions and washing© u hd Ea®rle« minimal
e aential medium olu foetal calf serum, buffered with 20 nM
bene© (BHH Qrerfcal- Ltd., Poole), and pre-erred with 100 unite/ml
of Cry-'tangcin (Glaxo Laboratories Ltd., Greanford, England).
Preliminary experiment© incorporated a full set of controls
including normal rabbit serum and 12JI-globulin fraction of normal
goat ©erua. It wa soon erfdent that non—-perilc ©b-orotion doe
to there reagents was sininal,'-© their routine u-e va" di- continued.
Thing this technique the iisminoglobulin in the te t serum bind¬
ing to the target cells in vitro was exjpressed as the Absorption
Ratio (A.R.)
counts per unit time m tubes kith test serum
AR - i
counts per unit time in tubes with normal serum
B. The target 0011* (2 - h x 10^), cultured in rftro for 9 -
<0 dec"j wer© needed into each well of a diapoeahle plastic rfcro-
culture plate (Linbro if~PP-96 or Punclon A/S wane, fVsaaarfr),
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eovered with a lid md Incubated overnight at "?7°C in a hurndLd at¬
mosphere to allow the caU" to adhere. The cell? vera washed
once with medium (?00pl) then mouse ' «n® fro® the various experi¬
mental grour ~ (25 - 100 jil diluted 1/5 - 1/30) wae addad^and the
plate Incubated at 3T°C for 30 ainute*. The plate wa cooled
to 1.5° -20°C and the cells washed three times with medium (200 ]ul
each). Rabbit an ti-mouse IgG (50 - 100 jal diluted 1/50 - 1/100)
va- then added, the plate Incubated at 15 - 20°C for 30 minute? and
12?
the cells again washed three tines (200 pi each). Finally- 2<*
labelled imaamoglobulin from goat anti-rabbit IgO (5 - 10 ja?) was
added, the plate incubated for 30 minutes at 15 - 20°C and the cells
washed an before. After each wash the cell? were -pun down at
~"00 rpm for 2 minutes, and when dry after the final wash the plate
was sprayed .tdkth plastic wound dressing, Individual wells cut out
with a hot wire, and the remaining ^-radiation counted in a scin¬
tillation spectrometer.
In this method the wa iting of cells and dilution of reagents wa¬
in RPHT l6It0 supplemented with 10? foetal calf *eruis, buffered with
20 »K licpe?, md preserved with 100 unit? per ml of prnicillin/strep-
tomcin.
Oaing this technique the imnunoglobulln in the test <-erum binding
to the target cells vitro was expressed as the Absorption Ratio
as in Method i!. Alternatively Individual era In m experimental
group were examined mad the result • (counts per unit time) expressed
in scattergram •'orm.
C. In this method a nlwher of modification' were introduced
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whleh were intended to make the a* say more sensitive* The- the
cell* were removed from the reaction tubes prior to anting to
reduce the background ^T-coant^ aid a specific rabbit antibody to
mast TgO (elated from a ww-* I»G iiannioabsorbent colwarn) wa- used
a the antiglobulin roeyent.
CBA fibrosarcoma cell* (ii - 7 * 10^) were incubated at 37°C for
"'O minuter with the test moure iterw (9-2 ml diluted 1/7 - 1/11) in
«udL table test tub**, then spun dovm and v» bed three tines, (t wl
each) The cell " were then resuspended in the sntiflobulln t
(0'2 ml. "or dilution see RestA&a) and incubated at t< - 20°C for
10 minuter* The;- were then washed 'our tines (l ml each) before
being transferred to freeh tuber^where they ware washed once more
before being counted in a V- Mntilletion ."pectroneter*
Tn this method the washing of cells and dilution of resgantr
was In WM 16&) plu- 10* foetal calf aerwn a- In Method £.
*
The lrosunoflnbull® in the te*>t "erur binding to the terpet
cells In vitro m" excreted s the Absorption Eatlo (ab),
cotarrs per omit time with cells ihcobateo with test seeom
AH -
COURTS PM OMIT TIME WITH CELLS INCUBATED WITH BORMAL flSBBX
D. This method is the ««&e a* Method B except that: «) the
cells were plated out the vme day as the arsayj b) the cells were
transferred to a fresh nlate for V-scintillation counting as follows.
Ice cold Rulhecco A (100 pi) wa*5 tr-ed for the la*t w«*h to remove
foetal calf serum. After ^inning down, the '•uperrmfcant vs neatly






RAMIgGserum,followedby thegloluUnfractionof GARIgG,labelledwith 12*1.
PROCESSINGC?ELLS 3SHJRES'-SCINTILLATIOR COUNTING
COMMENTS
Rone-cellsu t dir ■^-counterinreacti tubes.
Notsensitive-limitedin numberofsample^proc ssed duetoseparatewashingand oentrifUgationo"each sample.






GlobulinfractionofGAR IgG,labelledwith12*1- madespecificformouse IgGbyelutionfrom~ol d phaseimmuneabsorbent.
Removedfromreaction tubesand6-countin freshtubes.






Invitrocultu edcells dispensedintoeachwell ofardcrocultureplateon dayofassay.
RAMIgGserum,followedby theglobulinfractiono GAF;IgG,labelledwith 12*1.


















1 - RAM IgG
Note
RAM IgG reacts with all classes and sub-classes of mouse immunoglobulin
tested, except IgA.
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the cellr gently aspirated a:d -timed urine s 100 jnl Oxford pipette,
then transferred to the fresh plate kept on lee. Transfer -we**
completed by adding 100 pi of tryo "ln/~odium Terminate ~olution pw<!
(0*02 2? / 0-02%), the cells being transferred as vefore.
In this method the washing of cells and dilation of reagent"
wa- in KPMI 16U0 plus 10/ foetal calf serum as in Method n.
On two occasion- (when using anti -era to mou-e immunoglobulin
subcla ser, and when finding the optimum condition" for «ueb an
experiment) goat cnti-mou~r immunoglobulin "ertn» W8~ used together
with -labelled globulin fraction of rabbit anti-goat left. This
was because only goat antir erura to mou-e sub-cla-see was available,
b) Arssgr for cytostatic antibody
Thio a? say is basically as described by Le Mevel and Wells
Target cells ( 2 x 10^ - 1 x 10^), cultured a- described in Materials
and Methods 3 c# were plated into each well of a plastic a&creculture
plate (Lirabro 12-FD-96 or Munclon A/C Wuae, Denmark) and incubated
at 37°f overnight. The medium war gently aspirated, the cells
washed in W7H growth medium (Material," end Method" ."»«) (200 pi),
and test serum (2* pi) at a ranp-e of dilution" edded to each well.
The plate was incubated at 27°r for 20 minutes, tVn <minea nig com¬
plement (22 pi diluted 1/12) added and the plate mincubated at 27°C
"or 6 hour--*. After aspirating the --orum aid complement,
lobellr i lododeoayfcrlfline (0«f p Ci in 0*1 ml medium) was added and
the plate reincubated for 13 hours. Finally the cells were
washed ? times in medium (200 pil), sir dried, "-prayed with plastic
wound dressing, and the plastic well" "c->«rsted on a hot wire -aid
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and counted in a ^-scintillation speetroneter.
The percentage cytorfcaaia wr expre*»-ed a*>
CPM with taat seran and complement
1 - '
CPM with control verm* and oonplanent
or if control -erur: -'hewed cytostatic activity





e) stration o*1 sntl-C.rarvur antibody hy latex agglutination
The bacterial md latex (Tttfeoj 0-01 pi) •ox'-ren-ion* were flr^t
adjusted to five optical densities (<30 ns») of 1$ mi 19? respective¬
ly. : ron the«a .etoch "wpwflen* (defined a* 100??) a mixture
"ontMninp ^ bacteria mi Of latex (v/v) we- prepared in glycine
buffer pH 3*2, containing 0*t< BSA (C-BSA). The bu^er wa? attlad
last after giving the haetarla a pew minutes to coat the latex part¬
icles. """he teat -ere were diluted (2< pi volumes) in GP3A and one
volume was dispensed into each well of a plastic sdorotitre tray,
'ollo^ed by one volume of the bacteria-latex suspension. The plate?
were incubated at 17®C for ? hour", -nun at DO p for D minutes and
read directly ?or agglutination over a direct light source.
Heault- are expressed an the log reciprocal of the antiserum end
■point iilutlon (173) •
d) ^atlnatlon o" ir'-rnoplobullr cla-s end -ub-cla"'' lev«*l« in
raout!,e serum








































• • • TEST SERA
STANDARD SERA 12h% - 100$
' ' v;'-A:vT' V:vA^! "AA ?:/ -'




Meloy laboratories (Springfield, Ve 22151) or prepared in thi* lab¬
oratory by the method* outlined in Materials end Methods- ?.
Estimation.' of the i-wunoglobulln *ub-ela«* content of Individual
sera were performed by the ■"dn^le radial inwmnodiffu.'don method of
Mancini et al. (174* duplicate accsy* were «nderti*>. an on each
"--rum and all poster contained a range of dilution** of a standard
serum. The standard senna va~ a pool fron ?0 male and 10 feaale
CTJA mice ered a2 week*. In early experiment® the iwnmoglobulin
lcrcl- of test «era were exprc^sd *" a percentage of this standard
*orum; later result" hare been expressed as absolute value-.
A calibration eurv«, win? 12%, 2?, ^0, ?5 and 100? *tandant
moure -erum, *ra~ dram for each plate. The te<*t nou'-e serum,
diluted h„ a factor of "ay 3, wa- read off the calibration curve and
multiplied by the dilution factor. Example* of tM* procedure
era *hown in ^ig. 1I4..
In later experiments --era? Immunoglobulin level" were exproered
8" absolute values. To do this the standard mouse serum war
titrated again-t purified move immunoglobulin class and -ub-cls--
myeloma protein" of hnown concentration (Litton HKsnetlcs Inc.,
Kensington, Hcl, TTSA). It wa~ found to contain 11 we IgM/dl, 20 m®
IgVdl, 66 ng IpO/dl, IfOag IgP2/41, TgO^/dl.
e) F-cell cytotoxicity acc^r
This gives « measure of the Ability of cell" to oartiei-
pate in uitibody-deper dent lymphocyte cytotoxicity. In these
experiments effector cell* mere wou-e spleen cells depleted of macro-
*?1
phaw" by glace adherence* target cell- were Civlabelied chicken
-7U~
rr-1 Mood cell"? and «r*ttbo/V to target oolln we* wSfchlt anti-chicfcen
red Mood cell. Details of this method ere eivea In Caldear jgt al.
(175. K-eell cytotoxic activity va* ejcrreeeetl a* t-
% rel&a.e with antibody end pleen cell" -
% release with mleen. cells alone
% nrndLwum release with antibody pins coanleaent
- % release with rpleen cells alone
f) Magma -forming cell as "ay for antibody to flBBC
This technique was based on that orirlnally described by Jer»e
et al. (L76)» extended to measure mti-SRBC mtibody of all classes
md sub-classes. The assay aeasured the nunber of cells secreting
antibody to SRBC, the 198 antibody being detected by its ability to
fix courolement directly and cause lysis of the surrounding SflBC -
the so-called direct plaques. Detection of 7S antibody to SEtBC
required the use of an antibody to irraunoglobuiin secreted by the
antibody forming cells before plaque? would for® on the addition of
co«ple»*afc - the indirect plaque.
The monolayer adaption of the plaque-forsdLng cell msay was
«MN| in these studies, details of which are given O&MMAnMMI ( jwf
e) As gar for antlbcxty ggagggwo to alaat-BSA
This technique is baaed on that originally described by IFarr
(l_7$. It Measures the antibody specific for a defined antigen
in tfc. > of Antigen Binding Capacity and fieleative Binding Affinity.
Briefly, the control and teat sera were incubated with excess 3SA
labelled with ^"T as described in Material- and Methods and the
eoraplexed separated from free antigen by precipitation with <0,?
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•saaQnius sulphate. After washing, the precipitate war connted ia
a ^-counter, thereby obtaining a measure of 1??I *>SA In cosplex farm.
The result? were usedytogather with a rtmdsrd computer programme^
to give values of Antibody Binding Capacity (which gives a measure
of the total amount of antibody in an anti-erum, of ail imsrunoglo* uHn.
cla: :es, that is available to combine with antigen) and Relative
inding Affinity (which gives a mea~ure of the binding strength be tween
antibody and antigen).
5) UatE o? I90TQPEa
5l
The following low energy ^•emitters were used* Cr in the
form of sjodium chroasste as a cell label j !*"'l in the .form of iddo-
deoxyurldin* as a thymidine analogue) and 12% in the form of sodium
iodide for protein labelling* All were obtained from the Radio¬
chemical Centre, Aaershaw. Standard safety precautions were taken
when using the isotenesjalthough the5-® particular radiochemical® are
relatively innocuous due to their low energy ©mission® and short:
half-lives •
The ('^Cr)-sodium chroaate and (12%)-iododeo®yuridine were
used in the above form* ( *%) -aodiua iodide was used to label
immunoglobulin by the method of Hunter and Greenwood (179). Briefly
the protein (5-20 ag) in 2 ml of physiological saline was added to
the isotope (5a Ci) with continuous stirring. This man followed
by the Immediate addition of 0*2 al of chloramine-T (0*5 mg/ftl}.
After stirring for 5 minutes the reaction mixture and washing*' were
transferred to a 3/32* f&etdLmg Cellulose dialysis w, The final
volume of «pproadmatcly U al w»* dialy-ed for 3 days against four
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chsnges of physiological saline at li°C, the first dialysis buffer
containing 0*1$ KI.
After an experiment the #-radiation was counted in sin 1KB
Wallac 1280 Ultragaramar in all c- ses the background counts (approx.
120 CPM) were an insignificant percentage of the sample counts.
6) PRESENTATION OF RESULTS
The tumour diameters for each group were expressed as geometric
means together with the limits of one standard error from the mean}
anti C.parvum antibody titres were expressed as the arithmetic means
of the log0 titre * one standard error; and immunoglobulin levels
were expressed as the arithmetic mean values ^ one standard error.
Antibody, detected by the antiglobulin technique, was expressed as
counts per unit time in seattergram form when individual mouse sera
were tested, and as counts per unit time or Absorption Ratios when
serum pools were tested. Each sample was tested in duplicate or
triplicate and m experimental group or serum pool consisted of at
least five mice.
The significance of the results was determined by the Student
H*-test procedure. Values of P<T 0*05 were regarded as significant.
7) ADJUVANTS PSBD
The ad uvants used in these studies were: C.parvma CN 6l.3h
(Wellcome Research Laboratories, Beckenham, Kent^; C.parvm 10387,
tropionibact; rium frcudenreicbli 10U?0 (Dr. W.H. i^cEride, Department of
Bacteriology, University of Edinburgh)} B.C.G. (Glaxo Laboratories,
Greenford, Middlesex); Jordetella pertussis (Wellcome Reagents Ltd.,
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Beckenham, Kent)} complete said incomplete Freund's adjuvant (Difco
Laboratories, Detroit, Michigan).
The adjuvants obtained from commercial sources were standard
preparations; the ad'uvamts grown in the Department of Bacteriology,
Edinburgh, were formalin fixed.
A formalin fixed strain of C.parvum (CN 6l3lt) was used in these
studies, unless otherwise stated.
HESOLTS
1* WELOPKF??? OF JTITfiLOTTTLIN ASSAT
e) Tbriatlon of the uotafoe of mouse lratunoplobulin Kith the age of
the tumur target cf-llg
The first antiglobulin teehnloue used to detect the in vitro
binding of mouse ipminoglobulin to target cells was Method A (see
Table 10). It was, however, soon found to he cumbersome and
wasteful of tiste and reagents. It is illustrated * ere by an exp¬
eriment designed to test whether freshly prepared pronare-dlgcsted,
or ill cultured tumour target cells were preferable in the anti¬
globulin sassy. The re;suits (Table 11) are expressed as Absorption
Rctios (AR).
It can be seen that there was no significant absorption of immuno¬
globulin from turrour bearing mouse serum onto cells of any age. How¬
ever the anti-CBA fibros-rcoma serun appeared to be absorbed onto
"younger" cells to a greater extent than onto "older" cells. This
could be "hie to antigen deletion, but recent results froH this labora¬
tory (102) have shown that a freshly excised pronase-diccsted tumour
cell suspension contains typically 30% -receptor bearing cells,
which decreases gradually to 0% on In vitro culture. Therefore, it
may be that the assay is detecting uptake of immunoglobulin via the
Fc-reeeptor of infiltrating host cells.
b) Sensitivity Q'" antiglobulin Method A compared with Method
Method A, as used in Results la, is limited in the number of
individual samples that can be processed. Method 3 has the
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advantages that numerous samples can be processed at once in a
microculture plate, and it is economical in senna and cells. Using
in vitro cultured CBA fibrosarcoma target cells the two methods were
compared. It cm be seen from Table 1£ that Method B was wore
sensitive than Method A at the dilutions of reagents studied.
c) Optimum dilutions of reagents in antiglobulin Method B
Before starting any serious experimental work the conditions
(dilutions of reagents etc.) were optimised to give the highest
Absorption Ratios. In this series of experiments (see Tables 13, ill,
1<>) the positive serum used in Results 1 a and b was again used, and in
addition a syngeneic serum which £ priori would be expected to yield
anti-tumour antibody. This serum was from CBA mice exsanguinated
ill days after their syngeneic tumour grafts had been excised. The
target cells used in the antiglobulin assay were cultured CBA fibro¬
sarcoma cells.
On the basis of the results in Tables 13, lU and 1!> it was decided
to proceed using the following dilutions
Mouse scram t
Rabbit «nti~ffloue»e IgO : V^q
I-gost anti-rabbit IgG s ? - 10 jug per well
d) Examination of CBA fibrosarcoma target cell loss daring anti¬
globulin Method 3
A possible objection to this type of assay is that prolonged
washing and spinning down of cells may lead to cell loss. To counter
tJl
this objection the target cells were labelled with Cr (1 ja Ci per well)
for 1 hour at ??°C, then after washing twice a standard antiglobulin
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asssy was performed. The control in this experiment was cells
labelled and washed as above ' ut otherwise untouched until the end of
the assay. Results are expressed as a percentage of this control
and each sample was tested in quadruplicate.
The results (Table 16) show that the cells subjected to multi¬
ple washings and centrlfugations of the assay (16 in all) did not lose
more than 20% of their original number. The results were corrected
for channel overlap of the if-scintillation spectrometer as follows.
h7% of the counts recorded in the Cr cb tAnal for a Cr sample
appeared in the 1? 1 channel. Therefore the counts for the
51
sample must be reduced by k7% of the Gr counts in the Cr channel.
Fortunately the channel overlap from the to Hie ^Cr channel was
negligible
e) Absorption of reagents to plastic reaction wells in Method 3
Another objection that can legitimately b© advanced against the
antiglobulin assay as used :fn Methods A and 3 is that s sorption of
reagents to the plastic wells might constitute an unacceptable propor¬
tion of the final <5*-counts. To examine this the Absorption Ratio
(AR) of serum from G.parvmii-treated mice was plotted against the dilution
of mouse serum in plastic wells with and without C3A fibrosarcoma target
cells.
It was expected that the AR of serum fro® C.parvum-treated mice
would approach unity in wells without target cells. At the dilutions
studied this was true (Fig, 1<). However, the counts in empty wells
with normal serum were a significant proportion of the counts in wells
with target cells plus normal serum (approximately 7*t). Thus, in
-Cl¬
antiglobulin Method B it is only valid to draw conclusions from the
Absorption Ratios, ie. the relative uptake of the test serum against
noraal serum, and not from the absolute ^counts.
This diffieulty could be overcome by using Method C or B in which
the cells were transferred from the tubes or wells used in the anti¬
globulin assay to fresh tubes or wells for cf-counting. Using
Method C (Fig. 16) the Absorption Ratio of serum from C.parvum-treated
mice was at lea-t as high ass in Method B. Antiglobulin Method D is
illustrated in the next section.
f) Optimum dilutions of reagents in antiglobulin Method D
Antiglobulin Method D was used in two modifications: with rabbit
anti-mouse IgG plus 1^I-labelled globulin fraction of goat anti-rabbit
IgOj and with goat anti-mouse iaaEunoglobulln olus 12% -labelled globulin
fraction of rabbit anti-goat IpG. This series of experiments examines
whether variations in the concentration of mouse serum, or of the ijb-
labelled antiglobulin recent, affected the result of the antiglobulin
assny.
It can be seen from Table 1? that using the first variation the
lowest concentration of mouse serum, combined with the highest concen¬
tration of -labelled antiglob ulin reagent, gave optimum uptake of
serum from the experimental groups (compared to normal serum). Con¬
versely, using the second variation comparable results were only-
observed at the highest concentration of mouse serum and the lowest of
1^I-1& elled antiglobulin reagent (Table 18). These conditions were
used in subsequent experiments.
-81 a-
TABLE 11 VARIATION7 0? UPTAKE OF MOOSE
immunoglobulin with the age o*
CBA fibrosarcoma target cells
AGE OF TUMOUR CELLS ?s£s) TMS^a'




10 1 *7 ^1
17 1-7 1*1
a) NMS - normal serum from CBA mice
ims - tumour bearer serum fro® CBA ®ice
bearing a syngeneic fibrosarcoma.
PS - BALB/c snti-CRA tumour cell serum.
Note
There was no significant absorption by TMS
onto cells of any s however, the anti-CBA
serum seemed to be absorbed onto "younger"
cells more than to*blde# cells. It might
therefore be preferable not to use cells
"older" than seven generations.
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TABLE 12 COMPARXSOS Of JHTIQL03PIIH METHODS A AHB B I
VARIATION CP MOTSF !»! IglCTICTS











V, *&> irr 3*5 1*20
%» i*55 0«Sl ST HI
V„ 1*15 0-8h 71 1*37
yiQO 1-0 0-95 1-95 1 *20
a) PS - Positive seruts ie. anti-CBA fibro^arcon®
f eru* raised in 3ALlJ/e mice by m injec¬
tion of 1 x 10? coils s.c. followed by a
similar injection i.p. 7 days later.
IMS - Kormal CBA motxm gervm
THS - Serum fro* CBA id.ce Waring a syngeneic
fibrocarcoma
b) ST - Sot tested
Note
1) Method 3 was more sensitive than A
2) High concerntrationc of armse r<ero» gmm the
highest AS
3) Target cells were CBA fibrosarcoma
OPTIMUMCONDITIONSFORANTIGIflB LTNSSAY(METH DB)

















































-Postexci ionserum(serumfrCBAm ce1Udaysafteramp tationfpalpable<* ng neictu our) -NormalCBAserum -BALS/canti-C3Afibrosarcomaeru
1O
1
RAM-abbitanti-nauipIgGerure GAR-Antiglobulinreagent(i-labell dglfractioofoaanti-raliI G)
Note TargetcellswereCBAfibrosarcoma.






11,277 13,932 11,767 12,776
Targetcellssubjectedtothrttltlplwashin - deon rifngatiCHaf(16i )f ar-syneverlotmarh n20?ft iroriginali mb r.
CO
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Fig. 1$ UPTAKE OF IMMUNOGLOBULIN BY a) CBA TUMOUR CELLS PLUS
PLASTIC REACTION WELLS AND b) PLASTIC REACTION WELLS ONLY
DILUTION OF MOUSE SERUM
-81 e-
Note (Fig- 15>)
1) C.parvum (1 -U mg) injected i.p. Day 0; mice bled Day 21. Normal
serum from age matched controls was used to compute the Absorption
Ratio (A R).
2) Two pools of serum (I and II) from C.parvum-treated mice were examined.
3) At the dilutions tested the A R with cells was always greater than
without cells. Although seme uptake onto plastic was observed
this could be avoided by using Antiglobulin Methods C or D.
U) Antiglobulin Method B used.
-8if-
Fig- 16 UPTAKE OF IMMUNOGLOBULIN BY CBA TUMOUR CELLS
(ie. CELLS REMOVED FROM THE REACTION VESSEL FOR COUNTING)
A R = Counts per minute with serum from C.parvum treated CBA mice





1) CBA mice injected with C.parvum (1•U mg) i.p. Day 0; mice bled Day 21.
2) Antiglobulin Method C used.
3) This method was quite sensitive although there were severe limitations
on the number of samples that could be processed.
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■-5SE 0? ANTIGIflHJLIH ASSAY TO DETECT IHMDMOGLOHTTLIN REACTING Hi
VTTHO IJTTTT 5TNGEHEIC TUMOUR CELLS AFTEK r.PARVTTM ADMTlgTSTRATIOM
Effect of C.T^arrom treatment schedule on iraaunoglobulin binding
to tumour cells In vitro
i) Different routes of £^aanma administration in normal and
tuaour bearing: alee-
Previous studies performed in our department and elsewhere
have shown that i.p. administration of C.parvom markedly inhibits
the growth of a s.c. inoculum of tumour cells given three days
earlier. In contrast the s.c. injection of the same dose of
C.parvuiB at a site distant from tumour has no effect on tumour
growth (3). In view of these observations we decided to
compare the effect of s.c. and i.p. injection of C.parvua on the
development of serum immunoglobulin capable of binding to syngeneic
tumour cells in vitro in normal and tumour bearing mice. To
do this the following foups of mice were set upi A - untreated
control mice, 3 - normal mice injected s.e. (left thigh) with
I'll mg of C.parvum on Day 3, C - normal mice injected i.p. with
1-U rag of C.parvura on Day 3» D - mice inoculated s.c. in right
t?
thigh with 1 x 10* syngeneic fibrosarcoma cells on Bay 0, E -
mice as in D but also in ected s.c. (left thigh) with 1'h mg of
C.parvum on Day 3, F - mice as in D but also injected i.p. with
1 'U rag of C.parvuia on Day 3.
Each group was bled out on Day ?lt (ie. 2h days after inocu¬
lation of tumour). The results of this experiment are summarised
in Fig. 17 and Table 19.
-93-
It will be observed that in addition to inhibiting tumour
growth the i.p. administration of C.parvum (Group F) resulted
in the development of immunoglobulin reacting with syngeneic
tumour cells in vitro* In contrast the s.c. in-ection of
C.parvuBi (Group E) failed to influence tumour growth (Table 19)
and had little if any effect on immunoglobulin binding to tumour
cells in vitro. The i.t>. administration of C.pgrvunt to normal
mice (Groun C) resulted in the production of immunoglobulin bind¬
ing to tumour cells in vitro whereas s.c. infection (Groyo B) was
again without effect.
I.p. in'ection of C.r urvum into normal and tumour bearing
mice ^ave higher anti-C.narvum ariibody titres than s.c. in'ec¬
tion (Table 1 ).
ii) Different doses of £U&iK3ffla in normal mice—w——i *» i>iiii»iii»ii«iwMWMiB^i»iw<i>iai»miJiMWJiaaw»w«iiwi i i >i»m—w—i—
In this experiment the serological changes occurring in
normal mice following the administration of a range of doses of
C.parvure were investigated. Mice were either untreated (Group
A) or injected i.p. with 0-lit mg (Group B), 0'7 jag (Group C) or
1 -h »g (Group D) of C.pervum, said exsanguinated 7 or 21 days later.
The serolo ical changes observed are suraserised in Figs. 18 and 19
and T ble 20.
Immunoglobulin binding to tumour cells in vitro and anti¬
bodies to C.rarvur. were detectable 7 day?? after challenge and in
general had increased substantially by Bay 21 (Fig. 18 end Table
20). The binding to syngeneic tumour cells exhibited a dose
dependent effect whereas the development of antibody to C.oarvua
-83a-
Fig- 17
EFFECT OF ROUTE OF C.PARVUM INJECTION ON UPTAKE
OF IMMUNOGLOBULIN BY CBA FIBROSARCOMA CELLS













































ABC D E F
2000
A&D Untreated B&E CParvumS.C C&F C ParvumlP
Note
1) Tumour (1 x 10^ cells) s.c. Day 0; C.parvum (1*U mg) i.p.
or s.c. on leg opposite to tumour, Day 3} mice bled Day 2h-
2) Tn normal and tumour bearing mice i.p. injection of C.parvum
gave significantly higher uptake of serum immunoglobulin than
s.c. injection (P < 0*02).
3) In normal and tumour bearing mice s.c. injection of C.parvum
did not give significantly higher uptake of immunoglobulin
than untreated mice.
h) Only i.p. injection of C .parvum inhibited tumour growth (P< 0-0.3).
3) Antiglobulin Method B used.
-83b-
TABLE 19
THE EFFECT 0? THE ROHTE 0? ADMINISTRATION Of- THE RESPONSE TO




IN jam *a)GRGIJF TREATMENT
(Log? i S.E.) (Oeom. Mean £ S.E.)
A Normal controls 1*1? 1 °*11
B i*U mg C.pervum s.e. Day 3 Ii*35 + 0*20
C 1 'h mg C.paraatm i.p. Day ? 8-13 + 0*13
D
g




1 x 10' tumour cells Da 0
end
1'U mg C.parvum s.c. Day 3
3*70 + 0*1?
10*6




1 x 10 tumour cells Day 0
end




a) Anti-C.parvum mtidodies and tumour diameters were measured on
Day 2ii. ie. 2L days; after tumour Inoculation and 21 day* after
C.param in'r-ction.
b) Values in brackets are the limits of one standard error from the
geometric mean.
Note
1) The anti ody response to C.parvnra was significantly greater
following i.p. in'ection (P <0*001) than in control mice.
2) The antibody response to C.parvtun was significantly gre ter
following i.p. in'ection (p <_0*01) than in mice treated with
C.paraim s.c.
3) C.p-rvum fidrainistration i.p. slgni"icantly inhibits tumour growth




EFFECT OF DIFFERENT DOSES OF C.PARVUM IN CBA MICE ON

























A B C D
e
-- ©
A B C D
A.CONTROLS B.O Umg C.PARVUM
C.07mg C.PARVUM D. 1-4 rng C.PARVUM
Note
1) C.parvum was injected i.p. Day 0; mice bled Day 21.
2) On Day 7 only mice treated with 0* 1U mg of C.parvum gave a
significant uptake of immunoglobulin (P < 0-057"!
3) On Day 21 mice treated with 0-7 mg and 1*U mg gave significant
uptake of serum immunoglobulin (P < 0-005).
h) Antiglobulin Method B used.
-Sid-
Fig. 1°
IMMUNOGLOBULIN UPTAKE FROM THE SERUM OF C .PARVUM TREATED

























A B C 0
A. CONTROLS B.O-Umg C PARVUM
C. 0-7mgC PARYUM D.I Amg C PARVUM
Note
1) C.parvum was injected i.p. Day O; mice bled Day 21.
2) The uptake of serum immunoglobulin onto both target cells
was increased after administration of 0*7 and 1 - IT mg of
C.parvum (P < 0-001 ).
3) Antiglobulin Method B used.
-83e-
T ABLE 20
THE RESPONSE OF CBA NICE TO VARIOUS SOSES OF
C.PARVUM INJECTED i.p.
c-.parvuh antibodies
GR0Up DOSE OF C.pakvtm (lo^ 1 S.E.)(rail —
Day 7 Day 21
a None 2-07 ♦ 0*07 2*07 + 0'07
B 0*1h rag <•50 ♦ 0-27 9»N0 + 0*1<
C 0-7 mg 5*Illj 0#0 9-60 * 0*25
D 1 ♦!* rag 6-If ♦ 0«2li 9-2B * 0*18
Note
The response to C.pervur wrs not affected by the dose
administered.
-81i-
did not. Further analyses were undertaken to determine the
specificity of the immunoglobulin binding to CBA tumour cells
in vitro. These showed that C.oarvum administration resulted
in the production of immunoglobulin capable of binding to both
CBA end A/He.1 fibrosarcoma cells in vitro (Fig. 19).
Cellular T asis for the production of imunoglobulin binding to
syngeneic tumour cells in vitro after r.oarvum administration,
i) The effect of gold salts on jLnargBB. activity in tumour
bearing mice
A number of investigators have shown that the administra¬
tion of C.parvun results in an increase in the number and
activity of mononuclear phagocytes (180) and there is accumulating
evidence that such cells may play an important role in tumour
surveillance (i33)• In view of these facts we undertook
studies to determine if the serological changes elicited by
C.parrua could be influ enced by the administration of sodium
aurothiomalate, which is known to accumulate in phagocytic cells
and inhibit their lysosomal and phagocytic activity (181).
Xn order to do this the following groups of CBA mice were
set up: A - mice injected s.c. with 1 /" syngeneic fibrosarcoma
cells on Day 0. B - mice in'eeted with tumour cells as above
and 1*U ®g C.parvum (i.p.) on Day 1. C - mice injected with
tuiaour cells as above but receiving a course of in eetions of
sodium surothiomalate (sec Fig. 20). D - mice in'eeted with
tumour cells as above on Day 0, 1*1* ag of C.parvtun (i.p.) Day 3»
and the standard sodium aurothiomalnte treatment, The
-35-
animals were exsanguinated 21 days after C.parvum administration
(Day 2k) and the results of the experiment are recorded in
Fig. 20 and TaMe 21.
It will be o served from Table 21 that the anti-tumour
effect of C.nsmm was completely abrogated by treatment with
gold salts. Furthermore, this treatment modified the sero¬
logical c" ?es observed following C.parvum administration.
For example, the development of immunoglobulin binding to syn¬
geneic fibrosarcoma cells in vitro was completely inhibited
(Fig. 20) and anti-C.parvraa antibody was partially inhibited
(not significantly).
ii) The effect of C.parvum in T-cell-denrived mice
A considerable amount of attention has been paid to eluci¬
dating the mechanisms whereby adjuvants exert their anti-tumour
effects. For example, studies with C.parvus have shown that
it exerts an anti-tumour effect against a s.c. tumour Implant
in B-mice, if injected i.p., but is relatively ineffective if
injected di cctly into the same site as tumour cells (3)« In
the light of these observations we have undertaken studies on the
serological effects of C.parvum in tumour bearing B-mice (ie. mice
produced by thymectomy, X-irradiation and bone marrow recoristitution)
end in congenitally athymic mice.
Experiments with tumour bearing 3-sice involved the following
groupsi-
A. Tbymectomised, irradiated, bone marrow reconstituted
CBA nice (ie. 3-aice) injected s.c. witv icA syngeneic
-86-
tumour cells on Dey 0 (that is 35 days after reconsti-
tution).
B. Mice as in group A but also injected i.p. with 0-7 mg
of C.parvua on Dsy 3«
Further details of the thymectomies, irradiation and reeonstitu-
tion procedures are recorded in Materials and Methods 1. The
mice were exsanguinated on Day 25 (ie. 22 days after C.par-vum
administration) and the results are recorded in ?lg. 21 and
Table 22.
It will be observed from Table 22 that the anti-tumour
effect of C.parvuia was apparent in B-miee. The serological
changes in thla experiment were more variable than in previous
experiments with intact mice, in some cases possibly due to the
lack of suppressor T-cell activity. The variation was particu¬
larly apparent in Group A. Nevertheless, it should be noted
that with two exceptions in Group A, the administration of
C.parvum to B-sd.ce resulted in an increase in the levels of
immunoglobulin binding to tumour cells in vitro and entl-C.parvum
antibody. However, in general the increases were less than in
intact mice. This is illustrated in Fig. 21 which makes
explicit what has hitherto been implicit, namely that there may be
a correlation between immunoglobulin binding to tumour eelIs in
vitro and anti-C.parvum antibody.
Experiments with"nude" mice involved the following groups,
depending on the experiment:-
Control group: Normal BALB/c mice or heterozygous "nude" mice on
-86a-
Fig. 20
EFFECT OF GOLD SALTS ON THE UPTAKE OF IMMUNOGLOBULIN BY






















1) Tumour (1 x 10^1 cells) injected s.c. Day O; C.parvum (1*1; mg)
injected i.p. Day 3; sodium aurothiomalate was administered
by eight i.p. injections on alternate days starting Day 2;
mice were bled on Day 21;.
2) The uptake onto syngeneic tumour cells of immunoglobulin from
the serum of mice treated with C.parvum-gold salts was signi¬
ficantly lower than mice treated with C.parvum only and was
not significantly different from control mice.
3) The administration of C.parvum (Group B) significantly inhibited
tumour growth (P <T 0*001) but this effect was overcome by the
administration of gold salts (Group D).
1;) Antiglobulin Method B used.

























a)Anid.perrorentioodiesrtum urdi >a*t swo enes r d>nD«"?' ,i .2l>y?afteruu inoculationand21d yafterC.par-runinjection. b)Valuerinbrack tsrethHaltofnestandarder orfromthgeometricm m . Note Thetdsini-trationofC.parrura(GroupB)ni cantlyinhibit?tum urgr wth(P-=iQ*00i)butthisffecinovercomebytheadmini?trationofgoldrait(G upD),Thi--t ea whow verestismiTLeantlJrinhibitt *formationofsntibodicrtC.p-';rvTir-.
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Fig. 21
CORRELATION BETWEEN IMMUNOGLOBULIN TAKEN UP BY CBA FIBROSARCOMA















2 4 6 8
log2 anti-c.parvum antibody titre
10
□"B'mice H'B'mice + C Parvum
Note
1) Tumour (1 x 10^ cells) injected s.c. Day O; C.parvum (0*7 mg)
injected i.p. Day 3; mice bled Day 2$.
2) In general the administration of C.parvum to B-mice resulted
in serological changes of lesser magnitude than in previous
studies with intact mice. Only three mice gave responses
comparable to previous experiments.
(PC0-003)
3) C.parvum inhibited tumour growth in 'B'-mice/ Again the
effect seemed less than in intact mice.
1;) Antiglobulin Method B used.
-86d-
TABtE 22 THE EFFECTS OF & 1M7UR 1EAKDK?
T-CELL SETECIEHT MICE
(a)
ASSAY METBOTJT C.PAHVUM WITH C.PAKTOM
(c)
Tumour Hamster (ran)


























11*2 (10*7 - 11*3)
7*1 _♦ 0*9
106* •' + 11*7




a) Mice challenged on Day 0 with 1 x 10 1 tumour cells s.c., 3? Days
after reconstitution with bone m irow cell1*. C.pmrum (0*7 ng)
injected i.p. Day 3.
b) Tumour measured 23 days after tumour transplantation.
o) All serological assays perfomed on serum taken 25 days after
tumour transplantation.
d) A ne-r normal seruia standard was used in these assays. This




Tumour inhibition after C.parvum treatment ignlficant at P < 0*005
With the exception of the IgG^ vallies all other measurement? of
immmoglobulln levels in C.parvtua-treated animal5? are significantly
different than in the untreated group.
-86e-
Fig. 22 EFFECT OF C.PACTUM IN CONGENITALLY ATHYMIC MICE







































1) C.parvum (0*7 mg) injected i.p. Day 0; mice bled out on Day 18.
2) The athymic trait was inserted into the Balb/c background.
3) After C.parvum injection normal (P <T 0*025) and homozygous (P < 0*05)
^nude*mice had higher levels of immunoglobulin binding to CBA fibro¬
sarcoma cells than untreated controls.
U) Antiglobulin Method B used.
TABLE23
SEROLOGICALCHAN ESIF"I-nTDEwMICAFTERDMINISTRATIONOFf!.PA VTTM Heterozygous"nude"niceHom us" "i /\onaBALTi/cbackgroundL3r









































































a)Thememvalueforeachp r metere suredwasc lculatrle9individ ali b)0*7ragC.psrvumadministeredD y,Micled21. c)Therewasidvar tionsint eIgG.,andfd^ale eluntreatedreatehomozyg u"nud "c . *P-^0 09*^O'01***-0 1
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a 3ALB/c background, cither untreated or injected with 0*7 ag
C.uarnun i.p. or i.v*.
Experimental groups Homozygous "nude* mice on a BALB/c back¬
ground, either untreated or injected with' 0*7 mp C.parvun
i.p. or i.v. MJ.ce were bled out 18 - 21 days after
C.parvus; injection.
It can be seen from Fig. 22 and Table 23 that administration
of C.parvum to "nude" nice resulted in a significant increase in
the levels of immunoglobulin binding to allogeneic (CBA) fibro¬
sarcoma cells. In addition anti-C.oarvum antibody titres were
significantly elevated.
It should e noted that the highest values for the immuno¬
globulin binding to CBA fibrosarcoma cells in vitro after C.parvum
injection were similar tn homozygous and heterozygous "nude" mice.
In contrast, the anti•-C.narvur. antibody titres in heterozygous
"nudew mice were higher than in homozygous "nude" mice (T fole 23).
c) Effect of C.osrvma on imuno,glo'<ulin bound to tumour cells in vivo
In view of the observation by R® et al, (i"2) that tumour cells
may be coated in vivo with immunoglobulin, experiments were set up to
determine if C.psrvum therapy affected the amount of immunoglobulin
bound to tumour cells in vivo in our system. To this end an indirect
1
antiglobulin assay with rabbit anti-mouse IgG and "I-labelled globulin
fraction of goat anti-rabbit IgG was used to detect immunoglobulin on
freshly excised, mechanically disrupted CBA fibrosarcoma cells. Anti¬
globulin method 3 was used to detect immunoglobulin capable of binding
to CBA fibrosarcoma cells in vitro in the serum of autochthonous CBA
-M-
raice (ie. those nice examined for in vivo bound iraaunoglo"; ulin).
These studies revealed that the amount of iasiunoglol nlin 1 crand
in vivo was increased after C.parvus adirdnistrstion (Fig. 23 and Table
210- Furthermore, there was a correlation between Immunoglobulin
bound in vivo and In vitro to CHA fibrosarcoma cells (Fig. 210. This
is further illustrated by examining the ratios of in vivo hound to in
vitro bound immunoglobulin. Thus, the ratios were not significantly
different in the G.parvua-trented group or the untreated group, indicat¬
ing a direct relationship between in vivo and in vitro 'ound isirmmo-
globulin. It should be noted that these experiments do not reveal
whether the immunoglobulin detected in vivo wae bound via the Fab or
?e region.
d) Effect of different strains of (VflfflTiffpT normal and tumour—■————wmii ■ iin i mm—iwo—i iiiih
bearing mice, on immunoglobulin binding to syngeneic tumour cells
1T1 rtttTB-
It was of interest to see if other strains of C.parvu? elicited
the production of serum immunoglobulin capable of binding to syngeneic
fibrosarcoma cells. To investigate this C.parvua CN 6l3i{, C.pgrvun
I0li70 (?.freudenreich.il) and C.parvum 10337 were in.'e4ted into CBA
mice end their ability to inhibit tumour growth and to elicit immuno¬
globulin binding to syngeneic tumour cells in vitro was examined.
All of the strains injected into normal sice induced small tut
significant increases in serum immunoglobulin capable of blading to
syngeneic tumour cells in vitro (Fig. 2£). In tumour bearing mice
strain C?7 6Ilk and 101*70 agair evoked small but significant increases
in aerum immunoglobulin capable of binding to syngeneic tumour cells
TABLE24INVIVOA DF7T"R0TUM URBOUNDIMgNOQIOBUIIN INr.PfrfiVTTM-TREATEDTUMOURB RINGHlC ^a) PARAMETERMEASUR DUNTREATEDfdgy^V>P"V L E
Tumourdiaro ter(mm)13*5*70-005"->0*01(l7-Ji-l9-8)(13-1-lU'U)




Fig. 23 DETECTION OF IMMUNOGLOBULIN ON THE




























1) CBA fibrosarcoma (1 x 10^ cells) injected s.c. Day 0; C.parvum
(1-k mg) injected i.p. Day 3; on Day 2U mice were bled out and
a cell suspension was made from each tumour, keeping the tempera¬
ture at U°C.
2) Greater amounts of immunoglobulin were found on the tumour cell
surface in C.parvum-treated mice (P < 0-001 ) than in untreated mice.
3) Higher levels of serum immunoglobulin binding to CBA fibrosarcoma
cells were found in the sera of C.parvum^treated mice (P = 0-003)
than in untreated mice.
1;) C.parvum inhibited tumour growth (P < 0-01).
-88c-
CORRELATION BETWEEN IMMUNOGLOBULIN DETECTED ON THE













SERUM ANTIBODY (Counts/30 sec/103)
Note
With one conspicuous exception there is a correlation between
the amount of immunoglobulin in mouse serum capable of binding to
CBA fibrosarcoma cells, and the amount of immunoglobulin detected
directly on the tumour cell surface.
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Fig. 2U EFFECT OF DIFFERENT STRAINS OF C.PARVUM IN
NORMAL AND TUMOUR BEARING CBA MICE ON UPTAKE OF





























B; F - C.PARVUM 6134
C;G - PROP. FREUDENREICHII
D;H - C.PARVUM 10387
D
Note
1) Tumour (1 x 10^ cells) injected s.c. Day 0; C.parvum (strain 613U
and 10U70 (P. freudenreichii) 1-1; mg, strain 10387 0-7 mg) injected
i.p. Day 3; mice bled Day 2l|.
2) In normal mice all strains of C.parvum resulted in a small but signif¬
icant increase (P < 0*0£) in levels of serum immunoglobulin binding
to CBA fibrosarcoma cells. In tumour bearing mice the increase
was most significant for C.parvum IO387 (P < 0*001).
3) C.parvum strains 613H and IO387 inhibited tumour growth (P £ 0*01).
Strain 10U70 was ineffective.
U) Antiglobulin Method B used.
-88e-
Fig. 26 SPECIFICITY OF ANTI-TUMOUR ANTIBODY PRODUCED BY C .PARVUM
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+
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1) Tumour (1 x 10^ cells) injected s.c. Day 0; C.parvum (strain IO387)
0*7 mg injected i.p. Day 3j mice bled Day 2I4.
2) The uptake of immunoglobulin onto CBA fibrosarcoma cells from the
serum of mice treated with tumour and C.parvum 10397 was greater than
for mice treated with C.parvum IO387 alone (P<.0-00£). The uptake
onto CBA embryonic fibroblasts was not significantly different.
3) C.parvum strain IO387 inhibited tumour growth (P<i_0-00l).
U) Antiglobulin Method B used.
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Fig. 27 EFFECT OF DIFFERENT ADJUVANTS IN NORMAL AND
TUMOUR BEARING CBA MICE ON UPTAKE OF IMMUNOGLOBULIN
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1) Tumour (1 x 10^ cells) injected s.c. Day 0; adjuvants (C.parvum
0'7 mgj B.C.G. 9 x 10-5 organisms, B. pertussis 1; x 109
organisms) injected i.p. Day 3; mice bled Day 2U.
2) In normal and tumour bearing mice administration of C.parvum
caused significant increases (P < 0*01) in the levels of serum
immunoglobulin binding to CBA fibrosarcoma cells, while B. pertussis
caused a significant increase (P < 0-0£) in tumour bearing mice.
B.C.G. was ineffective in normal and tumour bearing mice^ as were
Freund's complete and incomplete adjuvant (0*1 ml). (Not shown)
3) C.parvum (P •<£" 0-001 ) and B. pertussis (P 0-03) caused significant
inhibition of tumour growth.
h) Antiglobulin Method B used.
-85>-
In vitro# whereas strain 1038? induce?! a leree Increase. The
difference between normal and 3A fibrosarcoma bearing mice treated
with C.rarvun 10387 suggested that part of the response might be 'due
to unique tumour antigens. . Fig. 26 indicates that this may be the
case because the relative uptake onto GBA fibrosarcoma cells in vitro
from the serum of mice treated with C.p*rvum 10387 nnd tumour was
greater than the uptake onto CBA embryo cells. The relative uptake
is defined here as the uptake compared with mice treated with C.pnrvum
10387 only.
e) Effect of different adjuvants, in normal and tumour bearing mice,
on immunoglobulin binding to syngeneic tumour calls in vitro.
It was also of interest to see if ad'uvants, ostensibly unrelated
to C.parvus)., could elicit Immunoglobulin cape1 le of binding to syngeneic
fibrosarcoma cells. Thus, normal md CBA fibrosarcoma bearing mice
were in 'ected with C.parvua, 3C0 end ^.pertussis, and ti etr a ility
to inhibit tumour growth and to ©licit isaaunoglohulln capable of bind¬
ing to syngeneic fibrosarcoma cells in vitro was measured.
At the stated doses the C.psrvum protocol produced the most
dramatic inhibition of tumour growth and the highest levels of immuno¬
globulin capable of binding to syngeneic tunonr cells (Fig. 27).
While b,pertussis produced minor effects on both of these parameters,
8CG was ineffective.
f) Characteristics of serum 1p?ttook1o' ulin inding to syngeneic
fibrosarcoma cells in vitro
For these experiments pools of serum were obtained from normal
CBA sice, C.parvua-treated mice, CBA mice bearing a syngeneic fibre-
-70-
ssrcoma, grid GBA nice bearing a syngeneic fibrosarcoma treated with
C.parvtm. To investigate v-> class of ircmttnog lo'mlin binding to
syngeneic fibrosarcoma cells in vitro the above serum pools were
separated on G-2Q0 sephsdex and the fractions examined by antiglo ulin
Methods 3 and D. In addition the snti--C.parvu» antibody titres of
the fractions were measured.
It cm. be seen (Table 2?) that sntlglo- >ulin method D was more
sensitive than 3 as it revealed a ?S as well as a 19S response in
C .oarvttm-treated tumour bearing mice. The f ?3 response correlated
with high anti-C.parvuw antibody titres whereas the 7S did not.
toother approach to this problem was to use antisera specific for
mouse class and sub-class immunoglobulins in the antiglobulin assay.
The results of such en experiment are presented in Ta' lea 2 6 and 27.
It can be seen that mice treated with C.parvua had increased levels of
IgK md IgGpe (on the borderline of significance taking a 10% increase
as significant) capable of binding to syngeneic fibrosarcoma cells
in vitro. Tumour bearing mine had an increase of IgG^, and tumour
bearing mice treated with C.parvuia mx increase of all classes and sub¬
classes except IgA. The results using 0-201 sephadex fractions snd
antisera specific for mouse class snd sub-class immunoglobulins were
in close agreement.
g) Specificity of serum IgTmanoglo^ulln binding to syngeneic fibre-
sarcoma cells in jdLfciff.
There are several possible explanations for the presence in serum
of C.nsrvum-treated mice of increased levels of immunoglobulin capable
of interacting with syngeneic fibrosarcoma cells. These include;
-91-
a) the production of increased levels of c-tophilie IgG which binds
to infiltrating host cells; b) the production of antibody against
en.tigenie 'determinants shared by P.oarrant and mammalian cells; c)
an increased production or a de novo synthesis of autoantibody; d)
an increase in the level of pre-existing anti-tumour anti- ody; e)
the production of antibody against unique tumour antigens. Some of
these mechanises were Investigated in the following experiments.
i) ^lor'-ing of imunogiobulln uptake with aggregated human IgG
It might be expected a priori that uptake onto in vitro
cultured cells would not he via Fc-receotors (and therefore would
-receptor
not be blocked with aggregates) as the number of ?e/bearing cells
In a fresh tumour cell suspension decreases rapidly in in vitro
culture conditions (102). This point was confirmed by prein-
cubating the In vitro cultured tercet cells with aggregated human
IgG. After washing, the cells were used in the standard anti¬
globulin assay using either Method B (T«ble 23), or Method D
(Tables 30, lO. It can e seen that only when using fresh
spleen cells as targets did preincubation with aggregates cause
inhibition of immunoglobulin uptake.
ii) Upta!re of immunoglobulin from whole serum onto malignant
ad non-malign amt cells
To obtain some insight into the antigenic determinants that
the antibody detected by the antiglobulin assay was reacting
against, it was necessary to use non-malignant target cells.
Therefore, C3A embryonic fibroblasts (in vitro cultured) and
spleen cells (freshly prepared) were used as target cell in the
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antlglobulln assay, concurrently with the usual CBA fibrosarcoma
cells.
It can be seen that immunoglobulin, 'ron the unfrsctlonetod
serum of nice treated with C.parwb hound to CBA fibrosarcoma
cells end CBA embryonic fibroblasts to about the sme extent
(Fig. ?8). Fortherieore, the uptake. onto spleen cells was
greater than onto fibrosarcoma cells. This latter phenomenon
was dependent on the number of target cells (Fig. 29, expt. 1)
and whether they contained glass-adherent cells (Fig. 29, expt. 2).
ill) Tfptabe of tnmmoplobulln from (1-200 serum fractions onto
malignant and non-malignant target cells.
In section 2? it can be seen that CRA mice, bearing s syn¬
geneic fit rossreosta and treated with C.parvum, are capable of a
comnlex antibody response to OBA fibrosarcoma cells. It was
therefore of interest to see if the same specificity towards
target cells was exhibited by both the 19S and ?S response. To
Investigate this the ma*or immunoglobulin containing 0-900 fractions
were tested in the antiglobulin assay (Method D) against CBA
embryonic fibroblasts, CRA spleen cells, and A/BeJ tumour cells.
In each experiment CBA fibrosarcoma cell targets were also tested
for a direct comparison.
Hie results in section 2g(ii) indicated that whole scrri *"ro»
C. p arms' -treated normal raice did not exhibit specificity for CBA
fibrosarcoma cells when compered with syngeneic embryonic fibro¬
blasts or spleen cells. Indeed, the relative uptake onto normal
CBA spleen cells was greatest. This appears to b® ref> cted in
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tho fbS serwtn fractions m this fraction of serasa from C.ntsmm-
treatud nice exhibited t greatest uptake (relative to the 1;>S
fraction of norr.nl gMppftl wKhNi CM normal Hldney fibroblasts were
used as target, cells (Table ? ').
A moro interesting point is whether C.parvus promotes an
in vivo reepoaa* to tumour antigens, either common or unique.
To examine this, serum from nine treated with C.parvun plus CBA
fibrosarcoma cells was eomoared with ?erun from nice treated with
C.p*rvww alone. Thus, it can be seen that the 73 fraction of
senna from nice treated with C.parrun plus CIA fibrosarcoma cells
exhibited a greater relative uptafee onto CM fibrosarcoma cells
than onto any of the other eells tasted (Tables 27 - 71). This
date is summarised in Table 7?.
iv) PTect of absorption on o^te' e oh serum inxnnoplo»T;lln onto
CPA Troearcoma cellr- ^ v^tpo
Another method of assessing the specificity of an antibody
reaction is absorption with agents which might be expected to
p«s*»aa relevant antigenic deterMtaants. Therefore, sera
fron (31 ftbrosorcoua bearing mice and € - oanreat-tre ated CBA fibro¬
sarcoma bearing nice were absorbed with either CM fibres sreona
cells, CPA spleen cells, or C.pgirvuB. tfs&ng eells, 1 rl of ecch
sorum (diluted 1/10) was absorbed three times for 1 hour at fc°
with 6 x 10^ methanol/«4cetic acid-fixed cells. Using C.nerroau
1 «1 of each senai (diluted 1/10) was absorbed 3 tires for 30 rdn.
at ?7°C with 1/10 pacfrsd cell volume of organisms,
These studios revealed that the cerur- immunoglobulin capable of
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TABLE 25
UPTAKE CtlTO CPA -T3RQSMCQHA CELLS 0?
g-gqq skphadbx factions o>-t smgrnmc sebum,
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MEDIUM ONLY CC3TTBDL 3,?8l
a) Group A - nonaal OBA controls! Group 8 - 1*U C.parrqi
l.p. Day 3j Group C - 1^x 10 CBA ^ibroaarcoaa c'ells <-.e.
Day Q| Group D - 1 x 10' C3A fibrosarcoma cell r#.c.
Day 0, 1 'h m, C.parvuxa i.p. Day 1j mice bled Day ?lt.
b) Result ? are exprescod as counts per 60 ree. (Method B)
and 300 sec. (Method D).
c) Mtd-C.parvaffl antibody titroe In paarcnthe*In mice
not treated with C.panniB the titre* were always <3.
-93 a-
8ot« (Table 25)
1) It is not valid to compare results expre-'red a- ab-oltjte
connt« par unit time* experimental groups mu« t be compared
with the relevant aouso ^«rum control*.
2) Uptake of imunoglobulin was niRilar In both methods; however,
only Method I) gave an increased uptake fro® 7S fractions in
Group D.
3) the uptake of immunoglobulin onto CBA fibrosarcoma cells
oorrespondods to the anti-C.parvua antibody titre except
when considering the 7S uptake by Method B.
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TABLE 26
rrr>?j*?F cy*n r*A vTmyrxrrcr'A cms op t-a mv im
agLma cp
(SCAT A!TTT<rwBw TOSB 10 ABTT-MWrSE IgA
M«S»e serum from Groi^j A*2*' 1,391^' 1,130
Mero*#» c*rsw from Group B i#73B 1,^
House reruu frost Group C m
"cm-** »erum from Group T> 2,Jjl6 1,2h?
a) Ore* A - normal CBA control"!, Ororr* R • t*Ii w C.nerros
i.p. iiajjr 3? Group C - 1 js 10? CM XXtrosareowa cells'ale.
Buy Of Group D « 1 x 10- CM fibrosarcoma calls «•«•
Sqr 0, 1*l« ag C.parvua i.p. lisp 3| s&ee bled bu» 2ii.
b) Each result is expressed as counts per 100 mec. md Is the
moan of triplicates.
<ott
1) faking absorption ratios of 1*3 and <msr to ba significants
scrum from Groan B zxre a si.maificant uptake of XgH when
oompared to series fro® Group A.
2) Absorption, ratio For optmm of XgH from Group 3 serum was
1-29.
3) Antiglobulin Method D used.






















































«)*ro\r>A-normalOB/cor.rol1G een3-4apC.rrrroi p.B y31G up0-x0CBAflbrosar©©**©ells. ,y0|-iwD1x' OFC&Afibrosarcomae<11?*.e.D j.0,1*1*H?.oarvuRl.p.Xfcv3;micebleday2U. b)>aehre.'.ultxpr*scdas-our'300e e.andir.thmanft iplic te-
I©to 1)akingAbsorptionR tiorf1*3a dnw(cou ariKith<, vyf mGroupA)be?ifnificar»«nmfro<ro pBg-re«.tal fI CverasifromoupC,wenuotrf#XfG.fieruafromG oupDgaeo*ntak<sfIfG,,Oj^n"IfO^ 2)"hepeciflcityoftgoataati^eraw-henbu ingnormalgo tsc umc ntrol. 3)AntiglobulinMethodIu-e .
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a)Preincubationt37°Cfor0m .Cellsthenwashedt ic . b)Count3per300s es. c)HP-Nopreincubation. Note 1)CBAtumourcellswerealsoincubatedwi hhOj gfAg .HumanI Gwiththesamer itssbove. 2)NormalscranandserumfromC.parvun-treatedmicrpoolsf ofiv*stividuaI . 3)AntiglobulinmethodBused.
Jig. ^0 -93e-
IJPTAKE OF IMMUNOGLOBULIN FROM THE SERUM OF C .PARVUM -TREATED
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1) C.parvum (1 'k mg) injected i.p. Day 3; mice bled Day 2I4.-
2) Uptake of immunoglobulin from the serum of C.parvum-treated mice was
significantly greater than for normal serum (P <1 0-001 for both
target cells).
3) Antiglobulin Method B used.
Fig. 29 -93f-
UPTAKE OF IMMUNOGLOBULIN FROM THE SERUM OF C .PARVUM-TREATED
CBA MICE ONTO SYNGENEIC FIBROSARCOMA AND SPLEEN CELLS
EXPT. 2
—I , 1 | |
1 ^20 1 ^60 1^10l
DILUTION OF MOUSE SERUM
EXPT.1
1^20 1^60 1/l00
DILUTION OF MOUSE SERUM
TARGET CELLS TARGET CELLS
—O CBA fibrosarcoma (3 x 10*1) C3—fU CBA fibrosarcoma (3 x 10**)
O—Q CBA spleen (U x 10**) C^O CBA spleen (U x 10**)
Ci—0 CBA spleen (12 x 10**) O—€) CBA spleen cells depleted
of glass-adherent cells
(U x 10U)
CPM WITH SERUM FROM C .PARVUM-TREATED MICE
AR =
CPM WITH NORMAL SERUM
-93f-
Note (Fig. 29)
(1 *U rag i.p.)
1) Serum from C.parvum-treated1 mice/was taken 21 days after injection.
2) Uptake of immunoglobulin from the serum of C.parvum-treated mice
(expressed as AR) onto CBA fibrosarcoma cells was constant until
a dilution of 0, whereupon it fell.
3) Uptake of immunoglobulin from the serum of C.parvum—treated mice
onto CBA spleen cells was dependent on the serum concentration and
the number of target cells. After depletion of glass-adherent
cells the uptake onto spleen cells followed a similar pattern to
fibrosarcoma cells although the AR was greater.












































TABLE 32 SUMMART Of SPECIFICITY DATA gggS
1,'PEDAL MP HAlIQRgT TARGET CELLS
COURTS PER WIT TIMECOUNTS PS?
with 73 nugrroH umr time with ?s
















> 1*9 CBA fibroparoorar )
a) Sero» B - 1-h *g C.parrow i.p. Day 3j Serum D - 1 x 10 CBA
flhtosoreona eellm sue. Day 0, I'll ng C.parrttm i.p. Day 3|
s&ce bled Day 21*.
Note
1) All target cell?;, with the exception of spleen cell?., were in ritro
cttltored cell lines. ~~ """""
2) Only CM fibrof arcoaa cells gore a oorri< tently hi|:h Absorption
Ratio.
3) The Absorption Ratios for the- 198 fraction" are ranked as follows t
CBA eabryo >CBA kicteey > CBA flbrc«arcowa.




































a)1-kKgoff.p rvunC5T6l3dministeredi.p.isy"fters.c.tran la tationx0vi ble CBAfibreareonec ll*. b)1al-era(HIx0)bso bed3elthC.parvuno«yneen ietum rspl ecel s* dnti- bodie-determinedinultanpon-lyabsorbedw b^orf ed- ras. Koto 1)Absorptioni&tfetumourreducedhesr.titurouan ib dylev l®iC.parvua-breat dich d littleeffectonC.parvtBBantibodytift .**"* 2)Absorptionwi hC.parrumreducedthelevelsfantitumorsr. bodie:nG. maitibodies. 3)Spleenva-leseff ctivethC.pwvujboruno rtah-o bingutct!t mourantibodi s. h)AntiglobulinMethodSwa*uset reninePo l2,etDf r3.
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binding to CBA fibroaarcoma cells in vitro, produced after G.parvura
adrain!~tration, could be absorbed out by CBA fibrosarcoma cells,
C.parvu®, and to a lesser extent by CBA spleen cells (Table 33)* It
is of interest that absorption with CBA fibrosarcoma cells, of serum
from CBA fibrosarcoma bearing mice, did not result in a decrease in
i?-aunoglobulin binding to CBA fibrosarcoma cells in vitro. However,
absorption with CBA spleen cells did. This could be due to Fc-
receptor bearing ceils in the spleen cell population, and illustrates
the necessity for adequate control sera. It should be noted that
absorption with either type of cell did not reduce the antl-C.p^rvuB
antibody titre. Only C.parvm was effective in this respect.
3. USE OF MTIGLOdULIK ASSAY TO DETECT ANTI-TUMOUR fllTIUODY ELICITED
WITHOUT THE INTERYEKXId? OF C.PACTUM
On the basis of reoorts fro® Thomson fat al. (l5U) and turdick et
al. (kS) that, respectively, excision of the tumour burden and hyper-
imiaunisation with tumour cells elicited antl-tumour antibody in a syn¬
geneic system, these methods were tried in our tumour model.
*) Production of sattl-tumour antibody by excision of tumour burden
CBA mice were injected on the tipper aspect of the foot with 1 x
10 syngeneic fibrosarcoma cells. ih Days later the tumour bearing
leg was amputated and the mice exsanguine ted at intervals. Depending
on the experiment, controls were either untreated idee, sham-operated
mice, or miee which still had a tumour burden. Three separate exper¬
iments are recorded, all of which use antiglobulin method B to detect
anti-tumour antibody.
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Using pooled serum from bleeds at various intervals it appeared
from "ig. 30 that serum from «; Isisls with their tumour burden removed
had higher levels of anti-tumour antibody than mice retaining their
tumour burden, or untreated raiee. However, when this experiment was
repeated using the serum from esoh individual mouse the picture was
not so clear in that the anti-tumour antibody levels in serum from
nice with their tumour burden removed were similar to controls (Fig. 31).
b) Production of anti-tumour antibody by hyperimisunistation with
syngeneic tumour cells
In the first experiment CPA mice were injected with 10^ X-irra
dieted (22,000 RAD) syngeneic fibrosarcoma cells s.c. to render the®
immune to a subsequent challenge of live tumour cells. At two
week intervals they were challenged a.c. with increasing doses of
2
live CBA fibrosarcoma cells starting with 10'. The mice were bled
fro» tb© eye (and the serum, pooled) at various intervals "ter chall-
*> 5
cnges of both 1 x 10 and It x 10 tumour cells (Table 3U) • Follow¬
ing the rinei challenge (It x 10^ cells j some mice had small nodules
st the site of injection! these had regressed by day 8.
In a second expetiraent the mice were mad immune to a final
6
challenge of it x 10 CBA fibrosarcoma cells end were exsanguinated
21 days later. Of the experimental croup of 10 mice challenged with
U x 106 tumour cells, it grew tumours. Thus, in ?ig. 32 there or
three experimental groups ncmelyt untreated mice? mice immune to it x
10^ CBA fibrosarcoma cells; and mice which succumbed to a challenge
£
of it x 10 cells. Individual sera from the three groups were
examined **or antibody against CPA fibrosarcoma cells and C3A embryonic
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(EACHPOINTREPRESENTSSE UMPOOL
EXPT.1 OSerumfroCBAmiceb aringsyngen ictu our OSerumfrommicew thtu ouramputated TUMOURAMPUTATED ~t,r 1023 DAY
FROMATLEASTOURMICE) EXPT.2
beforeand
oSerumfroCBAmice/afteramputation syngeneictumour TUMOURAMPUTATED A ~T1!'r~ 1023 DAY
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Note (Fig. 30)
1) CBA fibrosarcoma cells (1 x 10^) injected into foot of syngeneic
mice Day 0; foot amputated from knee at points shown when tumour
was palpable; mice bled on days shown and sera pooled.
2) In Experiments 1 and 2 immunoglobulin binding to tumour cells was
produced transiently after amputation.
3) Antiglobulin Method B used.
Fig-31APPEARANCE—OE ,IMMUNOGLOBULINBINDINGTCBAFIBROSARCOMACEL SAFT FTUM URMPUT TION0(EXPT.) Eachpointrepresentsserumf mindividualmice. 5.5 4.5 3.5 2.5 1.5EXPT.3 FO O o o oo o 4-o o o oo 4- SOCAMPTB© 0 4-O o Q CO 4-S.O.C.-ham-op A.M.P.-Tumour T.B.-Tumour1 o o o





















1) CBA fibrosarcoma cells (1 x 10^) injected into foot of syngeneic mice
and 1I4. days later the tumour bearing foot amputated at the knee-
Day 0; mice bled on the days shown and sera tested individually.
2) In Experiment 3 no significant increase in immunoglobulin binding to
tumour cells was seen after amputation.
3) Antiglobulin Method B used.
In retrospect, it might be pointed out that although the level of
immunoglobulin binding to CBA fibrosarcoma cells in vitro, in the serum
of mice deprived of their tumours, was no greater than for sham-opera¬
ted controls, it was greater than for tumour bearing mice.
-ac¬
table 34
appearjwce of *nttftt?*tur .0:?i body IV, cpa mice
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fibre*nroqam
oousts per uhit time with serum from
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formal mice
b) ht - not tested
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Fig.32 UPTAKE OF IMMUNOGLOBULIN FROM THE SERUM OF MICE IMMUNE TO
A SYNGENEIC CBA FIBROSARCOMA (USING ANTIGLOBULIN METHOD B)

















1) CBA mice were injected with 10^ X-irradiated syngeneic fibrosarcoma
cells then at two week intervals they were challenged with increasing
doses of live pronase digested tumour cells starting at 1 x 103 and
ending at U x 10^. After the last challenge U mice grew tumours
and 6 remained tumour free.
2) Using CBA fibrosarcoma cells as targets in the antiglobulin assay the
uptake of serum from tumour immune mice was significantly greater than
normal serum (P < O025). However the uptake from the serum of
tumour bearing mice was not significantly greater than normal serum.
Using CBA embryo target cells there were no significant differences
between serum from normal, tumour bearing and tumour immune mice.
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Fig. 33
UPTAKE OF IMMUNOGLOBULIN FROM THE SERUM OF MICE IMMUNE TO
A SYNGENEIC CBA FIBROSARCOMA (USING ANTIGLOBULIN METHOD C)





























1) To obtain tumour immune serum CBA mice were injected with 10^ X-irra-
diated syngeneic fibrosarcoma cells then at two week intervals they
were challenged with increasing doses of live pronase digested tumour
cells starting at 1 x 103 and ending at U x 10°. Normal serum was
from age matched controls.
2) In two experiments Absorption Ratios of 1-U and 1•were obtained for
immune serum.
3) Immunoglobulin from normal mouse serum was taken up onto tumour cells
compared with a medium only control.
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fibroblasts using antiglobulin method B (Fig. 32), and in addition the
first tvo groups were tested using antiglobulin method C against C"A
fibrosarcoma target cells only (Fig. 33).
The above results Indicate that both hyperimmunisation with
syngeneic tumour cells and amputation of a syngeneic tumour elicit
anti-tumour antibody detectable in the antiglobulin assay. How¬
ever, results from amputated mice were rather questionable. This
is because higher levels of circulating anti-tumour antibody were
observed in amputated mice than in mice with an intact tumour burden,
but the levels were not higher than in sham-operated controls.
Furthermore, when anti-tumour antibody was detected it appeared trans¬
iently. #
Results from hynerimmurdsed mice were again quantitatively rather
variable although anti-tumour antibody was always detectable after
immunisation. Furthermore, Table 3U indicates that a threshold dose
of cells was necessary before anti-tumour antibody could be detected.
The specificity of anti-tumour anti1 ody produced by hyperinsmunlsation
was also examined. Fig. 32 shows that only tumour-free immune mice-
had significant levels of antibody directed against syngeneic fibro¬
sarcoma cells, whereas mice with a tumour burden had not. Further¬
more, this antibody was not directed towards embryonic antigens as the
uptake of immunoglobulin from immune serum was not significantly diff¬
erent to normal serum when tested against embryonic fibroblasts.
U. ESTIMATION OF SERUM IMMTOOGmngLI?? CLASS AMD SPB-CLA5S
LEVELS AFTER C.PARVTTM ADMINISTRATION
These studies were carried out on the same serum samples as for
section 2 and both sets of results are meant to complement each other.
Rather than slavishly reproduce parts of section 2 here the experi¬
mental protocols are given with the relevant 51gores and Tables, and
only a summary of the results is given here.
a) Effect of route of administration and dose of fc^narara on serum
immunoglobulin class and sub-class levels
In addition to the inhibition of tumour growth, the i.p. admin¬
istration of C.parvus (group ?) resulted in a significant increase of
all immunoglobulin levels (except IgM) in the sera of tumour bearing
nice (Pig. 3b). In contrast, 6.parvun given s.e. (Group E) failed
to influence tumour growth and had little, if any, effect on circulat¬
ing immunoglobulin levels. The i.p. administration of C.parvum to
normal ale- (group C) resulted in a significant increase in both
and IgG?b levels, but the s.c. injection was again without effect
(group B).
The highest closes of C.parvum elicited the greatest increase in
immunoglobulin levels in normal mice; IgM and levels being signi¬
ficantly raised after injection of 1*b mg of C.parvus (Fig. 3C0.
b) Cellular basis for the changes in serum immunoglobulin class and
sub-class levels, after ft|prnis administration
The tumour-inhibitory effect of C.parvua was abrogated by treatment
with gold salts. Furthermore, the levels of all immunoglobulins
(except IgA) were significantly higher in tumour bearing mice given the
combined C.porvuw-gold salt treatment (group D), than in untreated tumour
bearing controls (group A). However, the IgM, IgG^ and IgG?b levels
In Group D were significantly lower than in mice receiving C.parvum
alone (group B) (Pig. 36).
-97a-
Fig. 3h
EFFECT OF ROUTE OF C .PARVUM INJECTION ON SERUM IMMUNOGLOBULIN
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B & e C Parvum s c C & F C Parvum
C D E F
IP
• NORMAL 0 TUMOUR BEARING
Note
1) Tumour (1 x 10^ cells) s.c. Day 0; C.parvum (1 -Lj. mg) I.p. or
s.c. on leg opposite to tumour, Day 3 J mice bled Day 2lj.
2) Immunoglobulin levels not significantly increased by s.c.
injection of C.parvum in normal or tumour bearing mice.
3) IgG2a (P<L0-02) and IgG2b 0*001) levels significantly
raised in normal mice after C.parvum injection i.p.
h) IgG2a (P^ 0*001), IgG2b (P<0*005), IgG-, (P<< 0*001 ),
IgA (P <0*005>) levels significantly raised in tumour bearing
mice after C.parvum injection i.p.
5) Only i.p. injection of C.parvum inhibited tumour growth (P-^O-O^).
Fig. 35
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EFFECT OF DIFFERENT DOSES OF C.PARVUM
ON IMMUNOGLOBULIN LEVELS IN CBA MICE





























A B C D A B C D A B C D A B C D A B C D
A.CONTROLS B.OKmg C.PARVUM C.07mg C.PARVUM D. IA mg C.PARVUM
(all doses)
1) C.parvturi/injected i.p. Day 0; mice bled Day 21.
2) IgM (P< 0-001) and IgG2b (P < 0-005) significantly raised after
injection of 1 -1; mg of C.parvum i.p.
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Fig. 36
EFFECT OF GOLD SALTS ON IMMUNOGLOBULIN LEVELS
IN C .PARVUM-TREATED TUMOUR BEARING CBA MICE
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q -j C. parvum
gold salts
A B C D A B C D A B C D
Note
1) Tumour (1 x 10^ cells) injected s.c. Day 0; C.parvum (1 -U mg)
injected i.p. Day 3; sodium aurothiomalate was administered
by eight i.p. injections on alternate days starting Day 2;
mice bled Day 2l|.
2) IgM (PC0-03), IgG2 (PC0-01), IgG2b (P 0-001) levels
significantly lower in mice receiving the combined C.parvum-
gold salt therapy than In mice receiving C.parvum alone.
3) The administration of C.parvum (Group B) significantly
inhibited tumour growth (P <r 0*01) but this effect could be
overcome by administration of gold salts (Group D).












































































b)Allvaluesobserved21dayft rd'uvantadministrationie.bdt mourransp tation. e)Thesignificanceoffect?bs rvedw sdetermi dbycowsaringOp .Bt1ithA,nG .FHE.
In alltables*denotesP'^0*09,«**01,*■**•0 1.Aothervalu sw reotsignificantlydiffer n . Note 1)xnemostnark deffectsw reonIgG^(®0JLstrains)a dMlev lstr i ?I0ij?01 337 j 2)strainsCM6l3band1038?ig ifictlyinhibitedtumourg ow h.
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a)Adjuvantadministeredl.p.3d ysft r.c.trans ls t tionof1x0'triablCBAfibro ar omacell b)Allvaluesobserved21daysft rdjuvantadminis ation.V l esiGp.3tEcompar dw he dFHith. c)»denotesP̂0*05,*1***tes0*001.Alloth rvaluwern tsignificantlydiff r nt. Note T)C.psrvmaCN613Uaid3.pertussisp otocolsexertedm rarkffectth nB C.G.proto lonIglev l (especiallyIgGoaandj^)ibothnormaltumourb a ingcej 2)C.pervuaN6l3halonecauseda preciablinhibitionofturnovergr wth
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The anti-tumour effect of C.perram was apparent In T-cell-deficient
nice, and the administration of C.parvum to thyraectoraised tumour bearing
sice r suited in an increase in the levels of all serum immunoglobulins
except IgflL (Table 22). In addition, "nude" mice exhibited elevated
serum immunoglobulin levels after C.parvuro administration (Table 23).
c) Effect of different strains of C.rqnpyi. in normal and tumour
bearing mice, on serum immunoglobulin class and sub-class levels
All the ad'uvsnts Induced a significant increase in seruia IgG^
levels in both normal and tumour bearing mice, whereas only C.parvus;
10387 (groups D and K) and Proplonibacterluw fre\idenreicMi (groups G
end G) elicited significant increases in IgM level®. Only the
C.parvum strain® (CR 613<U snd 10.38 ') caused significant inhibition of
tumour growth (Table 3$).
d) Effect of different ad'uvants, In normal ail tumour bearing mice,
on serum immunoglobulin class and sub-class levels
The C.parrtm (group B) and Bordetella pertussis (group D) treat¬
ments used resulted in a marked increase in IgG^ and IgG?h levels in
normal mice. In addition, they also caused a significant increase
in the levels of all immunoglobulins (except IgA) in tumour bearing
mice (groups F and H). The BCG protocol in general elicited small
Increases, for example levels in normal mice (group C) and IgG1
and IgGpb ievels *n tumour bearing mice (group G). Only the C.parvum
protocol produced substantial inhibition of tumour growth (Table 36).
SETECTIOW OF ANTIdQDT CITOSTATIC FOR CM FIBROSARCOMA CELLS IN THE
SERUM OF C .PAK^-TREATED MTPE
To investigate whether the results from the antiglobulin assays were
-99'
due to a genuine antigen-antibody interaction, an assay which utilised
this interaction was necessary. This requirement was fulfilled by
the complement-dependent assay for cytotoxic antibody as described by
Le Mevel and Wells (1 ?*>). The technique in fact measures cytostatic
antibody as the i?5j -iododeoxyurldine is added after the target cells
have been incubated with the test serum. A measure is thereby
obtained of the number of cells memaining that are capable of division.
These experiments investigated whether the in.lection of C.parvugi
into normal mice or tumour bearing mice elicited higher levels of cyto¬
static antibody than the relevant controls (ie. serum from normal and
tumour bearing mice respectively). The system was the syngeneic
C3A. model used previously and the experimental sera examined were from
Group A - normal CM mice; group 3 - CBA mice treated with G.parvum;
group C - C3A mice bearing a syngeneic fibrosarcoma; group D - CBA
mice bearing a syngeneic fl1 rosarcoaa treated with C.parvum.
It can be seen from Figs. 37 and 35 that the controls (normal and
tumour bearer mouse serum) could exert a cytostatic effect. When
this was the ease the results were expressed as followst-
% CYTQSTASIS -
counts per unit time with serum from
group a, b, c or d + complement
1 _ ■ , . -
counts per unit time with medium ♦
C0?4PLEMENT
x 100
When the control serum was inactive (lass than 30^ cytostasis)
the results were expressed as a percentage of this control (Fig. 39).
For groups C aid D this could be expressed as follow
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.37 CYTOSTATIC ACTIVITY OF SERUM FROM NORMAL MP C .PARVUH —
TREATED CBA MICE AGAINST SYNGENEIC FIBROSARCOMA CELLS
I I | I I I I I I













Normal serum (Group A)
Serum from C .parvum -
treated mice (Group B)
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Note (Fig. 37)
1) Group A - Normal CBA mouse serum
Group B - 1-U mg C.parvum i.p. Day 0* mice bled Day 21
2) In this experiment serum from normal CBA mi.ce was active in the
cytostasis assay and was therefore not used as control serum in the
equation to compute % cytostasis. A complement only control was
used to compute the % cytostasis for serum from Groups A and B.
3) The % cytostasis obtained with serum from C.parvum-treated mice was
higher and occurred over a greater dilution range than with serum
from normal mice.
Fig. 3 8 -99b-
CYTOSTATIC ACTIVITY AGAINST CBA FIBROSARCOMA CELLS OF SERUM
EROM a) MICE BEARING A SYNGENEIC FIBROSARCOMA, b) MICE BEARING
THE FIBROSARCOMA, TREATED WITH C.PARVUM
Note
1) Group C - 1 x 10^ CBA fibrosarcoma cells s.c. Day 0
Group D - 1 x 1 Cr CBA fibrosarcoma cells s.c. Day 0
1 -l; mg C .parvum i.p. Day 3> mice bled Day 2h
2) In this experiment serum from tumour bearing mice was active in the
cytostatic assay and therefore was not used as control serum in the
equation to compute % cytostasis. Instead a complement only control
was used to compute the % cytostasis for Groups C and D.
3) The % cytostasis obtained with serum from C.parvum—treated tumour
bearing mice was higher and occurred over a greater dilution range








DEPENDENCEOFTHECYTOSTATICF CTOFS RUMRO .PAHVUM-T ATEDTUMOURBE RING3A'MICE ONEXTRA EOUSCOMPL MENT CYTOSTASISCPMwithserumfromGroupD+co plement CPMwithserumfromGroup+co plement
x100
C2%CYTOSTASISWI HCOMPLEMENT





1) Group C - 1 x 10? CBA fibrosarcoma cells s.c. Day 0;
Group D - 1 x 10' CBA fibrosarcoma cells s.c. Day 0;
1*U mg C.parvum i.p. Day 3j mice bled Day 2U.
2) In this experiment serum from tumour bearing mice was inactive in
the cytostasis assay against CBA fibrosarcoma cells and was therefore
used as control serum in the equation to compute % cytostaeis.
3) With active guinea pig complement only one serum dilution showed marked




COUNTS PER TWIT TIME WE TP SERB!? FROM
TUMOUR BEARING MICE TREATED WITH
C.PAR7CM + COMPLEK0??
1
COUNTS PER OBIT TIME WITH SERUM FROM
TUMOUR BEARING MICE + COMPLEMENT
x 100
The results in Figs. 3? - 39 support the antiglobulin data in
showing that there is m antigen-antibody reaction between CBA fibro¬
sarcoma cells and serum from C.parvum-treated mice. However, it is
not possible to say that the antibody detected by the antiglobulin
assay is identical to the antibody detected in the cytostatic assay as
the detailed specificity studies whieh characterised the former have
not been carried out with the latter.
6. IMMUNOTHERAPY BASED 0* THE PRECEEDTNG RESULTS
The goal of all cancer research is to establish suitable thera¬
peutic regimes to control tumour growth. With this in mind we
used the classical Immunological modalities of active and passive
immunisation a) to sec if the recognition of embryonic antigens,
Indicated by Table 29, could be of use in immunising against a challenge
of viable tumour cellsj b) to see if antibody oroduced by C.parvura
administration, and known to bind in vitro to CBA fibrosarcoma cells,
could influence the growth of a CBA fibrosarcoma graft in syngeneic
mice.
a) Active immunisation with embryo cells
It is a routilo procedure In this laboratory to prevent the growth
of an inoculum of CBA fibrosarcoma cells in syngeneic nd.ee by a prior
in 'ection of X-iirradiated fibrosarcoma cells. It was of interest to
see if syngeneic embryonic cells could substitute for the immunising
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dose of tumour cells in this system. Thus feaale CBA mice were
irsaunised with either syngeneic X-irradiated or viable embryonic
fibroblasts (1 x 10^) s.c. on the right flank. Two reeks later the
rice were challenged on the opposite flank with either fre"hly excised
pronase-dicerted CBA fibrosarcoma cells or CBA fibrosarcoma cells grown
In vitro for 2-3 weeks.
tin fortunately in two experiments the results were totally discor¬
dant. In the first experiment (Table 3?) embryo cells appeared to
immunise against a challenge 6f in vitro cultured cells but not against
freshly seised pronase-digested calls. In the second experiment
(51g. U0) tumours grew in all groups and the rate of growth was only
marginally slower in the groups immunised with embryo cells.
Reasons for this discrepancy will be considered in the Discussion,
b) Passive Immunisation with serum from C.c-arvum-treated mice
The passive transfer of serum took the form of transplanting
tumour cells which had been incubated in medium alone or in serum
from various experimental groups. Transplant?.tlon was vis the l.v.
or s.c. route and then either the number of tumour cell lung coloni.es
was enumerated, or the tumour dimeters measured, after a suitable time.
It can be seen that tumour cells treated with serum from C.nervum-
tre'ted mice could on occasions grow better than cells incubated with
control scrum. Incubation with such serum never produced diminished
tumour growth1 (Table 33). The adverse effect was more srop&rent after
i.v. infection and when the lungs were not overgrown ith tumour.
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T ABLE 37
COMPARISON OF CBA FIBROSARCOMA CELLS MP SINOMEIC EMBRYO CELLS
AS IMMUNISING AGENTS AGAINST THE CBA FIBROSARCOMA







None 5 x 103 proria e digested
tumour cells % (67%)
None 7 x 103 cultured tumour
cells (Ii7 days) % (13%)
106 x R"C' tumour cells 5 x 103 pronase digested
tumour cells % 00%)
10^ x R tumour cells •37 x 10 cultured tumour
cells (1*7 days) % (0%)







None 1 x 1GP pronase digested
tumour cells % (71 %)
None 1 x 101 cultured tumour
cells (21 days) % (57*)
1 x 10' viable embryonic
cells
1 x 1CT pronase digested
tumour cells % (71%)
jJP
1 x 10" viable embryonic
cells
1 x 10^ cultured tumour
cells (21 days) % (33%)
1 x 10 x R embryonic
cells
1 x 10^ prona'-e digested
tumour cells s/7 (36%)
1 x 10^ x R embryonic
cells
1 x 10^ cultured tumour
cells (21 days) °/f7 (0 %)
a) Cells for immunisation were prepared by enryme digestion (see
Materials and Methods).
b) Cells for challenge were either (1) freshly excised from a tumour
bearing mouse, then pronase digested to obtain a single cell
suspension} (2) obtained from sn in vitro culture which produced
a single cell suspension without enzyme digestion.
c) x R ® X-irradlated.
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Fig. 1+0 EFFECT OF IMMUNISATION WITH EMBRYO CELLS ON THE
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CBA fibrosarcoma (cultured in vitro)




1) CBA mice were immunised s.c. with 1 x 10^ X-irradiated syngeneic
embryonic cells and challenged on the opposite flank with 1 x 10^
CBA fibrosarcoma cells (freshly excised pronase digested or in
vitro cultured)
2) No inhibition of growth was observed for either freshly excised
or ill yitr0 cultured tumour cells in this experiment.
TABLE38 THEEFFECTOFP JSTR /THWTT3"WITCBAMOUSESERUMNGROW H0^TRAN PLANTED57N0EMEICTUMO RC LL TUMOURINJECTIONURDIA E EORKOS.0?LONGNODULES(b)AFT RPREIREATKENTWI H
















































































e)Culturedsyngeneicm thylcholanthr neindu dfibr sarco ec lwarbtaddilution(x5)fse ®fI 5ni s.t 37°Cendtheninj cteds.c.or.v.Noextraneouscomplementw sadddu i ginc bation. b)Valuesfortumourdia et rsndn s.fnoduleoh? rr d?2ndiday*resp ctivelyfoll wingtumren ul nteJLo . c)Valuesinexp.vcomparedwithth sobservedp ol1A$llthexperim ntcompar dwithm d umo yc t o s. *denotesP-^0*05,#t s^0-Q1,#e^-0 0 1. Note '%1)CBAmouseser mfrom*Gr upA-untreatedCDic jrB•11g.parvus ,i .D y3|G p-x10'CBAfibrosarco cellss.c.DayOjGroup-1x0CRAfibro arcomacel s. .s0,-itagC.pa vui .y3MibledD2h 2)Onnooccasiondidpreir'ati ni yfthseraignifica tlyin bittumourgrowth.I deocc s nthsfr C.parvurn-treatedmiceenhancg owth,sex .i d.Th swaarticul rlyapp rentwhthnu b roflu gnodules wasnail.
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7. ASPECTS 07 TPS IfflPgg RESPONSE III King REARING PLASMA CELL TTTMOTTRS
One of the ways In which a neoplastic cell could prow progressively
would e for the tumour to ncm-specifically depress the immune response
of the host. Evidence from this laboratory indicated that the CBA
fibrosarcoma might indeed inhibit the immune response in tumour bearing
nice to defined antigens (183). However, the inhibition was confined
to the response against alua-BSA (alum-precipitated bovine serum
albumin)? the response to SRBC and tyoe III pneumococcus polysaccharide
antigen being unchanged or elevated. On analysis of the sub-class
of antibody involved in the anti-SHBC response, it appeared that the
TgQ^ response was depressed if the antigen and tumour were injected
simultaneously, whereas IpM and Ig€r?v> responses were elevated with an
established tumour
It was of interest to see if these results could be extended to
tumours of lymphoid origin and if antibody-dependent lymphocyte cyto¬
toxicity (K-eell activity) was affected by the presence of a lymphoid
tumour transplant. These experiments were carried out in BALB/c
nice using syngeneic olasmacytomas (see Table 1).
a) Effect of syngeneic transplanted miasmacytcmas on the antibody
response of BAL-Vc mice
He decided to investigate the antibody response to SRBC and alum-
RSA. The effect of plasmacytoma rrowth on the anti-SRBC response
was analysed in t. of splenic plaoue-forming cells (PFC) of IgM,
IgG,, IgG?^ and IgG?^ classes and sub-classes, and the anti-alum-BSA




Standard Imsranising doses of 1 mg USA in alum, or 3 x 10 ffiBC
were used and all infections were by the i.p. route. Mice received
A*
alna-BSA 5 days after s.c. tumour transplantation (see "ateriats and
Methods 3b). Iswuniaation with SR3C was eithr r at the time of s.c.
tumour transplantation or when the tumour was established. In this
latter case immunisation was delayed mtil it was lodged that the Mee
were within ill days of succumbing to the lethal effects of tumour
growth. Owing to variations in growth rate ssid mmber of cells
6 7
transplanted (3 x 10 - 3 x 10 ) this was not at a standard time
after tumour transplantation. The response to alum-USA was measured
llj days, and the response to SRBC ? days, after infection of the
resoeetive antigens.
The respite in Table 39 show that the growth of all plasmacytomas
significantly depressed the antibody response to &lura~USA as measured
in terns of Antigen binding Capacity. The splenic response to SRBC
in mice simultaneonsly transplanted with tumour cells was depressed
with 3 out of h plasmacytomas (Fig. itl)- This was most apparent
with the IgG1 response. During the late growth of tumours none of
the responses were significantly depressed and some were actually
elevated. Again this was most apparent with the IgG^ response.
b) Fffect of syngeneic transplanted plasmacytomas on K-cell cytotoxic
activity in the spleens of tumour bearing mice
The effect of an established plasmacytoma on the splenic K-cell
activity against antibody-coated chi chert red blood ce^ls was examined
as follows. Groups of DALB/e mice were in*acted s.c. with plasma¬
cytoma cells prepared by homogenisation of solid tumour (see Materials
-iQti-
and Methods 3b). Vihen the tumour was established and the id.ce
looked to be within "tlx days of succumbing they were killed by cervical
dislocation and their spleens assayed for K-cell activity as described
in Materials and Methods lie. The number of viable tumour cells
injected and the time of K-cell assay are shown in Tables JxO - 1x3.
Also measured in these experiments were the number of ?c-receptor
bearing cells in each plasmacytoma (by the method of Ssyraaniec and
James (10?)), splenic hyperplasia, and tumour cell infiltrate to the
spleen. J-lie latter could be visualised when homogenised spleen
cells from tumour bearing mice were eentrifuged, the tumour c*Hs
sediraenting before the erythrocytes and forming a white layer upon
which the red cells were supported. The height of this white
layer gave a rough measure of the tumour cell infiltrate to the
spleen. When these spleen homogenates were injected «.c. into
syngeneic BALB/c mice they gave rise to tumours.
The results show that splenic K-cell activity was increased
despite, or perhaps because of, a progressing plasmacytoma (Tables
1x0 - U3). Furthermore, some tumours appeared to metastasize to
the spleen (ADJPCS and KPC?S). Interestingly, MOPCliTA did not
metastasize, and the tumour had a high proportion of ?c-receotor
hearing cells, probably macrophages. However, M0PC1QltE had a low



















































e)Inoculatedr.c.5daysbeforesdsdnistrEtlonfaluia-BSA. b)Attimeofsacrifice. c)AntigenBindi gCapacity(0*2UjBSAnitrogenertes )sg metricmeanto therwi hth limitsof1S.E. d)RelativeRindingAff nity(arithm ticmean̂1S.E.) e)Valuessignificantlyl sthanforcon~ olrT Note 1)Valuesareforgroupsf3ALB/cmiceitdayft r1gfaluia-BSAi.p. 2)Thegrowthofallplasmacytomassignific ntlydepressedt a ibodyponselura-BSA.
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Fig. U1 INFLUENCE OF PLASMACYTOMA GROWTH ON
THE RESPONSE OF MICE TO SRBC
MOPC 47A(1qA) HPC 25 (1gGl) MQPC 104EM (lgH) ADJPC S (1gG2a)
CST ADL I SHCD
M 61 G2a 62b M G1 G2a 62b M 61 62a 62b M 61 G2a G2b
Note
1) The splenic response (in terms of PFCs of IgM. IgG , IgG? and IgG„,
specificity) was measured 7 days after 3 x 10° SRBC were administered
i.p. to BALB/c mice.
2) The response was expressed as a percentage of the control value (ie.
mice without growing plasmacytomas).
3) SRBC were injected at the time of tumour inoculation (early) or at
the time when tumour had grown (established).
U) denotes a response significantly different to controls.
5) 3 out of U "early" pl asmacytomas inhibited the PFC response - parti¬
cularly the IgG1 response. Established plasmacytomas either enhanced
the PFC response or left it unchanged - again the IgG^ response was
the most enhanced.
TABLE40K-CE LACTIVITYIffMICETE RINGMOPCh7.'PLASHACTTOYA^** SPLSEN WT.(g)TUMOURWT. (%BOOTWT.)NUCLEATEDI* S PERSPLEB: (x10-8)TUMOURr^LL INFTLTRT TOSPLEEN





































































b) c) Note 1) 2)
Fffectortoarwtcellrati . NT-nottested K-cellactivityinspleensoftumourbearingicegreath icontrolseffe tor/targetlr os of50/1aid2 . -receptor HighpercentageofFtybearingcellsinthisumour.
TABLE41K-CE LACTIYTTTIN"T CK-FARING'cOVOIObLPLASMACYTOMA^ SPLEBT WT.(g)TUMOURWT. (%BOUTWT.)NUCLEATEDiL S PERSPLEEN (x10--)TUMOUR"!LL INFILTR.3 TOSPLFIPN



























































K-cellactivityinspl ensoftumourbearingicegr aterthontrol®effecto /targetllra iof50/1






































































a)1*2x0plasmacytomacellsin' ctedTSsyOjram ersmeasuredD2?. b)Effectortoargetcellrati . c)NT-nottested# Note 1)K-cellactivityinspl ensoftumourbearingicegreat rhcon roleffe t /targetr ti of20/1. 2)Metastaticspreadtol en.














































































b)Effectortoargetcellratio. c)NT-nottested. Note 1)K-cellactivityinsple nsoftumourbear ngicegrea rthcontrolsaeffector/targ tc lr tios ofSO/1,201 /1. 2)Metastaticspre dtosple n.
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DISCE5Siq??
1. CPITIQUE 0? HCPE3IHBE7AL tETIJODS
It has often been said that in tumour immunology the technique
adopted is everything. It is therefore appropriate that the advan¬
tages and disadvantages o? the antiglobulin technique should be
discussed here.
The results obtained with the antiglobulin assay (CPM, Absorption
Ratio) vary with the cell number, antiglobulin specific activity,
dilution of resgents, and possibly with the day to day condition of
target cells. Therefore, a direct inference from CPM of the
absolute .amount of serum immuneglobulin bound to cells wouli be un¬
reliable. The results in CPM of the test serum must be compared
with a suitable control serum, in this esse normal mouse serum from
age matched controls.
However, as the serum of adjuvant treated mice contains greater
amounts of iamunoglo: ulin than untreated mice (see e.g. F1 •*. 3h),
it can be argued that untreated normal mouse serum is not an adequate
control for non-specific adherence of immunoglobulin to cells.
This brings up the issue of the specificity of the reaction, which can
only be adequately settled by using a range of malignant and non-malig¬
nant target cells (see e.g. Tables 29 - 31 )• Normal rabbit serum
or normal goat serum were used as controls for the specificity of the
rabbit anti-mouse IgG (Table 28) and for the goat anti-mouse immuno¬
globulin aatisere (Table 2?), respectively. The specificity of the
12*"
T--globulin fraction of goat anti-rabbit IgG was apparent when compared
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with -globulin fraction of normal goat serum (not shown). If
the mouse serum was omitted (medium only control) the CPM was 20? of
the GPH using nornil serum (Fig. 28). However, if G—210 fractions
were used the percentage could be greater.
In retrospect, how could the essay be improved? Thee studies
have witnessed a considerable change in the antiglobulin assay fro®
that originally used (see Table 10), and it finally gave results which
were both coherent and consistent. However, this is not to say it
could not be improved still further. For instance, although the
sb'r it anti-isouse IgG was absorbed with tumour cells, the antiglobulin
reagent (goat «n,ti~rab it IgG) was not. This could account for
part of the uptake of 1? T-labelled goat anti-rai l it IgG onto target
cellsj on the ether h pd it could be due to non-specific "stickiness".
Ion-specific effects are a constant problem, and can lend to
rpurious conclusions if adequate control® are not incorporated into
the experiment. It would, theoretically, be possible to overcome
non-specific effects by producing a homogeneous antibody by means of
imunoabsorhent columns, and wing it in the antiglobulin esssy.
This has been tried using a single indicator reagent with some success
(Figs. 16 and 33), although the logistic problems involved if the
double layer technique were used would be formidable.
Such manipulations as the above might be expected to increase the
sensitivity of the sassy dramatically, However, more modest impro¬
vement in the specificity of uptake of mouse immunoglobulin in vitro
might be achieved by altering the dilutions of mouse scrum used* It
is therefore realised that although the antiglobulin technique, as
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presently used, give® consistent results, it msy not have reached its
full potential.
Improvement might also be looked for whan performing absorptions
of serum. It is probe ly true that any antibody activity would be
absorbed out non-specifically if enough material was used for absorp¬
tion. Therefore, it would be preferable to titrate the absorption
of antibody activity using increasing numbers of cells and/or absorp¬
tions. In addition spleen cells are not a truly comparable control
wh<=n absorbing serum with tumour cells, as tumour cello have a consider¬
ably larger surface area.
The results nresentei should be examined with the above? reservation®.
However, there are positive advantage® to the antiglobulin assay, such
as economy of reagents, and the facility to process numerous experi¬
mental samples. The greatest advantage is that the assay is totally
objective. This is of particular value in tumour immunology where
one is constantly measuring barely significant differences. Thus,
although the phenomena measured slight be quantitatively rmr~ , there
cm he no doubt as to their rod.stance. Their interpretation, however,
is a legitimate object of contention.
Another advantage of the antiglobulin technique is that it is a
primary assay. This means that it measures the antibody participating
in the initial antigen-antibody reaction and is independent of secondary-
phenomena such as complement fixation. Thus, the antiglobulin tech¬
nique is capable of detecting antibody of all classes md sub-classes.
■108-
2. 5EKKART 0',' RESULTS
The antiglobulin ar,nsy hss been used to measure mouse isanmo-
flohulin binding to syngeneic tumour cells in vitro. These studies
showed that an i.p. injection of C.pervuu into CM sice elicited «n
increased level of inmmoglohuliri binding to taraour cells in vitro an i
that this was observed whether the rsic- had progressing tumours or not*
Hie effect was dependent on the dose mid route of C.parrum infection,
ooeurlng only after injection of high closes by a systemic route (Figs.
1? and 18).
Studies cm the cellular basis for the production of ie'-nraoglobulin
binding to ttaaeur cells in vitro. after C.parvus injection, showed that
gold salts could abrogate the effect (Fig. 20), thereby implicating
macrophages as it is known that gold salts inhibit phagocytic activity
(l8l). Results in T-cell-deprived mice were inconclusive due to
large variations within experiments! groins} also no direct comparison
with Intact nice wss sade. However, comparing results fro® previous?
experiments with intact nice, the production of immunoglobulin binding
to tunour cells in vitro appeared to be diainlehcd in trosour bearing
♦b'-wic* (Fig. ?l). Furthermore, the effect was still apparent when
< .parvus was injected into "nude" mice (Fig. 22 and Table 23)J in
this case thc^Satude" trait vis on a 34£8/e background and toe target cells
wore HBA fibrosfrcowa.
Other work showed that various strains of C.parvus. and other
ostensibly unrelated adjuvants, elicited Intnunoglobulin binding to
tanrar cells tr . Itro. Using 3C3 and d .pertussis (Fig. 21) the
effect was of a lesser magnitude than for C.psrvum C£ 6i3l? in normal
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end tuaour bearing nice. When using adjuvants related to C.parvua
CJ? 6l 3i* (fig. 2%) it war again found that they all give similarly low
level? of immunoglobulin binding to tumour cells in vltro when adminis¬
tered to normal .sice, hut C.parvum 10307 give particularly high levels
when injected into tumour bearing nice. Evidence is also presented
that the binding of mouf-e ifwcueoglobulin to tumour cells in vitro also
oceured in vivo (Pigs. 23 artd 2lj.).
The class >jnd sub-class of imsunoglobulin binding to tumour cells
in vitro were cocaE&ned, and it was immediately obvlou3 that there was
difference between the response of nice treated with C .prrvma send
nice treated site C.parvua plus CBA fibrosarcoma cells (Tables 26 and
21). This di fference had not been evident when whole mouse serum
and an antiserum reacting with all the mouse immunoglobulin classes
and subclasses i#ss used. Thus, it cars be seen that 'a '3 as well
as a 193 response is evoked in mice treated with C.p vn» plus CBA
fibrosarcoma cells, whereas only a 1 S response is seen in animals
treated with C.r.srvum only. The 19S response correlated with high
nnti-C.paasnm ar.ti ody titres, but the 73 did not (Table 2r').
Table 2^ shows that mice bearing a syngeneic fit rosarcoma, and
treated with C.parvum. Mount a complex sntibody response to syngeneic
tumour cells. It was therefor© of interest to see if the same
specificity towards normal target cells was exhibited by the 1?S and
73 responses. The raw data are presented in Tables 29 - 31 end are
summarised in Table 32. This indicates a certain degree of specific
antibody actlvi t in se car Tom C.psrvum-treated tumour bearing nd.ee,
for homologous tumour cells.
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Specificity was also examined by absorption of senm with syngeneic
fibrosarcoma cells, spleen cells nnd C.ofirytm. The results (fable
33) indicate that absorption of srran fron C ♦ parvuis-traated CM fibro¬
sarcoma bearing mice, with CBA fibrosarcoma cells, effectively abolished
the uptake of immmop lobulim in ji tro. relative to sen® fro» tumour
bearing sice. Absorption with spleen cells wes not so effective,
perhaps due to the spleen cells not possessing the tumour-specific
antigen, although other explanations are possible.
The above is a synopsis of the results obtained in Results 2, and
on the grounds of consistency ad reproducibility camot be doubted.
Results illustrated in Results 1, $, 6 and 7 ere store in the nature of
preliminary experiments! in some cases an experiment may only hare
been carried out once, and in others the phenomenon may not have proved
to be reproducible.
Following Thomson et al. (l5k) nnd Le evel et al. (15#), an
attempt was rede to elicit anti-tumour satibo<$y in the serum of rice by
either amputating their tumours, or hypfirimnanlsing them witl -syngeneic
tumour cells. The antibody detected by Thomson e-t al. speared to
> e specific when tested against e rather restricted range of target
cells. (hi toe contrary, Burdiek ejb al. (1#) showed, in an exemplary
series of experiments, that toe antibody in toe latter study was
directed against m embryonic antigen, expressed in varying amounts cm
different transformed cell lines.
The immunoglobulin binding to tumour cells in vitro is referred to
ss anti-tumour antibody in Results 3- This is because it right be
expected ja priori to be directed against tunour-assoei ated antigens ss
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the alee had only been treated with syngeneic tumour cells.
As regards the production of anti-tusfmr «ntl ody after amputa¬
tion of a palpable tumour, the results are inconclusive. In the
experiment which should have yielded the most significant results
(Fig. 31), anil-tumour antibody v»s not produced after amputation of
tumour when compared to sham-operated controls, although it was when
compared to tumour bearing controls. The literature is also
confusing on this point* thus Thomson et al. (1$L) detected a long
lasting anti-tumour antibody after tumour amputation, whereas
undid: et al. (i85) could not find the expected Inverse correlation
between possession of a progressing tumour end production of anti-
fcuacrar antibody.
The results concerning the production of anti-turour antibody
after hyperlmmunisation with syngeneic tumour cells passaged _in vivo
are more consistent. 'briefly, the prodi -tion of anti- tumour
antibody in this system needed e large number of tumour cells (Table
3h), and it apoeared to be specific for the tumour antigen? of the
fibros arcoma cells used for Immunisation (Fig. 32). In this system
uiwur V-earer mouse seruir. did not contain tumour-specific antibody.
Hie results in section !» are concerned with the changes in total
Immunoglobulin class and subclass levels in the serum of mice tarea ted
with either C.parvua, tumour or both. It can be seen that en i.p.
injection of C.parvom. in otherwise untreated ad.ee, resulted consistent¬
ly in elevated levels of IgG^, generally aeoompanied by elevated IgQj,a
and/or IgM level? (Tig. 3U» Table 36). Mice with a progressing
syngeneic fibrosarcoma invariably had lower levels of iaaunoglobulin
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then normal miceJ however,an I.p. injection of C.parvun in tumour
bearing mice raised the immunoglobulin levels to approximately those
in normal mouse serum, or higher.
These serological changes "were route and dose dependent! thus,
no elevation of immunoglobulin class and sub-cless levels was observed
after either s.c. injection of C.parvus) or of small doses. In
tumour bearing mice the elevated immunoglobulin levels, apparent after
C.parvus administration, could be at least partially diminished hy
treatment with gold salts (Fig. 36).
Such changes, however, were thymus-independent as all immuno¬
globulin class and sub-class levels (except IgQ1) were raised after
C.parvum administration to tumour bearing 'B'-mice (Table 22). In
"nude" mice also (which had low levels of all israunoglobulins except
IgK), C.parvuro elicited a rise in immunoglobulin levels (Table 23).
It is of interest that tb* level of serum IgQ1, the most thymus -
dependent sub-class (lit1), is the least responsive to change after
C.psrvua administration.
The effects of C.parvum strains CN 61lit mid 10387, rnd F.freuden-
reichil were examined for their effects on serum immunoglobulin levels.
All of the adjuvants induced a significant increase in serum Ig0o^
levels in normal and tumour bearing mice. Significant increases
in IgM levels were also noted in all mice treated with C.pervum 1033?
mid F.freudenrcichii (Table 35). In another experiment the abili¬
ties of BCG and ".pertussis to elicit increased serum immunoglobulin
levels were compared to that of C.parvtm (M 613h. Treatment with
C.parvum and B.pertussis resulted in a marked increase in IpGp^ end
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IgG^, levels in normal sice. In addition they also caused a
significant increase in the levels of all immunoglobulins (except
IgA) in tumour bearing mice. The BCX5 protocol elicited a. raised
level of IgQj^ in normal mice, and of IgG^ and IgC^ bear¬
ing mice (Table 36).
The results in section $ indicate that the serum of C.parvus-
treated nice has antibody which is capable of binding to an antigen
possessed by tumour cells, raid thereby activating complement (Figs.
37 - 3^). Furthermore, it is possible that normal mouse serum
and serum from tumour bearing mice contain an antibody which reacts
with tumour cells (Figs. 37 end 38).
These results are meant to be treated as preliminary for the
following reasons: no information other than that shown is availablef
i?e;
and the cytostatic effect was absent if the uptake of I-iododeoxy-
uridine was low. Recent unpublished observations incline us to
the view that a high uptake by target cells depends on certain serum
factors being present in the ambient medium.
The results in section 6 show the outcome of attempts at therapy
based on the results in sect!or 2. It appeared from Table 3? that
either a prior injection of X-irradiated embryo cells or X-irradiated
tumour cells could confer protection on the syngeneic host against
homologous tumour cells. It was well known that the C3A fibro¬
sarcoma in question was immunogenicj however, m the possibility of
immunisation with embryo cells was new, this part of the experiment
was repeated. Unfortunately this second experiment yielded no
evidence of protection by prior adid.nlstration of X-irradiated embryo
cells (Fig. hO).
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Aside from the trivial explanation of experimental error, the
following considerations night explain the discordant results:
a) the occurrence of embryonic antigen is a phase-specific event,
occurring maximally in the raid-gestation period (U7)j b) embryonic
tissue derived from raultiparous animals may be less likely to evoke
tumour resistance compared with embryonic tissue fro® prlniparous
animals (l86). It is of interest that, in another ttuaour model,
the rejection responses in rats immunised with X-irradiated embryonic
tissue were also reported to be inconsistent (186).
The transplantation of tumour cells oreincubated with serum from
( .parvura-treated sice also gave rather variable results. However,
it was quite obvious that s.c. or i.v. implantation of pretrcated
tumour cells never resulted in inhibition of tumour growth, and under
certain circumstances lead to enhanced growth (Table 38).
Section 7 recounts observations on the immune status of plasma¬
cytoma bearing mice. The responses to alum-precipitated bovine
serum albumin (alum-33A) end sheep erythrocytes were assessed in
3AL3/c mice; in addition splenic K-eell activity was examined.
The growth of all the plasmacytomas tested significantly depres¬
sed the response of mice to alura-3SA in terras of the Antigen Binding
Capacity, but had no effect on the Relative Binding Affinity of* the
antibody produced (Table 3?).
The influence of early or established tumour on the response to
®BC, in terras of splenic plaque-forming cells of IgM, IgO,, IgfX,.,
and IgCb>b specificities was variable. Early growth of HQPOliTA
(IgA), MP€2? (Ig01) and ADJPC? (IgG^fi) plasmacytomas depressed certain
IgG responses, especially IgG.,, while IgM responses were unaffected.
In contrast the early growth of an IgM-secreting plasmacytoma (MOPC
lObE) enhanced both IgM and IgG responses. Established plasma¬
cytoma? had no effect on the IgM responses to SRBC, although MOPC h?A
and ADJPC? gave, sorae enhancement of certain IgG responses (Kig. hi).
In the study of splenic K-cell actlvit In plasmacytoma bearing
mice the parameters measured again showed some variation between
the different tumours. Thus, although an established plasmacytoma
was always associ ted with enhanced splenic K-cell activity and spleno-
aegally, the IgG secreting tumours ADJPCp (lgG?&) and MPC?5 (IgG.,)
exhibited a capacity to metastasize to the spleen. Purthermore,
the IgA secreting plasmacytoma (MGPC h?A) exhibited a large percentage
of Pc-receptor bearing cells (T bles UO - U3^«
3. RELEVANCE OF RESULTS TO TUMOUR IMMUNITY
The introduction dilated, at some length, on the genetic mechan¬
isms underlying the immune response, and their augmentation by various
means. The mice used in this tv our model appear to ' e genetically-
endowed with the capacity to respond to the tumour antigens in question,
as evidenced by prior immunisation with X-irradiated cells. However,
the response in unimmunised mice is Ineffectual as they invariably
succumb to the lethal effects of a growing tumour. C.parvum re¬
dresses the balance somewhat, but is this due to an increased immune
response to tumour antigens?
Two mechanisms which could, hypothetically, mediate the anti-
tumour effect of C.Parvum have been discussed (see Introduction 6i0.
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These are a non-specific mechanism produced by systemic injection of
adjuvant and a specific mechanism produced by contact between adjuvant
and tumour cells. The latter has a respectable theoretical back¬
ground in that it appears to be an augmentation of the host response
to an antigen by adjuvant (120). On the other hand the non-specific
aechaniaa requires the new hypothe; $ that Macrophages have the
capacity to discriminate between malignant and non-raalignent cells
(187).
There is doubtless something appealing about this hypothesis^
indeed^it has been known since the days of Metchnifcoff that macrophages
c »uld ingest foreign natter, at least natter that was grossly different
from self. However, in a study on toe effects of macrophages cm a
wide range of malignant and non-malignant cell lines, Keller reported
that there was no correlation between susceptibility to eytostasis and
degree of malignant transformation (133).
There was, however, a correlation between susceptibility to the
cytostatic effect of macrophages and the rapidity of replication of
target cells (13?, 188). But, as rapid proliferation Is not an
exclusive attribute of malignant cells, there is an intuitive difficulty
in seeing how non-speeifically activated macrophages could exert a
selective anti-tumour effect. This is not to say that in m srti-
ficial situation, say an injection of 1 x 10 tumour cells s.c., that
toe tumour sells would not be ingested by activated macrophages due to
the anatomically anomalous position of the cell inoculum. In f*ct
this appears to be the ease, and the sequel is that a specific response
to tumour antigens is mounted (120).
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What is the bearing of the. results presented here, on the situa¬
tion as outlined above? The salient point is that en injection
of C.parvura can induce elevated levels of iramnoglobulin binding to
tumour cells in vitro. The production of this immunoglobulin
appear® i to be connected with the antl-tuaour effect of C.parvuat
injected i.p., as high levels of immunoglobulin binding to tumour
cells in vitro could be associated with a pronounced inhibition of
tumour growth. Thus, an i.p. injection of C.parvus into tumour
bearing nice produced inhibition of tumour growth and elevated levels
of immunoglobulin binding to tuiaour cells In vitro; s.c. infection
did neither. Similarly, the inhibition of tumour growth by
C.parvtua could be abrogated by gold salts, as could the production of
immunoglobulin binding to tumour cells in vitro.
Later results indicated that although the production of immuno¬
globulin binding to tumour cells ir vitro might be a necessary condi¬
tion for inhibition of tumour growth, it was not sufficient. Thus,
strains of d.parvum which elicited elevated levels of immunoglobulin
binding to tumour cells in vitro did not inhibit tumour growth.
Ftoth the production of immunoglobulin binding to tumour cells in
vitro, aid growth inhibition, after C.parvum injection appear to have
some elements of their respective mechanisms in common, as they are
bote influenced by gold salts (ie. sodium aurothioxaalate). The
available evidence suggests that this anti-inflammatory agent is rapidly
concentrated within phagocytic cells where it inhibits lysosomal
enzyme activity (l5l). Furthermore, gold salts inhibited the appear¬
ance of cells which were non-specifically cytostatic for tuiaour cells
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in vitro (Cullen mid Ghaffar, unpublished). Thus, It appears
extremely likely that gold salts depress asprophage function, leading
to a corresponding change In the serological parameters measured.
The results In T-eell-deprived mice were Inconclusive? neverthe¬
less, the impression wars gained that both Inhibition of tumour growth,
and production of Immunoglobulin binding to tumour cells In vitro.
were diminished compared to Intact controls. This could have been
due to the loss of the specific T-cell component in hoth. eases.
A wide range of classes end sub-classes of Iiwunoglobulln, from
the serum of C.psrvuw-treated tumowr bearing mice, are capable of
Indlng to syngeneic tumour cells in vitro. This does not support
the theory that only "blocking* antibody of a particular class or sub¬
class is produced in response to tumour antigens. However,it may¬
be that adjuvant shifts the production of antibody from one class or
sub-c c to another. Certainly the Immunoglobulin in the serum
of mice treated with C.parvum plus tumour, binding in vitro to homo¬
logous tumour cells, is different to that In the serum of tumour hearing
mice, both quantitatively and qualitatively. However, it Is not
known whether this is due to antigen-antibody complex formation in
untreated mice with a tumour burden, or to an Increased or da novo
synthesis of Immunoglobulin binding to tumour cells In. vitro, after
adjuvant administration to tumour bearing mice.
There are several conceivable explanations of the presence In
the serum of C.p arvum. -tree ted alee of immuneglobulin binding to tumour
cells in vitro. These includet ») non-specific "sticking" of
ipmranoglobulin to cells| b) the production of Increased levels of
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cytophilic immunoglobulin which binds to Fe-receptors (163)5 c) the
production of anti ody against antigenic determinants shared by C.parvtm
end target cells (l58)j d) an increased production or de novo synthesis
of autoentibody (i69)j e) an increase in the level of pre-existing
anti-tu, our mtibo<tr (157) J f) the production of antibody against unique
or common tumour antigens (lUs). Heedless to say, such mechanisms ere
not mutually exclusive.
Non-specific sticking of immunoglobulin to cells is difficult to
control (Discussion 1)J therefor^ it ia not possible to say unequivo¬
cally that immunoglobulin from the serum of mice treated only with
C.parvu "ads to tumour cells in vitro via m sntigen-anti'octy- reaction.
Certainly neither whole serum from C.pmrvun-treated rd«je (compared with
normal serum), or their 19S fractions, exhibited any target cell speci¬
ficity. However, the date from Results •>, which shows that the
serum, of C.parvum-treated mice can xerfc a cytostatic effect on CBA
fibrosarcoma cells, indicates that the antiglobulin erssy 1" measuring
m antigen-anti' ody reaction.
As regards uptake of souse immunoglobulin via Pe-receptor® on
target cells, there was every reason to suppose that there would he no
-receptor
Fc/besring cells in a cell population cultured in jltro for over two
weeks, because the propor Ion of Fe-receptor bearing cells in a CBA
fibrosarcoma oell suspension falls rapidly over two weeks from around
30% to 0% (102). Nevertheless, experiments were performed which
confirmed that only when using target cells containing macrophages (ie.
freshly prepared spleen cells) did blocking of uptake by aggregated
human IgO occur.
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If the trivial explanations a and b are discounted, there remains
the mechanisms c, d, e and f, for the uptake- of irsaunoglo: ulins onto
tumour cells in vitro. The possibility of shared antigens between
micro-organisms and certain tumour cells has been suggested for BCG
(1?0) end L.gonocytogenea (15T3 ) . Croas-reactions between bacteria
and normal tissue antigens have h n reported (l60), w: ich may explain
some of the results recorded here. Furthermore, a theoretical
basis has been put forward 0 $?). Hoover, the question of whether
micro-organisms possess antigens wMch ere in any way specific for the
neoplastic state of mammalian cells ie debatable, and receives no
upport from the work presented here.
Before the idea is completely dismissed, it might be as well to
ponder on the variability of tumour antigens, w lch arise in a seemingly
random manner. It may be that chance would decree a cross-reaction
between tumour cells and totally unrelated micro-orfanisms. Such a
mechanism would be of severely limited benefit ir V onotherapy, but
may have & modest role in explaining certain empirical observations.
As well as acting s.s fin immunological adjuvant C.parvua also
elicits antibody to mouse red blood cells (l3?) md rheumatoid factor
in some cancer patients on C.parvus therapy (136). Such factors
may confuse the results of the antiglobulin assay. However, when
it is considered that absorption with C.parvura effectively removes
immunoglobulin binding to mouse target cells in vitro, there is really
no evidence for the production of classical autoantibody by abrogation
of tolerance after adjuvant administration, in these studies.
Antibody cytotoxic for various types of tumour cells has been
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reported. Cytotoxic sera fro® "nude" nice were active against a
range of tumour target cells, indicating the antibody was either
directed against a common antigen (1? ) or that it contained a hetero¬
geneous collection of specificities. The cytotoxic activity was
not uniformly distributed in that sore rouse strains were high respon-
iers and sons low. Furthermore, ac inverse relationship was demon-
"tratcd, in a given mouse strain, between cytotoxicity of scrum, and
susceptibility of lymphoma cells to the cytotoxic effect (1?1).
Thus, in the above studies serum was only cytotoxic towards allogeneic
target cells, and was ineffective in syngeneic combinations.
TJ1 ctAvity may or may rot be directed against tumour associated
antigens} however, a similar mechanism may explain results showing
the binding of immtmoglobulin from normal mouse serum to tumour cells
in vitro ("If. 3?). Support for this suggestion come? from the
observation that normal mouse seru can be cytostatic for syngeneic
unsour cells (Fig. 3?)«
The most interesting of the possibilities is the promotion by
C.parvum of a response to tumour-specific antigens in tumour bearing
mice. As the most convincing evidence of a tumour-specific response
is the use of other target cells as negative controls, we have examined
the in vitro uptake of ir unoglohulin from C.ncrvup -treat " tumour
^earing mice onto malignant and non-malignant target cells. To
obtain s measure of the uptake due to & response to tumour-specific
antigens it night be expected that a comparison of the in vitro uptake
of immunoglobulin from the serum of mice treated with r,n r-rvua and
tumour, with that from the serum of mice treated with C.parvua only,
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raigfct be instructive. If this is done it can be seen that the 1!?S
response exhibits no specificity for CBA fibrosarcoma cells. How¬
ever, the IS uptake is consistently greater for CBA fibrosarcoma cells
than for any other target cells tested (Table s 29 - 32).
Other evidence for a tunour-r^ecific antibody response in tumour
bearing mice treated with C.parvus is: 1) the anti-C.parvum antibody
titles in the yS .fractions of serum from C.narvua-treated mice and
mice treated with C.parvus plus tumour are similar, but the immuno¬
globulin binding to tumour cells in vitro is much greater in the
Tatter (Table 2$)l 2) IgH, IpG., and IgG^ from the serum of mice
treated with C.parvan plus tumour bine to tumour cells in vitro to a
greater extent than similar immunoglobulins from the serum of mice
treated with C.parvum only (Tables 26 and 2?)j 3) absorption with
spleen cells leaves a "residue" of iiorauno,globulin still can able of
binding to tumour cells in vitro (Table 33).
It may be that the tumour-specific antibody respouse is obscured
by mechanisms a -e, which have been discussed previously. This may
be similar to the system described recently (1 2) in which the killing
of tumour target cells, by peritoneal cells from mice in/leetcd with
BCG plus X-irradiated homologous tumour cells, was examined. In
this system the peritoneal cells were non-specifically cytostatic for
a range of target cells. However, when the glass- dherent cells
were removed the remaining lymphoid cells were specifically cytotoxic
for the tumour cells used for immunisation.
The results in sections 3 and $ are to be seen as adjuncts to
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those in section 2. Thus, section 3 indicates that CM nice can
respond to the syngeneic tumour by counting a humoral response,
albeit a comparatively small and at present Ill-defined one.
Section *» 1 iicates that the immunoglobulin binding to tumour cells
in viti >, detected by the antiglobulin technique, may infaet be due
to an antigen-antibody reaction.
The work recounted in section It was undertaken in order to
relate serum immunoglobulin class and sub-class levels to the tumour
status of individuals with and without the benefit of systemic
C.parvus therapy. In general the possession of a growing tumour
lead to matie decreases of all immunoglobulin levels, particularly
Igu^ and IgG^, whereas administration of C.parvun to tumour bearing
nice elevated thcra to the levels prevailing in untreated mice, or
higher. The injection of C.marsum into normal mice also resulted
In elevated immunoglobulin levels, ®nd again this wee nost dramatic
•dth IgG9?i and IgG?^.
The mechanism of production of immunoglobulin after adjuvant
administration has b«ea investigated by Humphrey (lUh) and fm jet al.
(*h6) for BCO. For this adjuvant it appears that the "response"
is due to production of non-specific immunoglobulin, without the mark
of a particular antigen. In addition, a delayed-type h'nersensiti-
vity reaction to constituents of the 3CG is necessary, presumably
implicating T-cells.
Our results ere in line with the notion that there is a non-specif&c
production of ii®ronoglobulin after C.parvus administration, as exhaus¬
tive absorption of such serum with C.parvum. does not reduce the serum
ii®ranoglobulin levels to control values (not shown). However, a
fully functional thymus is not necessary as the elevated serum immuno¬
globulin levels are seen in T-cell-deprived mice treated with C.parvum
(Tale 22). This is in accord with the idea that adjuvant action of
C.parvum is more dependent on "B-eells and/or macrophages than is 3CG.
(Note however that the antibody response to C.parvum is partially T-cell
dependent (Table 23)).
In s recent study the effect of C.parvus therapy on serum immuno¬
globulin class and sub-class levels in cancer patients was investigated
(136). Ag in the adjuvant showed some selectivity in its ability
to elevate certain Immunoglobulin sub-class levels, in this case IgO^.
This, however, may not be directly analogous to the results presented
in section i» as human IgG? is putatlvely the homtologue of mouse IgG1,
which in general is least responsive (in terms of total serum concen¬
tration) to C.parvura.
It may be that the one high dose of C.parvum given to mice elicits
a predominantly T-cell-independent effect, whereas the numerous low
doses given to humans ©licit a predominantly T-cell-depertdent effect.
The data on serum immunoglobulin levels in individuals bearing
tumours is contradictory. Our own studies show s decrease in immuno¬
globulin levels, from day ? to day 21 after injection of tumour cells.
On the contrary, Wite has reported that mice injected with a transplant*
able sarcoma have elevated levels of IgQ^ from 9 - 2h days after tumour
transplantation (193).
The situation with regard to the immunoglobulin levels in cancer
patients with a tumour burden is also confusing. Thus, It hss been
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suggested that cancer -atients (melanoma end breast cancer) had higher
serum IgA and IgG than controls. However, it was unclear how many
of the patients were undergoing HOG therapy at the time (19U).
Results from this laboratory bare consistently shown that certain
immune responses, in mice with an established CBA fibrosarcoma, are not
decreased and say be elevated. Thus, the IgM and IgG responses to
SRBC and pneumococcal polysaccharide (Type III) were at least as great
as controls (lS3)j the IgM and responses to SRBC were elevated
(lS!j)j and K-call activity of spleen and lymph nodes was increased
(175). The response to altrat-BSA, however, nay be reduced in mice
with established tumours (iBix).
The effect of simultaneous injection of tumour and antigen on the
response to that antigen is more varis le. Thus, the response to
SRBC was unaffected, the response to pneumococcal polysacchsid.de (Type
III) was enhanced, and the response to alum-BSA was reduced (tS3).
further studies In this context showed that the IgG, response to SRBC
was depressed (l8J») and that K-cell activity was only present in the
spleens of mice with established tumours (19*0.
These studies were extended by examining the effect of transplanted
plasmacytomas cm the humoral responses to SRBC and alua-BSA (Section 7).
It was apparent that simultaneous injection of tumour cells and SRBC
could result in a decrease In responsiveness to SRBC, whereas injection
of antigen into mice with established tumours could enhance responsive¬
ness to SRBC. In addition the response to alura-BSA was reduced when
given ? days after tumour transplantation.
Thus, in general, simultaneous injection of tumour and antigen
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sjore effectively depresses the immune response to the antigen than
does injection of antigen into mice with an established tumour.
Furthermore, K-cell activity is directly related to the sire of the
tumour. This being so it is difficult to see how tumour cell
products might depress the immune response, as they are presumably
in greater abundance in mice with establish'd tumours. A more
likely explanation is that the immune system is temporarily para¬
lysed by the influx of a large number of tumour cells.
This would seem to be in accord with the observation by Worth ct
al. (196) that in mice an injection of tumour cells first resulted in
a state of severely suppressed anti-bacterial resistance (and resist¬
ance to tumour challenge), and then in a contrasting state of greatly
enhanced anti-bacterial resistance (and concomitant tumour immunity).
Finally, section 6 examined the effects of various imnrunothera-
peutlc regimes on tumour growth, with rather unsatisfactory results.
An attempt to utilise any embryonic antigen, hypothetically present on
the tumour cell surface, to inhibit tumour growth led to inconclusive
results. Reasons for this were put forward in Discussion 2.
Attempts to influence the hosts capacity to deal with tumour cells, by
coating of tumour cells with antivody prior to transplantation, raised
the distinct possibility of some form of enhancement (Table 38).
kith remarkable consistency Prehn has argued that a weak immuno¬
logical reaction leads to tumour enhancement, whereas a strong one
leads to tumour rejection (8). Thus, the development of fewer
tumour colonies in the lungs of atbymic "nude" mice after i.v. infection
of tumour cells would be explained by the incipient immune response
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being enhancing (197). A corollary of Prehn's theory is that an
immunological reaction against "weak" tumour antigens leads to enhan¬
cement, and a reaction to "strong" tumour antigens leads to rejection.
Embryonic antigens would be counted as weak tumour antigen? and this
might explain the enhancement in this system and in a similar system
described by Baldwin et al. in which i.v. administered tumour cells
of low irnmogealei ty , treated by i.v. BCG, showed enhanced growth
(198). In this context the enhancement of tumour growth with
antiserum raised against embryonic cells might be considered (112).
The difference between "weak* and "strong" tumour antigens raoy
reside partly in their density on the cell surface, as a aethylchol-
anthrene induced tumour in C^Bl mice is known to exhibit consider¬
able amounts of surface embryonic antigen, and is one of the few
tumours amenable to prophylaxis with embryonic antigen (h3).
Tumour antigens are not the only examples of antigens which,
paradoxically, are knows to exist but are of limited value to the
boat in combating the proliferation of cells possessing the antigen.
Thus, protozoans and other pathogens can exist in an immunologically
hostile environment (199), and hosts will succumb to growth of tumour
cells which are H-2 Identical but different at minor loci (200)
(whereas they reject tumour cell? that are not H-2 identical).
Surely then the problem is one of manipulation of the host and/or
tumour cells with the object of promoting an effective response against
weak tumour antigens. This may be envisaged as a quantitative
boosting in the level rather than a qualitative shift in the tyoe of
response aid, if the foregoing is true, spontaneous tumour?, or tumours
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of low immunogenic!ty, should increasingly occupy the tine of investi¬
gator?? . Ways of augmenting the response to weak antigens were
discussed in the Introduction (section ?)J however, since then further
date has been unearthed which supports the line taken here.
For instance, consider the 316 melanoma in C^Bl mice, an especi¬
ally malignant tumour which readily metastasises to the lung and
contains a low percentage of macrophages when grown subcutaneously (103).
The unmodified tumour cells were unable to sensitise syngeneic spleen
cells in vitro against the tumour antigen. However, syngeneic
spleen cells co-cultured in vitro with chemically modified 316 tumour
cells were thereby rendered specifically cytotoxic (201). Despite
its capacity to Invade other organs this tumour promotes an immune
response as measured by deposition of antigen-antibody complexes in
the kidneys of mice with a progressing tumour (202).
8CG has also been used to augment responses to tumours of low
immunogenic!ty. Thus, Hopper et al. (203) and Bartlett et al«
(20b) were able to suppress the growth of tumour cells by injecting
them in mixed inocula together with the adjuvant. In the first
Instance (203) no protection to reehallenge was obtained, in the
second it was (20b). The reason for this may be that the "antigenic
load" was not large enough in the former case. Thus, it has beer
shown that if tumour growth is suppressed totally by adjuvant then
injection of a mixture of tumour cells and 3CG is relatively ineffective
in conferring protection against rechallenge. However,infiltration
of a growing tumour with BCG, followed by excision of the growing
tumour,is more effective than excisior alone at immunising the host (20?).
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To conclude, it might he appropriate to consider ways in which the
work described might be developed. It would appear that the anti¬
body produced by systemic injection of G.parvum has, if anything, an
enhancing effect on transplanted tumour cells. The greatest effect
is generally produced using serum from C.parvus treated ird.ee| however,
there is a difference between the antt' ody produced by injection of
C.parvuat into normal mice md injection into tumour bearing mice.
Fractionation of such sera snd their use in Winn assays should yield
information of interest.
Further to this, the Winn assay may be made more sensitive by
injecting a range of tumour cell numbers and dilutions of serum. It
may be significant that such assays only seem to work with a vast
preponderance of effector cells to target cells.
It might also be timely to perform a similar detailed analysis on
other models of tumour immunity such as contact sensitivity, produced
by injecting tumour cells in contact with adjuvant or infiltrating a
growing tumour with adjuvant. Such procedures are considered to
influence tumour growth by specific immunological means, and therefore
might be expected to emphasize the 7S response at the expense of the
1response.
Methods to examine the class and sub-class of immunoglobulin
adhering to cells of a freshly excised tumour might also be explored.
In theory this should be a store relia le measure of tumour-antibody
interactions than the in vitro assay used in these studies. However,
the separation of Fc-receptor !>earlng cells from tumour cells, without
dislodging any immunoglobulin, appears at first sight to be a formidable
problem.
'and what is tb« us* of a book,' thought Alio*, 'without
pictures <tr conversations?'
frois "Alice's Adventures in Honderland
by Lewis Carroll
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